{"meta":{"query_hash":"a330434edc0c","filters":{"venue":"The Lancet Haematology"},"cohort_total":173,"direct_labels_cover":1,"predictions_cover":173,"exported":173,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/a330434edc0c","api":"https://metacan.xera.ac/api/v1/cohort?venue=The+Lancet+Haematology"},"results":[{"id":"W1822814480","doi":"10.1016/s2352-3026(15)00090-3","title":"Integration of red cell genotyping into the blood supply chain: a population-based study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood groups and transfusion","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NIH Clinical Center; National Institutes of Health; Australian Government; Canadian Blood Services; U.S. Department of Health and Human Services","keywords":"ABO blood group system; Genotyping; Medicine; Red blood cell; Antigen; Immunology; Blood type (non-human); Red Cell; Serology; Genotype; Typing; Population; Red blood cell distribution width; Database; Antibody; Internal medicine; Biology; Genetics; Gene","score_opus":0.03801000566112186,"score_gpt":0.2897165603883023,"score_spread":0.25170655472718045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1822814480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863535,0.00031217624,0.00042871694,0.0115873115,0.00013043192,0.0006987113,0.0000017001054,0.000038312992,0.00044913738],"genre_scores_gemma":[0.9986361,0.000009135296,0.0005071581,0.0006035359,0.00013032155,0.000036743226,0.000022779295,0.00001281382,0.000041368057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990494,0.00021098118,0.00026305483,0.00014659265,0.00017274272,0.00015722295],"domain_scores_gemma":[0.999151,0.00013057751,0.00010893471,0.00046616193,0.00010299414,0.000040356823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005875904,0.000101573976,0.00048666747,0.00005006858,0.0000827363,0.0000063988145,0.00015565628,0.00006617646,0.00002069232],"category_scores_gemma":[0.00008105706,0.000051387073,0.00004908201,0.0001735826,0.000050394134,0.000022281107,0.000023923254,0.000193267,0.0000072472276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016861962,0.001662585,0.94315493,0.0003155242,0.00019651563,0.00014593884,0.02682825,0.00019125831,0.014836891,0.0076149567,0.0008158823,0.0025510488],"study_design_scores_gemma":[0.02965093,0.0037057323,0.8979677,0.00035589596,0.0023613523,0.00054726686,0.010987378,0.0071106716,0.037176576,0.008599786,0.0010737709,0.00046295475],"about_ca_topic_score_codex":0.0010532223,"about_ca_topic_score_gemma":0.00093479146,"teacher_disagreement_score":0.04518727,"about_ca_system_score_codex":0.000012837211,"about_ca_system_score_gemma":0.000056205838,"threshold_uncertainty_score":0.2095504},"labels":[],"label_agreement":null},{"id":"W1851987558","doi":"10.1016/s2352-3026(15)00113-1","title":"The merits and limits of pooling data from nuclear power worker studies","year":2015,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pooling; Nuclear power; Nuclear engineering; Nuclear physics; Artificial intelligence; Engineering; Computer science","score_opus":0.18244402527363593,"score_gpt":0.37687541712973466,"score_spread":0.19443139185609873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1851987558","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0290206,0.041742265,0.0000059996382,0.92594,0.00062266417,0.00022762553,0.000083400126,0.000039777056,0.0023176896],"genre_scores_gemma":[0.08882951,0.012354125,0.0005803109,0.89064,0.0057553775,0.000015050827,0.0004148933,0.00011453063,0.0012962071],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987007,0.00019288147,0.00031116436,0.00028836034,0.00021691303,0.0002900151],"domain_scores_gemma":[0.9973774,0.0008799317,0.0002582678,0.001354957,0.00010022225,0.000029229823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004831248,0.000177578,0.0011246011,0.000040535244,0.000114558534,0.000024558309,0.0005781917,0.00020775913,0.000032288543],"category_scores_gemma":[0.0006858421,0.00009025757,0.000035245914,0.000073695155,0.00044053374,0.00006287327,0.00033258006,0.00087247416,0.000057261765],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006540157,0.0000045781935,0.00060068275,0.00006444814,0.00046321668,0.0001828267,0.00084442593,1.22066e-7,0.000015023442,0.00012492553,0.99685454,0.0007798235],"study_design_scores_gemma":[0.00058227923,0.000026601412,0.0006162575,0.0002562733,0.0003326761,0.0003929255,0.00045055337,0.000100092075,0.0000185443,0.001136894,0.9959869,0.0000999997],"about_ca_topic_score_codex":0.000031897533,"about_ca_topic_score_gemma":0.000010003133,"teacher_disagreement_score":0.05980891,"about_ca_system_score_codex":0.0000139088,"about_ca_system_score_gemma":0.000057676465,"threshold_uncertainty_score":0.37905148},"labels":[],"label_agreement":null},{"id":"W1915793285","doi":"10.1016/s2352-3026(15)00190-8","title":"Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Pre- and post-test probability; Deep vein; Prospective cohort study; Venous thrombosis; Thrombosis; Cohort; Surgery; D-dimer; Radiology; Vein; Pulmonary embolism; Cohort study; Algorithm; Internal medicine","score_opus":0.02107327035383646,"score_gpt":0.29525428826330535,"score_spread":0.2741810179094689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1915793285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954606,0.00009104277,0.00041873517,0.00017231058,0.000075405005,0.0032986193,0.000012635006,0.000048568145,0.00042206154],"genre_scores_gemma":[0.99723196,0.00000899854,0.00239409,0.000060173825,0.000022195401,0.00022819135,0.00002609275,0.000024513995,0.0000037726638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745435,0.0006102998,0.00068832276,0.00039136567,0.0005304273,0.00032522134],"domain_scores_gemma":[0.9978921,0.00015525156,0.00068166957,0.0008748948,0.00030095526,0.00009514935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009512011,0.00023716985,0.002366832,0.00029605578,0.00008311532,0.000019523892,0.0002940634,0.00007516311,0.000004541184],"category_scores_gemma":[0.000102421924,0.00013393303,0.000070673384,0.0012657541,0.0002104709,0.00007417528,0.0001894714,0.00020403675,7.718053e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008284753,0.0027948504,0.98501265,0.00031455245,0.0027244352,0.00006332789,0.007128281,0.0010231003,0.000019710207,0.00053281494,0.000005950269,0.00029746277],"study_design_scores_gemma":[0.00369459,0.0013196922,0.86729795,0.00022914937,0.0039628115,0.000036009777,0.012293034,0.11099025,0.000033359847,0.00002694132,8.01899e-7,0.00011539914],"about_ca_topic_score_codex":0.0011299814,"about_ca_topic_score_gemma":0.0056050806,"teacher_disagreement_score":0.1177147,"about_ca_system_score_codex":0.00021957571,"about_ca_system_score_gemma":0.00009316525,"threshold_uncertainty_score":0.5461631},"labels":[],"label_agreement":null},{"id":"W1965842006","doi":"10.1016/s2352-3026(14)70020-1","title":"Treating clots in cancer: moving closer to an answer?","year":2014,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; Hamilton Health Sciences; Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Rivaroxaban; Medicine; Vitamin K antagonist; Pulmonary embolism; Low molecular weight heparin; Antithrombotic; Venous thrombosis; Thrombosis; Warfarin; Deep vein; Internal medicine; Atrial fibrillation","score_opus":0.041572187774547784,"score_gpt":0.350342778595155,"score_spread":0.3087705908206072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965842006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697037,0.00016302931,0.00016002795,0.020222872,0.00022437124,0.0004018927,0.0000018516058,0.000075895776,0.00904638],"genre_scores_gemma":[0.9876699,0.00011844421,0.00071024336,0.01074546,0.00047179474,0.00013476376,0.000004819833,0.000021207406,0.00012335388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888796,0.00013312683,0.00021638632,0.0002480823,0.00010735149,0.0004071045],"domain_scores_gemma":[0.9992536,0.0000965559,0.000057221925,0.00048267187,0.000025052743,0.0000849497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045361512,0.00012161475,0.00083720137,0.00008696407,0.000068658504,0.000013485616,0.00019240983,0.000058949212,0.00010101868],"category_scores_gemma":[0.00009357175,0.00008274525,0.00003440638,0.00016357297,0.000039505565,0.000041315994,0.00008164795,0.00014719114,0.00006798904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041780254,0.0011164726,0.64656955,0.00081138074,0.00019480393,0.00039728085,0.012614715,0.001423556,0.002976105,0.15016487,0.041447457,0.14186598],"study_design_scores_gemma":[0.0034694178,0.0008480941,0.91144645,0.00051637064,0.0002172209,0.00021058395,0.00092520216,0.0032474722,0.0019556466,0.0035619992,0.073196,0.00040553248],"about_ca_topic_score_codex":0.0013546321,"about_ca_topic_score_gemma":0.0027145082,"teacher_disagreement_score":0.2648769,"about_ca_system_score_codex":0.00004545904,"about_ca_system_score_gemma":0.000021980833,"threshold_uncertainty_score":0.33742535},"labels":[],"label_agreement":null},{"id":"W2026016649","doi":"10.1016/s2352-3026(15)00003-4","title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis","year":2015,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; McMaster University","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Splenectomy; Meta-analysis; Immune thrombocytopenia; Relative risk; Randomized controlled trial; Confidence interval; Gastroenterology; Platelet; Lymphoma","score_opus":0.15312143755456406,"score_gpt":0.40161448540477473,"score_spread":0.24849304785021067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026016649","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014797254,0.98963577,0.000018696344,0.00035171412,0.000019403764,0.008310744,0.0013716015,0.0000144031255,0.0002628662],"genre_scores_gemma":[0.0001117655,0.99708855,0.00042545528,0.00007830674,0.000009270857,0.0014540083,0.0006440685,0.000034025972,0.00015452575],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9974514,0.00039381484,0.0013338049,0.0003402701,0.00022076508,0.0002599224],"domain_scores_gemma":[0.9968106,0.00039769112,0.0013039527,0.0011601967,0.00026843688,0.000059134825],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00044722777,0.00047539623,0.06881621,0.0001469546,0.000041135074,0.000005164859,0.00021968395,0.00020074914,0.000036692214],"category_scores_gemma":[0.00007515257,0.00020878183,0.0026269408,0.00032534395,0.00016113676,0.000019956673,0.000061211,0.000075806835,0.0000050045046],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008751555,0.000112943875,5.867447e-7,0.82252455,0.17557348,0.00011766875,0.00017909851,6.771768e-8,1.8422924e-8,0.00017073346,0.00009871233,0.0011346339],"study_design_scores_gemma":[0.0026000692,0.0008441381,2.7688432e-7,0.018982762,0.95128196,0.0012493595,0.0000525433,4.6657902e-7,0.0000014383802,0.000059487298,0.024793467,0.00013403218],"about_ca_topic_score_codex":0.0000423223,"about_ca_topic_score_gemma":0.000046655023,"teacher_disagreement_score":0.8035418,"about_ca_system_score_codex":0.00020736111,"about_ca_system_score_gemma":0.00040235292,"threshold_uncertainty_score":0.9450082},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":["metaepi_broad"],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W2104054161","doi":"10.1016/s2352-3026(15)00068-x","title":"Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":149,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Amyloidosis; AL amyloidosis; Immunoglobulin light chain; Biopsy; Pathology; Internal medicine; Antibody; Immunology","score_opus":0.06521785889323627,"score_gpt":0.3157278044658536,"score_spread":0.2505099455726173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104054161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828028,0.009827933,0.000020182939,0.0060958616,0.000443402,0.0006067928,0.000009796099,0.000035286146,0.00015791958],"genre_scores_gemma":[0.9964895,0.00019818137,0.00014750402,0.0022040678,0.00012460681,0.0002635792,0.00006522978,0.000029046614,0.00047827294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817985,0.00036362666,0.0003934393,0.00046033497,0.00018834988,0.00041440566],"domain_scores_gemma":[0.99891496,0.00010307321,0.00016945232,0.00065041636,0.0000756683,0.000086424545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000454665,0.00029455323,0.00077958876,0.0000738523,0.000058888887,0.000018790795,0.0004336903,0.00016759161,0.000016045618],"category_scores_gemma":[0.0002699999,0.0002076547,0.00008167942,0.000088542016,0.0001928646,0.000011257113,0.0002849344,0.00020164385,0.000024038214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002535874,0.00036214624,0.99161184,0.000021505208,0.00018684224,0.00010615309,0.00068106805,0.000009587816,0.0011605195,0.00027902293,0.0051929527,0.00013479413],"study_design_scores_gemma":[0.004878328,0.00031244635,0.98994434,0.000018516694,0.00007787785,0.00015327858,0.00046115997,0.00002044448,0.0010662944,0.00014314914,0.0026253553,0.0002987867],"about_ca_topic_score_codex":0.00015729638,"about_ca_topic_score_gemma":0.00089962926,"teacher_disagreement_score":0.013686686,"about_ca_system_score_codex":0.00013778511,"about_ca_system_score_gemma":0.00013199935,"threshold_uncertainty_score":0.84679127},"labels":[],"label_agreement":null},{"id":"W2127175732","doi":"10.1016/s2352-3026(15)00114-3","title":"Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":195,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Hospital for Sick Children","funders":"Novartis Pharmaceuticals Corporation; Novartis; GlaxoSmithKline","keywords":"Eltrombopag; Medicine; Placebo; Immune thrombocytopenia; Internal medicine; Thrombopoietin receptor; Thrombopoietin; Romiplostim; Pediatrics; Surgery; Platelet","score_opus":0.03145599271383102,"score_gpt":0.2921678993521696,"score_spread":0.26071190663833854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127175732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97726256,0.011261746,0.000027669572,0.0023011954,0.00006040232,0.008857725,0.000015605186,0.000023726392,0.00018935747],"genre_scores_gemma":[0.9978471,0.000780874,0.00011286342,0.000067240835,0.000069988404,0.00088447577,0.000018528066,0.000020185204,0.00019874901],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99888265,0.00013544879,0.00028692768,0.00023342443,0.0001436228,0.0003179532],"domain_scores_gemma":[0.9987446,0.00044815204,0.00018144082,0.00048463684,0.00007089644,0.00007025203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002768977,0.00022295797,0.0020433404,0.000033046494,0.00012515626,0.000012964176,0.00013193418,0.000048890015,0.000016250466],"category_scores_gemma":[0.000050378818,0.0000886875,0.00016318906,0.00006157984,0.00019520572,0.00002457475,0.00002468047,0.0000677726,0.0000064500714],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7041311,0.011044488,0.22036822,0.0002164373,0.033284467,0.0007959207,0.021484585,0.00027285458,0.00039373402,0.00055703026,0.0009567144,0.0064944504],"study_design_scores_gemma":[0.9498045,0.012748397,0.022701968,0.0000516969,0.006826102,0.0023372544,0.0033298007,0.0011585905,0.00045908938,0.000053526674,0.00035453122,0.00017454532],"about_ca_topic_score_codex":0.0001915736,"about_ca_topic_score_gemma":0.00034074023,"teacher_disagreement_score":0.2456734,"about_ca_system_score_codex":0.000078139965,"about_ca_system_score_gemma":0.00010899242,"threshold_uncertainty_score":0.36165714},"labels":[],"label_agreement":null},{"id":"W2135936995","doi":"10.1016/s2352-3026(14)70018-3","title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials","year":2014,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":284,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; London Health Sciences Centre","funders":"Bayer HealthCare","keywords":"Medicine; Rivaroxaban; Vitamin K antagonist; Pulmonary embolism; Regimen; Population; Internal medicine; Venous thrombosis; Randomized controlled trial; Warfarin; Cancer; Low molecular weight heparin; Surgery; Thrombosis; Atrial fibrillation","score_opus":0.02850244584894512,"score_gpt":0.31415890950065106,"score_spread":0.28565646365170594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135936995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914187,0.00088052143,0.00033441337,0.0010109409,0.00014587375,0.005961119,0.000057690162,0.00002239846,0.00016831042],"genre_scores_gemma":[0.9973245,0.00075491186,0.00028214304,0.00019104943,0.0000713114,0.0012733305,0.000055114575,0.00003210529,0.000015489337],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972702,0.00063448655,0.0009912299,0.00035584866,0.0003051096,0.0004431001],"domain_scores_gemma":[0.9949094,0.0032215759,0.00093223166,0.00071989885,0.00014768414,0.00006919314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014093379,0.0003496024,0.007801197,0.00026971672,0.00011693231,0.00002074505,0.00021642687,0.00007843215,0.000034722405],"category_scores_gemma":[0.00023881969,0.0001521411,0.0003342652,0.00043569776,0.00038899994,0.000040211067,0.00003390545,0.00008575292,6.8382946e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46377733,0.017305374,0.3000314,0.002182062,0.13110699,0.00007135743,0.017711954,0.004385579,0.00089286116,0.027914794,0.00041961152,0.034200694],"study_design_scores_gemma":[0.63123316,0.010311846,0.29861116,0.0003342399,0.05158059,0.00000817749,0.00047008556,0.0056847795,0.0010564313,0.00018698491,0.00019309614,0.00032944235],"about_ca_topic_score_codex":0.001809886,"about_ca_topic_score_gemma":0.0040518884,"teacher_disagreement_score":0.16745582,"about_ca_system_score_codex":0.00009296787,"about_ca_system_score_gemma":0.00008292926,"threshold_uncertainty_score":0.6204134},"labels":[],"label_agreement":null},{"id":"W2155403628","doi":"10.1016/s2352-3026(15)00028-9","title":"One million haemopoietic stem-cell transplants: a retrospective observational study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":434,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; Princess Margaret Cancer Centre","funders":"World Health Organization","keywords":"Medicine; Observational study; Retrospective cohort study; Stem cell; Oncology; Internal medicine; Intensive care medicine; Genetics","score_opus":0.18156565499117197,"score_gpt":0.3366682449817053,"score_spread":0.1551025899905333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155403628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823362,0.0003115042,0.0021763986,0.0062291464,0.00031564652,0.0013949656,0.000032955464,0.00016010864,0.0070430273],"genre_scores_gemma":[0.99727863,0.000060396385,0.00081885274,0.00086766825,0.00022452872,0.00011346222,0.00006244493,0.00003491194,0.00053911755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977506,0.000398079,0.00047872245,0.00038163792,0.00057124876,0.00041971717],"domain_scores_gemma":[0.9985884,0.00027386495,0.00014519606,0.00060944114,0.00022161787,0.00016151299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010253595,0.00021402995,0.0010571607,0.00009291072,0.000097671036,0.000017310109,0.00024965848,0.00014090718,0.00008224189],"category_scores_gemma":[0.000044868724,0.00016009412,0.000076696844,0.00032017153,0.00014635206,0.00007600462,0.000024493185,0.00034897792,0.00032435244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031835195,0.0035970605,0.93197775,0.0013383166,0.0004869676,0.0016831531,0.036782615,0.000056939745,0.003373947,0.009030226,0.007955425,0.00053410314],"study_design_scores_gemma":[0.044750873,0.0052532637,0.87952524,0.00089143397,0.0029878134,0.01010702,0.015761353,0.0014296223,0.02414285,0.011750967,0.0021530904,0.0012464427],"about_ca_topic_score_codex":0.00005979326,"about_ca_topic_score_gemma":0.00006188072,"teacher_disagreement_score":0.052452456,"about_ca_system_score_codex":0.00010504675,"about_ca_system_score_gemma":0.0001720421,"threshold_uncertainty_score":0.6528449},"labels":[],"label_agreement":null},{"id":"W2162020809","doi":"10.1016/s2352-3026(15)00020-4","title":"90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Université de Nantes; Université de Bretagne Occidentale","keywords":"Radioimmunotherapy; Medicine; Tolerability; CD22; Refractory (planetary science); Internal medicine; Oncology; Nuclear medicine; Gastroenterology; Lymphoma; CD20; Adverse effect; Immunology; Antibody","score_opus":0.04679705980917849,"score_gpt":0.3532113727698215,"score_spread":0.30641431296064303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162020809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99167806,0.00020365989,0.00016481474,0.002617671,0.00006888354,0.0017226788,0.000028650813,0.0001148681,0.0034006932],"genre_scores_gemma":[0.9981154,0.000060741673,0.0002890576,0.0004952631,0.00017221666,0.00030694393,0.00007852217,0.00003429602,0.00044751988],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980975,0.00022170393,0.00045512282,0.00048184668,0.00027804243,0.00046579321],"domain_scores_gemma":[0.9983337,0.00043710083,0.00019558592,0.0006600158,0.00013950157,0.00023412067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037107922,0.000277498,0.0010020072,0.00007363234,0.00011274664,0.000016920854,0.00025965297,0.00019213148,0.00006054754],"category_scores_gemma":[0.00017043459,0.00016705297,0.000046374713,0.00054928096,0.00026241745,0.00009339877,0.00005486544,0.00064398017,0.0000872092],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37496278,0.08599649,0.15546493,0.00395325,0.0039875773,0.04806326,0.05922281,0.0010110297,0.21531825,0.004187621,0.039112683,0.008719332],"study_design_scores_gemma":[0.67573667,0.025293665,0.045052134,0.0024159595,0.006967308,0.025761697,0.018224264,0.026988871,0.16071218,0.0011462278,0.008624675,0.003076343],"about_ca_topic_score_codex":0.000024401,"about_ca_topic_score_gemma":0.00003224025,"teacher_disagreement_score":0.30077392,"about_ca_system_score_codex":0.00020823134,"about_ca_system_score_gemma":0.00034168756,"threshold_uncertainty_score":0.68122226},"labels":[],"label_agreement":null},{"id":"W2187343014","doi":"10.1016/s2352-3026(15)00197-0","title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"AbbVie Biotherapeutics; National Cancer Institute; Celgene; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Clinical endpoint; Oncology; Phases of clinical research; Thalidomide; Clinical trial","score_opus":0.11369672653323207,"score_gpt":0.37215393679621306,"score_spread":0.25845721026298096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2187343014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99148124,0.00013137363,0.000067302346,0.0026345227,0.000034843302,0.005340327,0.00007841082,0.000027305243,0.00020467152],"genre_scores_gemma":[0.9981137,0.00001628532,0.00081489293,0.00015707087,0.000031501382,0.00036741327,0.00043432356,0.000026004258,0.000038819875],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99715656,0.0009968039,0.00049755344,0.00046507982,0.00045387328,0.00043009987],"domain_scores_gemma":[0.997297,0.0015325933,0.00024198866,0.0006145177,0.00016883822,0.00014510147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001398663,0.00024632845,0.0010068399,0.00012348485,0.00012206314,0.00005756608,0.00029279655,0.00008596364,0.0000077564055],"category_scores_gemma":[0.0013231273,0.00012071763,0.000014818566,0.00038456506,0.00023008655,0.0002068052,0.00013425626,0.00041064303,0.00001124583],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45022562,0.012773151,0.5274171,0.0000163512,0.000185446,0.0005486017,0.0028923962,0.0000134965885,0.00003118163,0.00004375922,0.00026918165,0.0055836593],"study_design_scores_gemma":[0.67172056,0.0050938874,0.3198141,0.000113098205,0.00009527765,0.00004213724,0.0005661527,0.002184971,0.000085042666,0.00013034626,0.000043673826,0.000110719346],"about_ca_topic_score_codex":0.0022107828,"about_ca_topic_score_gemma":0.0042669615,"teacher_disagreement_score":0.22149497,"about_ca_system_score_codex":0.00014152925,"about_ca_system_score_gemma":0.00017729295,"threshold_uncertainty_score":0.4922722},"labels":[],"label_agreement":null},{"id":"W2199894139","doi":"10.1016/s2352-3026(15)00200-8","title":"Eltrombopag in patients with high-risk myelodysplastic syndrome or acute myeloid leukaemia: cautious optimism","year":2015,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Eltrombopag; Myelodysplastic syndromes; Internal medicine; International Prognostic Scoring System; Placebo; Tolerability; Oncology; Adverse effect; Platelet; Bone marrow; Pathology; Immune thrombocytopenia; Alternative medicine","score_opus":0.02247899036029892,"score_gpt":0.2737507969408261,"score_spread":0.25127180658052717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2199894139","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6855386,0.0002592988,0.000070910304,0.30945575,0.0006828548,0.0024911556,0.0005048774,0.00027732065,0.0007192381],"genre_scores_gemma":[0.33442816,0.0013221047,0.00582872,0.6219523,0.0062674563,0.0015608028,0.007111749,0.0012173206,0.020311408],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932251,0.00090153166,0.00095392857,0.0012355006,0.0014402205,0.002243705],"domain_scores_gemma":[0.99509746,0.0010576588,0.00065665395,0.002425563,0.00047494035,0.00028773956],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00085880223,0.0010258916,0.0045597213,0.00067594793,0.00018115781,0.000061739636,0.0014501709,0.0020739764,0.00035065637],"category_scores_gemma":[0.00060962565,0.00057293667,0.00015845364,0.000865563,0.0009649456,0.00013395098,0.0005392557,0.009378469,0.0009888374],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003717617,0.00012346791,0.021510616,0.0007222535,0.0010704318,0.05768656,0.00026030594,0.000047712183,0.0000022113875,0.000050232422,0.9146577,0.00015086922],"study_design_scores_gemma":[0.12530662,0.017622668,0.25997716,0.0045168228,0.011087102,0.14395174,0.00022415849,0.000791026,0.0001031045,0.0035902143,0.4270051,0.005824273],"about_ca_topic_score_codex":0.0008763614,"about_ca_topic_score_gemma":0.00021490491,"teacher_disagreement_score":0.48765263,"about_ca_system_score_codex":0.0014989987,"about_ca_system_score_gemma":0.00201381,"threshold_uncertainty_score":0.999789},"labels":[],"label_agreement":null},{"id":"W2225295868","doi":"10.1016/s2352-3026(15)00257-4","title":"Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":244,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"Bayer HealthCare","keywords":"Medicine; Rivaroxaban; Pulmonary embolism; Deep vein; Fondaparinux; Thrombosis; Low molecular weight heparin; Vitamin K antagonist; Surgery; Anticoagulant; Population; Warfarin; Internal medicine; Atrial fibrillation; Venous thromboembolism","score_opus":0.07625267285548144,"score_gpt":0.3885107301357913,"score_spread":0.31225805728030986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2225295868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924852,0.00014931384,0.0034140304,0.0006864909,0.0004031391,0.0026344294,0.000034120872,0.000018351071,0.00017489945],"genre_scores_gemma":[0.9990857,0.00013148112,0.0004383049,0.00001368743,0.00005931375,0.00022105823,0.000029726409,0.000013241355,0.0000074638215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989225,0.00019807092,0.00031942103,0.00019515262,0.00021779475,0.00014703927],"domain_scores_gemma":[0.9987376,0.00046040822,0.00019624627,0.0003551273,0.00021239296,0.000038246133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078785943,0.00013009463,0.0009474521,0.000059070666,0.00007064134,0.000011756743,0.00014985428,0.000038221937,0.000016730235],"category_scores_gemma":[0.00009482123,0.0000729486,0.00008937165,0.00008301683,0.00017058465,0.000072393974,0.000047497437,0.000038232185,0.0000010593694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020464256,0.009807317,0.9030895,0.00094668387,0.005247328,0.0000127122985,0.009587155,0.00055550126,0.00022543181,0.04644179,0.00022153663,0.0034007865],"study_design_scores_gemma":[0.016698124,0.013080967,0.9619641,0.00012875794,0.0010711338,0.000015902704,0.0016770922,0.00253537,0.0010644732,0.0014722311,0.0002087514,0.00008314699],"about_ca_topic_score_codex":0.00016583197,"about_ca_topic_score_gemma":0.00020999569,"teacher_disagreement_score":0.05887455,"about_ca_system_score_codex":0.00010812722,"about_ca_system_score_gemma":0.000034191966,"threshold_uncertainty_score":0.29747576},"labels":[],"label_agreement":null},{"id":"W2286860957","doi":"10.1016/s2352-3026(16)00002-8","title":"Caesarean delivery and risk of childhood leukaemia: a pooled analysis from the Childhood Leukemia International Consortium (CLIC)","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; World Health Organization","keywords":"Medicine; Caesarean delivery; Caesarean section; Pediatrics; Odds ratio; Obstetrics; Logistic regression; Pregnancy; Internal medicine","score_opus":0.014018937127553659,"score_gpt":0.2662453954563988,"score_spread":0.25222645832884516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286860957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825894,0.00073451706,0.00088144484,0.013879439,0.00012169754,0.0003471056,0.00036835793,0.000053026644,0.0010249852],"genre_scores_gemma":[0.9960015,0.0019095946,0.00032396708,0.001133597,0.0003817124,0.00002955152,0.000049592432,0.000023683997,0.0001468067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978665,0.00039995453,0.00047822925,0.00040763596,0.000417697,0.0004299492],"domain_scores_gemma":[0.9959673,0.002470533,0.00032441926,0.00095243595,0.00017078001,0.00011452331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006163393,0.00021728389,0.0011156069,0.00015045799,0.00013948676,0.000018247489,0.00063675916,0.000187512,0.00035187855],"category_scores_gemma":[0.0011916511,0.000095918214,0.00020252111,0.0003609382,0.00082958094,0.00006465058,0.00036397026,0.00040920242,0.0000589163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082105177,0.00014721473,0.9646165,0.000024091365,0.010658398,0.00020178419,0.0019190703,0.000016926751,0.0015272932,0.0023318124,0.009744858,0.007991049],"study_design_scores_gemma":[0.0074376315,0.00010720383,0.98120606,0.00010920737,0.004330636,0.0007815274,0.00033787134,0.0006582083,0.0022320456,0.0017424849,0.00089634175,0.0001607881],"about_ca_topic_score_codex":0.001914354,"about_ca_topic_score_gemma":0.0005538355,"teacher_disagreement_score":0.016589604,"about_ca_system_score_codex":0.0002528367,"about_ca_system_score_gemma":0.0004702588,"threshold_uncertainty_score":0.3911431},"labels":[],"label_agreement":null},{"id":"W2288291042","doi":"10.1016/s2352-3026(16)00020-x","title":"Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood transfusion and management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; Victoria Hospital; University of Alberta; London Health Sciences Centre; McMaster University; Canadian Blood Services","funders":"Canadian Institutes of Health Research; Health Canada; Canadian Blood Services","keywords":"Medicine; Hazard ratio; Proportional hazards model; Retrospective cohort study; Blood transfusion; Cohort; Cohort study; Red blood cell; Emergency medicine; Confidence interval; Internal medicine; Pediatrics","score_opus":0.027130346781898834,"score_gpt":0.3432596311308283,"score_spread":0.31612928434892945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2288291042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768645,0.00034967682,0.0014710337,0.015623425,0.0001098155,0.0013435538,0.0000014329346,0.00007735018,0.0041591697],"genre_scores_gemma":[0.99643975,0.0006413559,0.0019334024,0.00046436014,0.000060137616,0.00011225162,0.0000012360895,0.000017132914,0.00033035874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867964,0.00025038645,0.00028731226,0.0003550299,0.0001510055,0.00027661552],"domain_scores_gemma":[0.99927366,0.00008348899,0.00007019312,0.000482058,0.000029271363,0.00006135291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009548683,0.00014281643,0.00073438947,0.0000641047,0.000066487024,0.000010414376,0.00013196141,0.00008287191,0.000050357325],"category_scores_gemma":[0.000046077297,0.00007508734,0.00003797878,0.00014409564,0.00013823848,0.000042530584,0.000055489152,0.00017420464,0.00000407564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002862042,0.0013608864,0.9767613,0.00043853695,0.00013883572,0.0007491563,0.0016302345,1.7443269e-7,0.007764621,0.00034425536,0.00045340316,0.01007239],"study_design_scores_gemma":[0.014337616,0.0007734735,0.9701305,0.00029840326,0.0012854958,0.00056552177,0.0014952127,0.000038254348,0.00739729,0.0010164031,0.0023921146,0.00026973351],"about_ca_topic_score_codex":0.000073483214,"about_ca_topic_score_gemma":0.0001657668,"teacher_disagreement_score":0.019575223,"about_ca_system_score_codex":0.000010012775,"about_ca_system_score_gemma":0.00002959108,"threshold_uncertainty_score":0.30619726},"labels":[],"label_agreement":null},{"id":"W2291152756","doi":"10.1016/s2352-3026(16)00004-1","title":"Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Rituximab; Fludarabine; Clinical endpoint; Cyclophosphamide; Pharmacokinetics; Population; Internal medicine; Clinical trial; Surgery; Chemotherapy; Lymphoma","score_opus":0.06490262390275962,"score_gpt":0.4059350666630088,"score_spread":0.3410324427602492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2291152756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97641,0.002087906,0.0006491348,0.003653086,0.000612435,0.015470979,0.00008362078,0.0000736325,0.00095923245],"genre_scores_gemma":[0.99071425,0.0061422894,0.00029877594,0.00033719023,0.0008809124,0.0009052402,0.00003104452,0.00008141665,0.00060890545],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99663365,0.0003483552,0.001012618,0.0006520397,0.00035640708,0.0009969204],"domain_scores_gemma":[0.9925575,0.005542221,0.00044294825,0.0010153278,0.00020720976,0.00023476877],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009876386,0.00048312597,0.004189887,0.00012225482,0.00018788165,0.000043002292,0.00064931443,0.000267875,0.00023059451],"category_scores_gemma":[0.0009918149,0.00026296094,0.00023168107,0.00016940302,0.00083181873,0.000065550936,0.0001917445,0.00017437838,0.000049143324],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9560397,0.0019738246,9.4092275e-7,0.00029695674,0.0014035185,0.0006894276,0.00046529944,0.000007594952,0.0071754185,0.00062294625,0.00048420273,0.030840125],"study_design_scores_gemma":[0.9484953,0.019493662,0.0000011894734,0.00017533578,0.0010755098,0.0030117673,0.00002605565,0.01085116,0.012951172,0.00019778377,0.0034534626,0.00026758204],"about_ca_topic_score_codex":0.000581543,"about_ca_topic_score_gemma":0.00007900969,"teacher_disagreement_score":0.030572543,"about_ca_system_score_codex":0.015651658,"about_ca_system_score_gemma":0.014284384,"threshold_uncertainty_score":0.99998224},"labels":[],"label_agreement":null},{"id":"W2296827990","doi":"10.1016/s2352-3026(16)00006-5","title":"Idiopathic multicentric Castleman's disease: a systematic literature review","year":2016,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":324,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Castleman disease; Disease; Histopathology; Pathology; Dermatology","score_opus":0.0399324007817195,"score_gpt":0.35000770677926374,"score_spread":0.31007530599754424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296827990","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[4.430068e-7,0.9889805,0.000013505987,0.0049721724,0.0005140457,0.0044816164,0.00014272737,0.00014522181,0.0007497892],"genre_scores_gemma":[0.000016664706,0.99374914,0.000010578296,0.0033713179,0.0005360105,0.0009990159,0.00012762837,0.00009449189,0.0010951718],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99583507,0.0012692881,0.0011758683,0.000568245,0.00038874632,0.00076279347],"domain_scores_gemma":[0.9965007,0.00038076183,0.0010971085,0.0016194378,0.00015320802,0.00024882448],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009923751,0.00065656134,0.009541657,0.0001683711,0.00012700842,0.000035789268,0.0005992418,0.0004624082,0.00012944195],"category_scores_gemma":[0.0014221242,0.00029394918,0.0010371729,0.00073382905,0.00015043501,0.000050453928,0.00012842476,0.0008795685,0.00091949117],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029751665,0.000039542723,0.0000049963255,0.95065194,0.0003740134,0.0018701073,0.000041872518,1.2858512e-8,1.5532589e-8,0.0010606106,0.023612238,0.022314914],"study_design_scores_gemma":[0.0005794926,0.000025538551,9.413007e-7,0.58245564,0.005453165,0.0023614997,0.000004831195,0.0000012426977,1.0014916e-8,0.000066049244,0.40885112,0.00020047156],"about_ca_topic_score_codex":0.0000021200135,"about_ca_topic_score_gemma":0.0000032642117,"teacher_disagreement_score":0.3852389,"about_ca_system_score_codex":0.00022899765,"about_ca_system_score_gemma":0.00055102515,"threshold_uncertainty_score":0.99995124},"labels":[],"label_agreement":null},{"id":"W2299219969","doi":"10.1016/s2352-3026(15)00247-1","title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":431,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Agence Nationale de la Recherche","keywords":"Medicine; Bromodomain; Internal medicine; Leukemia; Oncology","score_opus":0.011626998762010418,"score_gpt":0.2695873245110347,"score_spread":0.2579603257490243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299219969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996678,0.000040201056,0.000601014,0.0016149093,0.00011517765,0.00065084547,0.000023627115,0.000021794858,0.0002544163],"genre_scores_gemma":[0.9989757,0.000011357368,0.00015191283,0.00033209365,0.00017071547,0.000091596754,0.000044995068,0.000019029803,0.00020258145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987852,0.0002160844,0.0002532556,0.00031449983,0.0001416317,0.00028933832],"domain_scores_gemma":[0.99923885,0.00002610705,0.00011881409,0.00049818336,0.000070124675,0.000047902897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002456848,0.00015686745,0.00033335044,0.000049941154,0.000065965476,0.000012491513,0.0002525552,0.000115667746,0.000030709376],"category_scores_gemma":[0.00007934574,0.00008108587,0.00003148707,0.00012480267,0.00013335938,0.000009972955,0.000101780555,0.00009596818,0.000031057003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005667623,0.0025882074,0.90065134,0.000028098937,0.00031021668,0.00011707987,0.0005000814,0.000006100984,0.056344748,0.001398303,0.025361825,0.007026392],"study_design_scores_gemma":[0.14409839,0.012830899,0.5567939,0.00024243846,0.00026489783,0.00032946022,0.00050951086,0.000037354912,0.24765867,0.0021926782,0.033175204,0.0018665849],"about_ca_topic_score_codex":0.000009447534,"about_ca_topic_score_gemma":0.00009216399,"teacher_disagreement_score":0.3438574,"about_ca_system_score_codex":0.000021937669,"about_ca_system_score_gemma":0.000052075382,"threshold_uncertainty_score":0.33065858},"labels":[],"label_agreement":null},{"id":"W2299743455","doi":"10.1016/s2352-3026(16)00007-7","title":"The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research","year":2016,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Disease; Scopus; Clinical trial; Family medicine; MEDLINE; Pathology","score_opus":0.09367360481369282,"score_gpt":0.3704219862791781,"score_spread":0.2767483814654853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299743455","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010116915,0.015446202,0.0002666083,0.97585106,0.00047049165,0.0022128625,0.0002795418,0.000091186645,0.0043703443],"genre_scores_gemma":[0.0064397734,0.0024824,0.00035556435,0.9577155,0.016793827,0.00093149644,0.00011234736,0.00020071906,0.014968391],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99556166,0.0011141746,0.00036506096,0.0007544543,0.0006389051,0.0015657528],"domain_scores_gemma":[0.99620634,0.0014018223,0.00021370525,0.0014236592,0.00020496604,0.0005494826],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0008852951,0.00045263933,0.0012996225,0.00010037587,0.0007736782,0.00017061952,0.0006941481,0.00059611094,0.0001382543],"category_scores_gemma":[0.0009228497,0.00022200929,0.00013545557,0.0006875145,0.00076581875,0.00004414257,0.0003318121,0.0024362837,0.00016530773],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002407872,0.000016474169,0.0019738183,0.00027024842,0.00028439297,0.00090606743,0.0006421674,0.000007983103,3.8108354e-7,0.004925242,0.9877983,0.00076710124],"study_design_scores_gemma":[0.0014036003,0.00011234569,0.00047765576,0.0006960948,0.00028020365,0.000038713977,0.00025902022,0.000022439073,5.358491e-7,0.03778283,0.95863223,0.0002943387],"about_ca_topic_score_codex":0.00009290509,"about_ca_topic_score_gemma":0.000060620023,"teacher_disagreement_score":0.03285759,"about_ca_system_score_codex":0.00014079774,"about_ca_system_score_gemma":0.00111508,"threshold_uncertainty_score":0.9998651},"labels":[],"label_agreement":null},{"id":"W2307552230","doi":"10.1016/s2352-3026(16)00023-5","title":"Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Ottawa; Thrombosis and Atherosclerosis Research Institute; Ottawa Hospital","funders":"","keywords":"Medicine; Edoxaban; Incidence (geometry); Warfarin; Venous thromboembolism; Major bleeding; Surgery; Post-hoc analysis; Cumulative incidence; Internal medicine; Rivaroxaban; Atrial fibrillation; Cohort; Thrombosis","score_opus":0.030735056996386033,"score_gpt":0.30220614690830827,"score_spread":0.27147108991192226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307552230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593997,0.0000152196135,0.00012847573,0.0029067108,0.000043308522,0.00084491255,0.0000065967015,0.000013040684,0.000101743855],"genre_scores_gemma":[0.9997481,0.000005075695,0.000081461716,0.00006643254,0.00003556903,0.0000035252847,0.000010820197,0.000008146643,0.00004083816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899435,0.00015961433,0.00032503178,0.00013904549,0.0002495677,0.00013237045],"domain_scores_gemma":[0.99892956,0.00012248397,0.0003505871,0.00043662256,0.00014715425,0.000013569918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022818259,0.00009424694,0.00088797935,0.00017266869,0.0000361026,0.000003237791,0.00010868907,0.00003509567,0.000027944368],"category_scores_gemma":[0.00006463445,0.000035845896,0.000059154136,0.00064325886,0.000120332435,0.00006169949,0.000037950907,0.000044782162,0.0000016853662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001897428,0.00010392305,0.9941869,0.00002980431,0.00064563635,0.0000027557787,0.0009537321,0.00005815048,0.0002208194,0.0013464434,0.000009211242,0.0005452192],"study_design_scores_gemma":[0.0035377957,0.00092973956,0.9934324,0.00004860616,0.0013843225,0.0000025107424,0.0002533067,0.00007322656,0.0001942169,0.000083324696,0.000009548672,0.000051017],"about_ca_topic_score_codex":0.000055164805,"about_ca_topic_score_gemma":0.00037807034,"teacher_disagreement_score":0.0038081394,"about_ca_system_score_codex":0.000017789453,"about_ca_system_score_gemma":0.00002711764,"threshold_uncertainty_score":0.14617532},"labels":[],"label_agreement":null},{"id":"W2328734504","doi":"10.1016/s2352-3026(16)00027-2","title":"Real life studies and good clinical practice – Authors' reply","year":2016,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Rivaroxaban; Medicine; Clinical trial; Major bleeding; Thrombosis; Deep vein; Discontinuation; Apixaban; Surgery; Internal medicine; Warfarin; Atrial fibrillation","score_opus":0.11797207888146037,"score_gpt":0.4285029927085008,"score_spread":0.3105309138270404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328734504","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002785093,0.005693995,0.00002105063,0.9704054,0.001989132,0.0007858636,0.000014819948,0.00015389438,0.018150728],"genre_scores_gemma":[0.0011624508,0.046222053,0.0010216602,0.93087393,0.016988212,0.0001394947,0.000024444726,0.00006650033,0.0035012432],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965982,0.000874333,0.0008163835,0.00068955857,0.0003400119,0.00068150484],"domain_scores_gemma":[0.99437636,0.0033759251,0.00061661826,0.0013159538,0.00020128353,0.00011384099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022182507,0.00036577962,0.0034542854,0.00008366918,0.00015180295,0.000026914238,0.00032731745,0.00066207384,0.00006243473],"category_scores_gemma":[0.003505906,0.00019151004,0.00017491594,0.00007653629,0.000689427,0.000061340186,0.000459608,0.0017229572,0.0002705055],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118291515,0.000058124555,0.00073680683,0.0009835539,0.0016205239,0.0034557772,0.0003238529,1.8310027e-8,6.97119e-7,0.008259834,0.9828693,0.0015732007],"study_design_scores_gemma":[0.0012786859,0.0003752208,0.0029889192,0.00048953854,0.0020228769,0.0016088679,0.00021959655,9.725547e-7,0.000001981857,0.0021667709,0.9886258,0.00022072997],"about_ca_topic_score_codex":0.00007426629,"about_ca_topic_score_gemma":0.000010802758,"teacher_disagreement_score":0.04052806,"about_ca_system_score_codex":0.000040773,"about_ca_system_score_gemma":0.00013441716,"threshold_uncertainty_score":0.7809553},"labels":[],"label_agreement":null},{"id":"W2387483003","doi":"10.1016/s2352-3026(16)30020-5","title":"Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Liver Disease and Transplantation","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Pfizer Canada","keywords":"Medicine; Thrombosis; Portal vein thrombosis; Prospective cohort study; Surgery; Venous thrombosis; Internal medicine","score_opus":0.05248537413696818,"score_gpt":0.33909567047879163,"score_spread":0.28661029634182345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2387483003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962767,0.00082814804,0.000093627,0.0012497033,0.0002976711,0.00033253105,0.000025581126,0.000039586925,0.0008565001],"genre_scores_gemma":[0.9969953,0.0023613248,0.00018879303,0.000099702236,0.00014876087,0.000020630801,0.000013546323,0.000008612382,0.00016337576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992221,0.00008996968,0.0002544431,0.00019321144,0.000106875836,0.00013340956],"domain_scores_gemma":[0.9993099,0.0002086615,0.00014076686,0.00023557572,0.00005389874,0.000051188257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008892457,0.00009586251,0.00049053534,0.000037596346,0.000020072444,0.00000220284,0.00008268819,0.00007029132,0.00012943633],"category_scores_gemma":[0.000033183045,0.00005078717,0.0000618533,0.000027758246,0.00030870517,0.00004422684,0.000016498263,0.000052522584,0.000021992666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010006498,0.00030165896,0.9918304,0.00010069887,0.00060446135,0.000113253875,0.0008490594,9.232176e-8,0.0031664919,0.0012406908,0.00029385637,0.0004987042],"study_design_scores_gemma":[0.006075203,0.00036738047,0.9900708,0.0001917177,0.0006375768,0.0004047589,0.000081715465,0.000025316034,0.0015430641,0.00027438824,0.000264667,0.000063416264],"about_ca_topic_score_codex":0.00005045826,"about_ca_topic_score_gemma":0.000082259,"teacher_disagreement_score":0.005074553,"about_ca_system_score_codex":0.000122831,"about_ca_system_score_gemma":0.00008246514,"threshold_uncertainty_score":0.20710407},"labels":[],"label_agreement":null},{"id":"W2471363772","doi":"10.1016/s2352-3026(16)30057-6","title":"Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; McMaster University","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo","keywords":"Medicine; Venous thromboembolism; Subgroup analysis; Edoxaban; Randomized controlled trial; Cancer; Internal medicine; Intensive care medicine; Meta-analysis; Warfarin; Rivaroxaban; Thrombosis","score_opus":0.041082264923723126,"score_gpt":0.3122955605451675,"score_spread":0.27121329562144436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471363772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98505914,0.0001263742,0.000248345,0.006765612,0.0007374136,0.006122514,0.00041318327,0.000037252023,0.0004901752],"genre_scores_gemma":[0.9974395,0.00026049267,0.00010703198,0.0005705173,0.0003918451,0.0010250217,0.000109764645,0.00003706025,0.00005876253],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973058,0.00017365509,0.0008901033,0.0005760183,0.00042076732,0.0006336556],"domain_scores_gemma":[0.9970082,0.0006532083,0.00068483636,0.0013571621,0.00020580964,0.00009075164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008326155,0.00032715386,0.0033940312,0.0002350828,0.00014844922,0.00002127303,0.0005912668,0.00019331643,0.00006575359],"category_scores_gemma":[0.00010702546,0.00014718008,0.0003902665,0.00074127904,0.00032941267,0.0000855746,0.00017440676,0.00022015085,0.0000065403315],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89951783,0.0020437937,0.08524419,0.0001471327,0.0047763614,0.000015232846,0.0021127916,0.00015167726,0.00008846261,0.002216036,0.0023165692,0.0013699103],"study_design_scores_gemma":[0.6894189,0.00068580697,0.302349,0.00026825035,0.0051769554,0.0000016703301,0.00006399417,0.000070725866,0.0006166004,0.0003030832,0.0008263252,0.00021870891],"about_ca_topic_score_codex":0.0049928515,"about_ca_topic_score_gemma":0.007101589,"teacher_disagreement_score":0.21710481,"about_ca_system_score_codex":0.000121956575,"about_ca_system_score_gemma":0.00017118777,"threshold_uncertainty_score":0.75477314},"labels":[],"label_agreement":null},{"id":"W2510857252","doi":"10.1016/s2352-3026(16)30080-1","title":"Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute; Ottawa Hospital; University of Ottawa","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo","keywords":"Medicine; Edoxaban; Pulmonary embolism; Warfarin; Internal medicine; Cardiology; Hazard ratio; Deep vein; Thrombosis; Atrial fibrillation; Rivaroxaban; Confidence interval","score_opus":0.009076682641923814,"score_gpt":0.23669895629810483,"score_spread":0.227622273656181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510857252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921082,0.0006527052,0.000016631058,0.0051811463,0.00026382864,0.0014078339,0.000022447477,0.000027714364,0.00031947787],"genre_scores_gemma":[0.9989417,0.00021827804,0.000019988243,0.00057787006,0.00007205541,0.00009862429,0.00001243821,0.000019424175,0.00003958005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814194,0.00028555328,0.00041202558,0.00039086238,0.00037667557,0.00039294446],"domain_scores_gemma":[0.9985146,0.00013273636,0.00026060952,0.0008859547,0.00014238292,0.00006371285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037786053,0.0002249003,0.0017569078,0.00026062306,0.00012269613,0.000010616324,0.00027994803,0.00007917416,0.00011987386],"category_scores_gemma":[0.000050949333,0.000092995935,0.00012300769,0.00081376964,0.00024112132,0.00006167315,0.00021936344,0.00017047218,0.00000928932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010964595,0.0052545695,0.9776953,0.00015643367,0.0028758969,0.00036969152,0.0017218686,0.000019281804,0.00002590386,0.0031985529,0.00065087044,0.006935211],"study_design_scores_gemma":[0.0032913203,0.001289039,0.9906435,0.00015036983,0.003070249,0.00005313378,0.00026861404,0.000021790029,0.000029867835,0.0002192889,0.0008308402,0.00013201286],"about_ca_topic_score_codex":0.00014725051,"about_ca_topic_score_gemma":0.00031135077,"teacher_disagreement_score":0.012948214,"about_ca_system_score_codex":0.000059390477,"about_ca_system_score_gemma":0.000041190073,"threshold_uncertainty_score":0.37922642},"labels":[],"label_agreement":null},{"id":"W2520058836","doi":"10.1016/s2352-3026(16)30109-0","title":"High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis","year":2016,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; McMaster University","funders":"Canadian Institutes of Health Research; Canadian Blood Services; McMaster University","keywords":"Medicine; Prednisone; Dexamethasone; Internal medicine; Meta-analysis; Corticosteroid; Clinical endpoint; Relative risk; Immune thrombocytopenia; Randomized controlled trial; Platelet; Gastroenterology; Confidence interval","score_opus":0.09557640942711129,"score_gpt":0.35346586600180996,"score_spread":0.25788945657469864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520058836","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045462366,0.9819866,0.00021271197,0.0019048298,0.000023256116,0.015172716,0.00046149504,0.00010156567,0.00009139477],"genre_scores_gemma":[0.00011650007,0.9904295,0.0014719894,0.000780416,0.000024913163,0.005201037,0.0008776267,0.000098602504,0.0009993914],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99577403,0.0009502574,0.0015131397,0.00080997136,0.00026918208,0.0006833955],"domain_scores_gemma":[0.99484146,0.0013788554,0.0015480695,0.0019210622,0.00017072137,0.00013984404],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00093940727,0.0009356929,0.05109075,0.00021076768,0.00014991821,0.000035080215,0.0004739444,0.0003136268,0.00017112613],"category_scores_gemma":[0.00017514442,0.00035913443,0.0018676595,0.0006772963,0.00028498945,0.000062081934,0.00013682978,0.00030598414,0.00006679423],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012333094,0.00013281907,0.0000018061878,0.70655316,0.29147363,0.00048092252,0.000029125973,1.0035544e-7,9.5886506e-8,0.00020731798,0.00040279745,0.000594918],"study_design_scores_gemma":[0.0029104035,0.0002767778,0.0000037855266,0.059066433,0.9231938,0.0070925104,0.0000049712858,0.0000013153441,6.0765313e-7,0.00007854693,0.0070181587,0.0003526859],"about_ca_topic_score_codex":0.00005759419,"about_ca_topic_score_gemma":0.000054725835,"teacher_disagreement_score":0.6474867,"about_ca_system_score_codex":0.00011182281,"about_ca_system_score_gemma":0.00022160597,"threshold_uncertainty_score":0.99988604},"labels":[],"label_agreement":null},{"id":"W2525440522","doi":"10.1016/s2352-3026(16)30108-9","title":"The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"ABVD; Medicine; Dacarbazine; Internal medicine; Hazard ratio; Vinblastine; Oncology; Interim analysis; Cohort; Chemotherapy regimen; Chemotherapy; Clinical trial; Vincristine; Confidence interval; Cyclophosphamide","score_opus":0.023154701309825797,"score_gpt":0.28746616756845117,"score_spread":0.2643114662586254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525440522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520016,0.0002436637,0.0000012274143,0.002396562,0.00007569286,0.0010993786,0.000027449063,0.000016725886,0.0009391227],"genre_scores_gemma":[0.99947786,0.00028888293,0.000022324894,0.000025802026,0.000018812561,0.000105717394,0.0000037317066,0.000012100254,0.000044770575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985336,0.00041211807,0.00046773933,0.00023889268,0.00011938295,0.00022823462],"domain_scores_gemma":[0.99896103,0.0003732376,0.0001771121,0.0004088106,0.000038431077,0.00004138932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044954938,0.00014754978,0.0008538362,0.00007794062,0.00003534266,0.0000047208014,0.00010517279,0.000033244392,0.00000791539],"category_scores_gemma":[0.00013268398,0.00006269641,0.000054381773,0.00012252043,0.0002846177,0.000025078818,0.00007678675,0.000036856465,0.000003718579],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013368734,0.0015598837,0.9905528,0.00001831409,0.0002637587,0.00018750911,0.0008447571,2.1361768e-7,0.00035709722,0.00047911564,0.000048634105,0.0043510357],"study_design_scores_gemma":[0.01784639,0.0015499414,0.9784752,0.00010457906,0.00014989103,0.00016135938,0.00083782163,0.00010532672,0.00051240565,0.00009378062,0.00011637843,0.00004691422],"about_ca_topic_score_codex":0.00045183222,"about_ca_topic_score_gemma":0.0010331783,"teacher_disagreement_score":0.016509516,"about_ca_system_score_codex":0.00043595125,"about_ca_system_score_gemma":0.000053640193,"threshold_uncertainty_score":0.25566855},"labels":[],"label_agreement":null},{"id":"W2530375062","doi":"10.1016/s2352-3026(16)30114-4","title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco; National Institute of General Medical Sciences; University of California, San Francisco","keywords":"Busulfan; Medicine; Hazard ratio; Cumulative incidence; Transplantation; Proportional hazards model; Internal medicine; Retrospective cohort study; Survival analysis; Dosing; Surgery; Hematopoietic stem cell transplantation; Oncology; Confidence interval","score_opus":0.004853650410942675,"score_gpt":0.21903164101673758,"score_spread":0.2141779906057949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530375062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966594,0.00014939529,0.0013342558,0.000857751,0.000026528356,0.0005979234,0.000092298564,0.000021000349,0.00026144192],"genre_scores_gemma":[0.9986093,0.00084911,0.0003455391,0.000040797106,0.000023777078,0.00003484303,0.000033513028,0.000011893595,0.000051212588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987066,0.00023655331,0.00030732568,0.00028288193,0.00023594599,0.00023073106],"domain_scores_gemma":[0.99920315,0.00026827925,0.00018817373,0.00020347151,0.00008954863,0.000047355294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052941154,0.0001403341,0.0008528359,0.00012975224,0.000027367878,0.000006407507,0.00005110198,0.00012618661,0.000032305623],"category_scores_gemma":[0.00004793094,0.00008061057,0.00003838954,0.0002777226,0.00011406013,0.000064256026,0.000008642372,0.0001131151,0.0000018590928],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015341704,0.000056150293,0.99438727,0.00022971297,0.00035593472,0.000041106734,0.002376029,0.0000013261055,0.0008504861,0.0000678368,0.0000044875633,0.00009547389],"study_design_scores_gemma":[0.004990101,0.00012450253,0.9874648,0.00019628752,0.0016405021,0.00028029346,0.00015892496,0.000053348707,0.00494564,0.00004662015,3.3311198e-7,0.00009867531],"about_ca_topic_score_codex":0.00024997687,"about_ca_topic_score_gemma":0.002305588,"teacher_disagreement_score":0.0069225137,"about_ca_system_score_codex":0.00005845055,"about_ca_system_score_gemma":0.000018488417,"threshold_uncertainty_score":0.32872033},"labels":[],"label_agreement":null},{"id":"W2554412408","doi":"10.1016/s2352-3026(16)30131-4","title":"Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Canadian Institutes of Health Research; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Medicine; Deep vein; Placebo; Thrombosis; Double blind; Anticoagulant therapy; Surgery; Warfarin; Randomized controlled trial; Anticoagulant; Cactus; Clinical trial; Internal medicine; Alternative medicine; Atrial fibrillation; Pathology","score_opus":0.06913215043298578,"score_gpt":0.34538233384565553,"score_spread":0.27625018341266977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554412408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9367726,0.00062567793,0.0036496536,0.03735124,0.0010669201,0.018505087,0.000008965802,0.0001983028,0.0018215533],"genre_scores_gemma":[0.9864873,0.0016642894,0.00037674906,0.0031384346,0.0009862368,0.0069056964,0.0000143381285,0.0000640217,0.00036289863],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974655,0.00027282437,0.00074312347,0.00044474387,0.00028925552,0.0007845824],"domain_scores_gemma":[0.99677813,0.0017300509,0.00035142398,0.00090677803,0.00010341477,0.00013019952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013038854,0.00035543018,0.0034562168,0.00013626312,0.00020883277,0.000039345447,0.00040406192,0.00019571849,0.00041004276],"category_scores_gemma":[0.00026808263,0.00016204281,0.00048249343,0.00012648011,0.0002179956,0.00007016865,0.000076007476,0.00014283393,0.00016033609],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96872187,0.0008836023,0.00018156428,0.00018916295,0.0015359545,0.000032235435,0.0004888744,0.0000034198051,0.0008379109,0.0122289965,0.012680355,0.0022160567],"study_design_scores_gemma":[0.989281,0.0012088317,0.00032053186,0.00016329746,0.00095812965,0.00010149295,0.000073667194,0.00022505638,0.0013076828,0.0019080392,0.0042105294,0.0002417271],"about_ca_topic_score_codex":0.000041400937,"about_ca_topic_score_gemma":0.00004805609,"teacher_disagreement_score":0.049714737,"about_ca_system_score_codex":0.000060451133,"about_ca_system_score_gemma":0.000095425385,"threshold_uncertainty_score":0.6607914},"labels":[],"label_agreement":null},{"id":"W2587788787","doi":"10.1016/s2352-3026(17)30014-5","title":"Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; McMaster University","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo","keywords":"Medicine; Rivaroxaban; Fondaparinux; Pulmonary embolism; Thrombosis; Deep vein; Surgery; Population; Internal medicine; Warfarin; Atrial fibrillation","score_opus":0.10240684985394638,"score_gpt":0.39715872318639955,"score_spread":0.2947518733324532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587788787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813799,0.00003702689,0.00016077221,0.0062949606,0.00026411872,0.007446219,0.000033695316,0.000028715096,0.0043545705],"genre_scores_gemma":[0.99795645,0.00018262473,0.00033106754,0.0004579909,0.00014470224,0.00077302346,0.000060497965,0.000032631957,0.000061010996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778575,0.00034387436,0.0006871253,0.00041169455,0.00030739052,0.0004641474],"domain_scores_gemma":[0.99674106,0.0003091654,0.00066710694,0.0020310392,0.00017334225,0.00007828419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010736596,0.00027025724,0.002210529,0.000087859196,0.00060109916,0.00011058795,0.0013818349,0.00012284286,0.00014083154],"category_scores_gemma":[0.0003482503,0.0001410835,0.00009420691,0.00018031952,0.000585254,0.00022531506,0.0005516473,0.00031431738,0.00002263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34850794,0.062538296,0.47133753,0.0014008764,0.0035273924,0.00009723248,0.009535905,0.000033408072,0.0007649622,0.049259394,0.03769516,0.015301895],"study_design_scores_gemma":[0.34210902,0.0022955087,0.65178776,0.00025625248,0.0006183837,0.000009952582,0.000150485,0.00009313907,0.00022769155,0.0010151365,0.0012444636,0.0001922294],"about_ca_topic_score_codex":0.0012208363,"about_ca_topic_score_gemma":0.0018231088,"teacher_disagreement_score":0.1804502,"about_ca_system_score_codex":0.000057736845,"about_ca_system_score_gemma":0.0002146242,"threshold_uncertainty_score":0.5753218},"labels":[],"label_agreement":null},{"id":"W2594646846","doi":"10.1016/s2352-3026(17)30019-4","title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"Gilead Sciences; Lymphoma Research Foundation","keywords":"Ofatumumab; Idelalisib; Medicine; Internal medicine; Population; IGHV@; Clinical endpoint; Chronic lymphocytic leukemia; Ibrutinib; Rituximab; Clinical trial; Oncology; Gastroenterology; Lymphoma; Leukemia","score_opus":0.09379685803426602,"score_gpt":0.4174588566744332,"score_spread":0.3236619986401672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594646846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98929584,0.0005368013,0.00015298564,0.0010938795,0.000073246454,0.0081081465,0.000016591352,0.00003067535,0.0006918124],"genre_scores_gemma":[0.9983819,0.00032286317,0.00028576303,0.00009260706,0.00012893199,0.0005162674,0.00007868112,0.000038038077,0.0001549214],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997902,0.00031586815,0.000586253,0.0004204661,0.00023776901,0.0005376393],"domain_scores_gemma":[0.99708986,0.00087701844,0.00044287572,0.0013175855,0.0001530048,0.0001196272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015840717,0.00021988679,0.0017249242,0.0001029663,0.0002464803,0.000070010574,0.0007707727,0.00019040683,0.00002600506],"category_scores_gemma":[0.0010489519,0.0001371361,0.00003404752,0.00011396311,0.0006956849,0.00021390001,0.00020650677,0.00021607925,0.0000034881075],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9847146,0.0010329195,0.00013036288,0.0008155611,0.00022012412,0.00022377302,0.0006057353,0.000023567405,0.001168962,0.004400827,0.0004072657,0.006256248],"study_design_scores_gemma":[0.964321,0.007899914,0.00021598663,0.0004023568,0.00026166145,0.0008493622,0.00003370324,0.023043197,0.0021530797,0.00043744236,0.00023689336,0.000145382],"about_ca_topic_score_codex":0.0010739255,"about_ca_topic_score_gemma":0.0006607085,"teacher_disagreement_score":0.023019629,"about_ca_system_score_codex":0.0044361935,"about_ca_system_score_gemma":0.0060141324,"threshold_uncertainty_score":0.99962085},"labels":[],"label_agreement":null},{"id":"W2595724571","doi":"10.1016/s2352-3026(17)30042-x","title":"Anti-thymocyte globulin dosing—per kg or per lymphocyte?","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Thymoglobulin; Anti-thymocyte globulin; Medicine; Transplantation; Graft-versus-host disease; Internal medicine; Dosing; Globulin; Randomized controlled trial; Immunology; Gastroenterology; Tacrolimus","score_opus":0.06145293338250934,"score_gpt":0.34101584162831067,"score_spread":0.2795629082458013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595724571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95026505,0.00072979496,0.0010592666,0.019616213,0.0007579702,0.00056059443,0.000017712064,0.00016575003,0.026827645],"genre_scores_gemma":[0.99296546,0.0007419444,0.0018434362,0.0022282586,0.0004973005,0.00003581162,0.000018769075,0.000039639985,0.0016294023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837106,0.0001483352,0.00036080828,0.00034051776,0.0002514992,0.0005277825],"domain_scores_gemma":[0.9978777,0.00027100305,0.00021331935,0.001447054,0.00007879448,0.00011210746],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055329007,0.00022529729,0.001133388,0.000051369887,0.00042756848,0.00006443243,0.00052462245,0.00020572645,0.0008816962],"category_scores_gemma":[0.00020574045,0.00013111136,0.00010267296,0.000047007477,0.00041474873,0.00009265578,0.000079020785,0.00022352891,0.0015862399],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015317692,0.0012272076,0.67659086,0.009512113,0.0018871699,0.021028131,0.018673176,0.000067128094,0.09786093,0.06708953,0.061065305,0.029680783],"study_design_scores_gemma":[0.03529402,0.0006892565,0.5196748,0.0019822968,0.002029076,0.08102171,0.0010240871,0.001470897,0.1399129,0.002494868,0.21282098,0.0015851264],"about_ca_topic_score_codex":0.00011048284,"about_ca_topic_score_gemma":0.00006603442,"teacher_disagreement_score":0.15691607,"about_ca_system_score_codex":0.000055938046,"about_ca_system_score_gemma":0.00018099269,"threshold_uncertainty_score":0.99919116},"labels":[],"label_agreement":null},{"id":"W2606110123","doi":"10.1016/s2352-3026(17)30052-2","title":"Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Centers for Disease Control and Prevention; Partenariat Canadien Contre Le Cancer; Swiss Re; World Health Organization; Swiss Cancer Research Foundation; Cancer Institute NSW; Cancer Research UK","keywords":"Medicine; Pediatrics; Demography; Childhood leukaemia; Population; Environmental health","score_opus":0.0781453487170645,"score_gpt":0.3765434257869886,"score_spread":0.29839807706992405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606110123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847814,0.00065713236,0.0003106556,0.0019270363,0.00011260417,0.0020087063,0.010147495,0.000023350438,0.00003163859],"genre_scores_gemma":[0.992602,0.000023444514,0.0010409979,0.00013764742,0.0001905178,0.000088619665,0.0058458974,0.000033595403,0.000037274054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977987,0.00018865691,0.0007007034,0.0005088753,0.000403233,0.00039987732],"domain_scores_gemma":[0.9943679,0.002897717,0.0007037685,0.0018684719,0.00009235287,0.00006980721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074261724,0.0002307653,0.0019234247,0.0000994551,0.00020800826,0.000050333394,0.0012455469,0.00017661946,0.000015650216],"category_scores_gemma":[0.00162465,0.00017387523,0.000045060086,0.000085943626,0.00046138308,0.000105553634,0.0004155436,0.00025680548,9.74797e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018212628,0.00038271988,0.98328596,0.000116243755,0.0003717563,0.000014481649,0.0013014532,0.0000096498125,0.0000356281,0.00015361361,0.012101686,0.00040556194],"study_design_scores_gemma":[0.019149458,0.0005012041,0.9756145,0.0001576055,0.00042556564,0.000009137763,0.0008257395,0.0011665215,0.00061309896,0.00093394844,0.00043609706,0.00016711895],"about_ca_topic_score_codex":0.020865526,"about_ca_topic_score_gemma":0.015115221,"teacher_disagreement_score":0.017328195,"about_ca_system_score_codex":0.00006904175,"about_ca_system_score_gemma":0.00034322307,"threshold_uncertainty_score":0.9856546},"labels":[],"label_agreement":null},{"id":"W2611645469","doi":"10.1016/s2352-3026(17)30078-9","title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"European Commission; F. Hoffmann-La Roche","keywords":"Medicine; Rituximab; Follicular lymphoma; Vincristine; Internal medicine; Prednisone; International Prognostic Index; Clinical endpoint; Surgery; Cyclophosphamide; Lymphoma; Oncology; Chemotherapy; Randomized controlled trial","score_opus":0.09747788966554995,"score_gpt":0.3848782168562778,"score_spread":0.2874003271907279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611645469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98584074,0.0027343002,0.00007051475,0.0043284097,0.00037871918,0.005907883,0.00019739932,0.000023887822,0.0005181235],"genre_scores_gemma":[0.99534345,0.0027794803,0.00080248486,0.00006072934,0.00022968506,0.0006169652,0.00006754973,0.000029732766,0.00006990601],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982826,0.000104715014,0.0006384521,0.00039771592,0.00016119394,0.00041533133],"domain_scores_gemma":[0.996672,0.001267988,0.000607769,0.0012240678,0.00011149777,0.00011669394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030330417,0.00031025155,0.0028521772,0.000053627136,0.00036677756,0.000038955975,0.00041631013,0.00015417078,0.000028701577],"category_scores_gemma":[0.0004015086,0.00019115675,0.00017527299,0.000046636378,0.00046942427,0.000054332955,0.0001426173,0.000039472725,0.0000076116285],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9021352,0.023858728,0.00017677358,0.00027773442,0.0014056563,0.0011020876,0.0005365448,0.0000015016478,0.000101488215,0.0035326749,0.00017836875,0.06669322],"study_design_scores_gemma":[0.96017516,0.024649078,0.00031515077,0.00014569193,0.0018767794,0.0017069663,0.00003092737,0.00018111493,0.0051067844,0.00033819367,0.0053130314,0.00016114365],"about_ca_topic_score_codex":0.00039012326,"about_ca_topic_score_gemma":0.00015617507,"teacher_disagreement_score":0.066532075,"about_ca_system_score_codex":0.00015648079,"about_ca_system_score_gemma":0.00021796825,"threshold_uncertainty_score":0.7795146},"labels":[],"label_agreement":null},{"id":"W2620735312","doi":"10.1016/s2352-3026(17)30079-0","title":"Subcutaneous rituximab—a meaningful advance in care","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Rituximab; Follicular lymphoma; CD20; Lymphoma; Internal medicine; Oncology","score_opus":0.031390697028140034,"score_gpt":0.3347144156308049,"score_spread":0.3033237186026649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620735312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95721525,0.002751225,0.0000029988255,0.012494483,0.00021765429,0.00027880073,0.0000071071886,0.00004055695,0.026991941],"genre_scores_gemma":[0.9981073,0.00036632866,0.00033563637,0.000819025,0.00013822394,0.00005729479,0.000007977198,0.000012385437,0.00015580523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992081,0.000040118524,0.00015188084,0.00020541236,0.00008156795,0.00031295212],"domain_scores_gemma":[0.99875766,0.000094321134,0.00010354935,0.00096193247,0.0000369916,0.000045542085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007904527,0.00012024893,0.00070237514,0.000028045704,0.00018184181,0.00002211793,0.00026394174,0.000070422444,0.000052024432],"category_scores_gemma":[0.00012927146,0.00007371531,0.000054994118,0.000026916805,0.00015902263,0.000048565686,0.00008579882,0.000118239994,0.00021268181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007563279,0.00042131206,0.9125187,0.0002820607,0.00008589057,0.019564051,0.0035492245,0.0000078734365,0.000083243816,0.04414778,0.0017967945,0.016786786],"study_design_scores_gemma":[0.03400969,0.0010688518,0.8209107,0.0008312914,0.0004208474,0.03393999,0.0016652313,0.00018201067,0.0076654768,0.008839169,0.08983455,0.0006321979],"about_ca_topic_score_codex":0.00022233947,"about_ca_topic_score_gemma":0.0008357824,"teacher_disagreement_score":0.09160796,"about_ca_system_score_codex":0.00010361492,"about_ca_system_score_gemma":0.00006529781,"threshold_uncertainty_score":0.30060232},"labels":[],"label_agreement":null},{"id":"W2620858201","doi":"10.1016/s2352-3026(17)30086-8","title":"Evaluation of direct oral anticoagulants in superficial-vein thrombosis – Authors' reply","year":2017,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"","keywords":"Medicine; Rivaroxaban; Fondaparinux; Thrombosis; Deep vein; Pulmonary embolism; Surgery; Warfarin; Internal medicine; Atrial fibrillation; Venous thromboembolism","score_opus":0.15771978270394627,"score_gpt":0.3941540336071454,"score_spread":0.23643425090319914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620858201","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28268957,0.0010009984,0.0000047643434,0.6926612,0.0012964807,0.0017587449,0.000049371105,0.000065745,0.020473076],"genre_scores_gemma":[0.7765511,0.000904664,0.00014613653,0.21866056,0.0025673977,0.00027192023,0.000286189,0.00009411347,0.00051788695],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959797,0.0011111482,0.0006764013,0.00055998797,0.0010250589,0.00064766227],"domain_scores_gemma":[0.99688846,0.00024508353,0.00056654523,0.0019536803,0.00030797327,0.000038275004],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004572652,0.00035361934,0.003930036,0.0002761713,0.000117751275,0.000031597745,0.00065920746,0.00061599317,0.00032461804],"category_scores_gemma":[0.0010473696,0.00024532902,0.0001983738,0.0001413762,0.0003270258,0.000058322075,0.00021050968,0.0010815755,0.00007805088],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034246284,0.00020916159,0.008269064,0.0007574066,0.0005313989,0.0005172882,0.00048587032,0.000009044506,0.00005416211,0.00030819228,0.9873472,0.0014769892],"study_design_scores_gemma":[0.0067986813,0.0006950163,0.33278993,0.0033169023,0.011982326,0.00062141876,0.00018495199,0.0013010532,0.0014251583,0.00756875,0.6322508,0.0010649953],"about_ca_topic_score_codex":0.0015962201,"about_ca_topic_score_gemma":0.00050691754,"teacher_disagreement_score":0.49386156,"about_ca_system_score_codex":0.00013121072,"about_ca_system_score_gemma":0.00028544632,"threshold_uncertainty_score":0.9999999},"labels":[],"label_agreement":null},{"id":"W2759462495","doi":"10.1016/s2352-3026(17)30168-0","title":"Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Celgene","keywords":"Medicine; Lenalidomide; Placebo; Maintenance therapy; Chronic lymphocytic leukemia; Internal medicine; Oncology; Physical therapy; Multiple myeloma; Leukemia; Chemotherapy; Alternative medicine; Pathology","score_opus":0.09344758497031419,"score_gpt":0.39512861509315317,"score_spread":0.301681030122839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759462495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714752,0.00361912,0.00005691914,0.003977781,0.0005034528,0.012943684,0.000008073845,0.00014906462,0.007266731],"genre_scores_gemma":[0.9874634,0.0029808658,0.00004990174,0.0005961367,0.0014941369,0.0033409519,0.000027946173,0.00009470862,0.0039519244],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947338,0.00071733416,0.0012828078,0.00086888304,0.0005754093,0.0018217574],"domain_scores_gemma":[0.99435705,0.001315121,0.00081358536,0.0030407761,0.00019585158,0.00027758785],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034343018,0.00059656246,0.0041690096,0.00026036706,0.00045784347,0.00019366694,0.001562489,0.00044896966,0.0003504171],"category_scores_gemma":[0.0015647566,0.00035808826,0.00054022484,0.00023032686,0.0010865226,0.00021064456,0.00025914254,0.0008241406,0.00030805997],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.98759323,0.0002826446,0.00016812762,0.0002142183,0.0005019492,0.0027946255,0.00039126727,0.00003393973,0.00063362974,0.00062695565,0.004297188,0.0024622178],"study_design_scores_gemma":[0.9795233,0.0014898514,0.000025560368,0.0004200694,0.00025872883,0.0033305902,0.00004349849,0.008004277,0.0034322713,0.0003570378,0.0027656995,0.00034909355],"about_ca_topic_score_codex":0.0027595689,"about_ca_topic_score_gemma":0.0022887513,"teacher_disagreement_score":0.015988255,"about_ca_system_score_codex":0.014009917,"about_ca_system_score_gemma":0.011847749,"threshold_uncertainty_score":0.9998871},"labels":[],"label_agreement":null},{"id":"W2763497846","doi":"10.1016/s2352-3026(17)30169-2","title":"Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood transfusion and management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Impact; Population Health Research Institute; Canadian Blood Services; McMaster University; University of Waterloo","funders":"Health Canada","keywords":"Medicine; ABO blood group system; Randomized controlled trial; Blood transfusion; Red blood cell; Relative risk; Emergency medicine; Anemia; Pediatrics; Surgery; Internal medicine; Confidence interval","score_opus":0.01867941203148179,"score_gpt":0.28309712518680114,"score_spread":0.26441771315531937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763497846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97205377,0.00015187613,0.0000111034915,0.008328873,0.0002545634,0.002535478,0.0000065339414,0.000013308602,0.016644526],"genre_scores_gemma":[0.9986948,0.00017968894,0.000024547857,0.0006068648,0.000051148567,0.00012121611,0.000003884775,0.000006233631,0.0003116142],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989779,0.00012129104,0.00040624817,0.00015319702,0.0001554958,0.00018586499],"domain_scores_gemma":[0.9985322,0.00015034196,0.0003253466,0.0009217669,0.000032708638,0.00003766654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007316938,0.00011341483,0.0016252013,0.000099982186,0.0001211236,0.000017593371,0.0002861946,0.00007978167,0.00010518457],"category_scores_gemma":[0.0001937701,0.000057137677,0.00024891138,0.00011667085,0.00025278467,0.000038482005,0.00011336755,0.0002109655,0.0000011700083],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8284147,0.0026025646,0.13244396,0.0009598265,0.016344413,0.0006328695,0.0056798807,0.000036057972,0.001269788,0.0073321993,0.0031620828,0.0011216844],"study_design_scores_gemma":[0.8760694,0.00020056107,0.114822015,0.000024501987,0.0072212867,0.000014346902,0.00015223672,0.00036767422,0.00037784895,0.00019440614,0.00047580324,0.00007990244],"about_ca_topic_score_codex":0.00011381887,"about_ca_topic_score_gemma":0.00053101603,"teacher_disagreement_score":0.047654748,"about_ca_system_score_codex":0.0000051382276,"about_ca_system_score_gemma":0.0000483584,"threshold_uncertainty_score":0.23300068},"labels":[],"label_agreement":null},{"id":"W2770267496","doi":"10.1016/s2352-3026(17)30210-7","title":"Pulmonary embolism rule-out criteria (PERC) rule in European patients with low implicit clinical probability (PERCEPIC): a multicentre, prospective, observational study","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Pulmonary embolism; Clinical prediction rule; Observational study; Emergency department; Clinical endpoint; Prospective cohort study; Population; Emergency medicine; Pre- and post-test probability; Pediatrics; Clinical trial; Intensive care medicine; Internal medicine","score_opus":0.10146699731447746,"score_gpt":0.37991003006226565,"score_spread":0.2784430327477882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770267496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852706,0.00002837992,0.000012352059,0.0040021944,0.0003807577,0.003431691,0.000020052266,0.000078876714,0.0067750835],"genre_scores_gemma":[0.9972446,0.000040094073,0.0005602297,0.0013694952,0.00035055017,0.00025174007,0.000043015873,0.000044017346,0.000096261545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970734,0.0006170506,0.00071947975,0.0006912261,0.00032897657,0.0005698272],"domain_scores_gemma":[0.99751806,0.00017352805,0.00034046514,0.0016388929,0.00020666572,0.00012236551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013349596,0.00029056985,0.001536771,0.0000586942,0.00036133573,0.00009553172,0.0006657422,0.00009098738,0.00012861253],"category_scores_gemma":[0.00056174444,0.00018385841,0.00009855148,0.00007307968,0.0003931103,0.00021140237,0.0004953535,0.00043597995,0.00014375563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056580006,0.0063500563,0.9878255,0.00016876313,0.00013696481,0.00035567812,0.0014271284,0.0000032586652,0.000012404246,0.00065068656,0.0006704271,0.0018333308],"study_design_scores_gemma":[0.0062567242,0.0003510825,0.9910215,0.00014923389,0.00017458924,0.000036776793,0.00029655106,0.00008285348,0.0000045865777,0.0010955457,0.00032670485,0.00020383933],"about_ca_topic_score_codex":0.00022725256,"about_ca_topic_score_gemma":0.00031322835,"teacher_disagreement_score":0.011973984,"about_ca_system_score_codex":0.00007940766,"about_ca_system_score_gemma":0.00006516513,"threshold_uncertainty_score":0.7497528},"labels":[],"label_agreement":null},{"id":"W2778275419","doi":"10.1016/s2352-3026(17)30237-5","title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":315,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Clinical endpoint; Anemia; Clinical trial; Phases of clinical research; Intention-to-treat analysis; Janus kinase inhibitor; Surgery; Gastroenterology; Janus kinase; Bone marrow","score_opus":0.11587736312776528,"score_gpt":0.37323862342992187,"score_spread":0.25736126030215656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778275419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98164046,0.00022767656,0.0000030974804,0.0027760305,0.0001401348,0.007576644,0.00005878023,0.000050320366,0.0075268866],"genre_scores_gemma":[0.99530834,0.00051660504,0.00045868338,0.0004949636,0.00017317479,0.0022249243,0.00014138708,0.00006411266,0.00061781396],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975234,0.00028801264,0.0004987899,0.0006243167,0.0003133896,0.0007520874],"domain_scores_gemma":[0.99712545,0.0005358399,0.00050980545,0.0014536178,0.00019550262,0.00017980824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043082674,0.0004489796,0.0021524713,0.00008905321,0.00048449228,0.0001917005,0.0006410302,0.00015622978,0.00038151184],"category_scores_gemma":[0.00023348155,0.00022609605,0.000059116173,0.00014588771,0.00039025542,0.00021293745,0.00013567969,0.00030404225,0.00016481214],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75083715,0.0049989442,0.23706076,0.000049909737,0.0005355105,0.00025151923,0.00026168133,7.783832e-7,0.0000120629475,0.00047230686,0.0021327322,0.0033866293],"study_design_scores_gemma":[0.9516559,0.02521544,0.017717531,0.0003481806,0.0003646058,0.000065446315,0.00004172769,0.000019104984,0.001236718,0.000030849013,0.0030071547,0.0002973058],"about_ca_topic_score_codex":0.00041187144,"about_ca_topic_score_gemma":0.00038010103,"teacher_disagreement_score":0.21934323,"about_ca_system_score_codex":0.00009810919,"about_ca_system_score_gemma":0.00024208766,"threshold_uncertainty_score":0.9219929},"labels":[],"label_agreement":null},{"id":"W2796060639","doi":"10.1016/s2352-3026(18)30033-4","title":"Defining clinically relevant measures of iron overload around haemopoietic stem cell transplantation","year":2018,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital","funders":"","keywords":"Transferrin; Medicine; Myelodysplastic syndromes; Transferrin saturation; Thalassemia; Transplantation; Hepcidin; Internal medicine; Anemia; Immunology; Bone marrow; Iron deficiency","score_opus":0.032589941141006724,"score_gpt":0.2934212889216883,"score_spread":0.26083134778068157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796060639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97691256,0.0025572586,0.0007084004,0.004141114,0.0003407473,0.0002667293,0.000009018933,0.00006474162,0.014999409],"genre_scores_gemma":[0.99584746,0.0023167934,0.0005657367,0.0009570428,0.00011684985,0.000006883185,0.000008872815,0.00001912108,0.00016123531],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985821,0.00017274724,0.00051654817,0.00021197225,0.00019785247,0.00031875464],"domain_scores_gemma":[0.9989427,0.00028472205,0.00021235102,0.00040278587,0.00009723475,0.000060207167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000552837,0.00013580445,0.00073058234,0.00004835359,0.00009634295,0.000006176789,0.00016223075,0.00021673355,0.00004076708],"category_scores_gemma":[0.000056365352,0.00008479336,0.000097568794,0.00013304802,0.00046594447,0.000031139785,0.000022380958,0.00030161152,0.0001479573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03306868,0.002854636,0.4832724,0.016165333,0.0013678956,0.003309374,0.07287794,0.00044619516,0.067275405,0.09109471,0.03888284,0.18938458],"study_design_scores_gemma":[0.123751014,0.033969313,0.30313164,0.013418586,0.015336394,0.053970523,0.050048076,0.0118712755,0.26530036,0.04788936,0.07572764,0.0055858055],"about_ca_topic_score_codex":0.00004470373,"about_ca_topic_score_gemma":0.000028599612,"teacher_disagreement_score":0.19802496,"about_ca_system_score_codex":0.00001479396,"about_ca_system_score_gemma":0.00008732703,"threshold_uncertainty_score":0.3457773},"labels":[],"label_agreement":null},{"id":"W2799781194","doi":"10.1016/s2352-3026(18)30048-6","title":"Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort","year":2018,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Children's Hospital of Eastern Ontario; McMaster Children's Hospital; McMaster University; Laurentian University; Thunder Bay Regional Health Sciences Centre; Hôpital de l'Enfant-Jésus; University of Manitoba; Izaak Walton Killam Health Centre; Alberta Children's Hospital; Hospital for Sick Children; University of Saskatchewan; Dalhousie University; British Columbia Children's Hospital; Centre Hospitalier Universitaire Sainte-Justine; Public Health Ontario; University of Ottawa; Institute for Clinical Evaluative Sciences; SickKids Foundation; University of Toronto","funders":"Baxalta; Medical Research Council Canada; CSL Behring","keywords":"Medicine; Haemophilia; Clotting factor; Haemophilia A; Hemarthrosis; Cohort; Pediatrics; Clinical endpoint; Physical therapy; Clinical trial; Surgery; Internal medicine","score_opus":0.04112767167180755,"score_gpt":0.30516733662658213,"score_spread":0.2640396649547746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799781194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733004,0.00015697943,0.0000042731376,0.0116786035,0.00045678864,0.0060066613,0.00019791922,0.00006909045,0.008129264],"genre_scores_gemma":[0.9960537,0.000020885866,0.0002723094,0.0003081457,0.0006178218,0.00028706313,0.00008752178,0.000052695734,0.0022998897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663395,0.00038750458,0.0006998428,0.00069108343,0.0005843821,0.0010032218],"domain_scores_gemma":[0.9967592,0.0002713229,0.00023616327,0.0017589882,0.000701505,0.00027283057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012434542,0.00035836385,0.0013927917,0.00020830281,0.00053716276,0.000024342093,0.0007996278,0.00032882256,0.00012681457],"category_scores_gemma":[0.00083728496,0.00018549821,0.00022451761,0.00079353654,0.0012526909,0.000065321125,0.00018956963,0.0006032391,0.00009768955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034019048,0.00057132076,0.97629076,0.00045367324,0.0007030094,0.0002700104,0.0011323257,8.733429e-7,0.0009821837,0.0008410881,0.014210602,0.0011422646],"study_design_scores_gemma":[0.010305004,0.0073128953,0.9699012,0.00020612043,0.00045678165,0.0010425332,0.00044489303,0.000037908685,0.0046636946,0.0037579474,0.0014922818,0.000378746],"about_ca_topic_score_codex":0.01231073,"about_ca_topic_score_gemma":0.03150915,"teacher_disagreement_score":0.022753246,"about_ca_system_score_codex":0.00037044927,"about_ca_system_score_gemma":0.0010920329,"threshold_uncertainty_score":0.9942664},"labels":[],"label_agreement":null},{"id":"W2807247022","doi":"10.1016/s2352-3026(18)30069-3","title":"Venous thromboembolism after induced abortion: a population-based, propensity-score-matched cohort study in Canada","year":2018,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Public Health Ontario; Manitoba Health; University of Manitoba; Mount Sinai Hospital; Institute for Clinical Evaluative Sciences; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Propensity score matching; Venous thromboembolism; Abortion; Cohort study; Cohort; Obstetrics; Population; Internal medicine; Pregnancy; Thrombosis; Environmental health","score_opus":0.054458499810033645,"score_gpt":0.2942833932425204,"score_spread":0.23982489343248675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807247022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946263,0.000026571988,0.00003801373,0.0028900842,0.0004921624,0.0014597741,0.0000036854951,0.00005970665,0.00040370907],"genre_scores_gemma":[0.9953528,0.0000015406929,0.000086853666,0.0040595937,0.00025716476,0.00017780832,0.000019167273,0.000024252191,0.000020815563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983555,0.00022897022,0.00039753338,0.0003224273,0.00032600373,0.0003695625],"domain_scores_gemma":[0.99890906,0.000060726612,0.00013718846,0.00067538046,0.00013708386,0.00008056228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039208797,0.00018056254,0.0012486099,0.00008032929,0.00012325551,0.000010650215,0.00016687601,0.00009276387,0.00032840707],"category_scores_gemma":[0.00005977996,0.00012744765,0.000035463556,0.00031434622,0.00006267752,0.00004201998,0.000052537664,0.0002658859,0.00005532716],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021478374,0.00027177072,0.9977511,0.000033586864,0.000066237386,0.00030136658,0.00047496145,0.00000486329,0.00014322986,0.00053567725,0.00013406781,0.00006832803],"study_design_scores_gemma":[0.0017812875,0.00027565792,0.99581367,0.00004942878,0.00013218491,0.00021492004,0.0001450662,0.00018410185,0.00077842403,0.00045781737,0.000029078588,0.00013838138],"about_ca_topic_score_codex":0.43619877,"about_ca_topic_score_gemma":0.8617608,"teacher_disagreement_score":0.42556202,"about_ca_system_score_codex":0.00019684537,"about_ca_system_score_gemma":0.00078658614,"threshold_uncertainty_score":0.5675556},"labels":[],"label_agreement":null},{"id":"W2808391935","doi":"10.1016/s2352-3026(18)30051-6","title":"Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies","year":2018,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Research England; U.S. Food and Drug Administration; Aalborg Universitetshospital; Astellas Pharma; Eisai; Aalborg Universitet; Genentech; Celgene; Gilead Sciences; National Institutes of Health; Laura and John Arnold Foundation; Pfizer","keywords":"Medicine; Adverse effect; Intensive care medicine; Context (archaeology); Clinical trial; Multiple myeloma; Cancer; Population; Hematology; Disease; Transplantation; Internal medicine; Oncology","score_opus":0.16852219324577863,"score_gpt":0.42282099634139564,"score_spread":0.25429880309561703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808391935","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058020327,0.9371599,0.000053122847,0.0011894613,0.00028602305,0.0020509928,0.000019790492,0.00005319881,0.0011672068],"genre_scores_gemma":[0.026697075,0.9708965,0.001513278,0.0002063625,0.0001908155,0.00025221668,0.0000624507,0.000060006383,0.00012131692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953092,0.00068018923,0.0024466184,0.00058603496,0.0003521642,0.0006258141],"domain_scores_gemma":[0.9946544,0.0007724823,0.0032211242,0.001210948,0.000069797694,0.000071216135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019816284,0.0005025891,0.006043126,0.0001402292,0.00013135026,0.0000041246212,0.0004308834,0.00044405274,0.00004111211],"category_scores_gemma":[0.0006248928,0.0002362351,0.00036327288,0.0002722048,0.000651083,0.000041757332,0.00041810042,0.0008156793,0.000018314711],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006136363,0.0022094585,0.28678215,0.2834639,0.006783833,0.025262618,0.00539502,0.000020646812,0.000023504304,0.043758202,0.0070544844,0.33863255],"study_design_scores_gemma":[0.017209368,0.0014322564,0.037238114,0.1476223,0.017118966,0.30290806,0.0015266046,0.0010011243,0.00007572479,0.05654297,0.41457486,0.0027496496],"about_ca_topic_score_codex":0.000063366104,"about_ca_topic_score_gemma":0.00005291597,"teacher_disagreement_score":0.40752035,"about_ca_system_score_codex":0.00039781688,"about_ca_system_score_gemma":0.00074394414,"threshold_uncertainty_score":0.96333873},"labels":[],"label_agreement":null},{"id":"W2811238399","doi":"10.1016/s2352-3026(18)30093-0","title":"Rituximab as a first step in tackling transformation","year":2018,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Cancer Research UK; European Hematology Association","keywords":"Follicular lymphoma; Medicine; Lymphoma; Population; Rituximab; Biopsy; Internal medicine","score_opus":0.029958309741099653,"score_gpt":0.29690645844765395,"score_spread":0.2669481487065543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811238399","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.063058175,0.0008217366,0.000020857653,0.921368,0.0003748813,0.0007874872,0.000025116251,0.0000735755,0.013470154],"genre_scores_gemma":[0.17171499,0.00073298754,0.00031208122,0.8214969,0.0040539205,0.000429114,0.00052575336,0.000059322767,0.00067491195],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985034,0.000111267815,0.00038996042,0.00028767044,0.00021554988,0.00049216236],"domain_scores_gemma":[0.9989426,0.00026069893,0.00014147337,0.00057680364,0.000047064943,0.000031347907],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002021196,0.00026867955,0.0014654318,0.00013306031,0.0000842839,0.000021152782,0.0002095889,0.0005886152,0.00027850957],"category_scores_gemma":[0.00004842394,0.00016472716,0.00013243608,0.00012618123,0.00014671347,0.000043744123,0.000032127275,0.00064905116,0.0012662299],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017218819,0.00018512145,0.0033157254,0.00086786406,0.00014564056,0.0044407235,0.0014618671,5.5618784e-7,9.178273e-7,0.0008226843,0.9878095,0.00077723165],"study_design_scores_gemma":[0.0066991053,0.00022732538,0.0014816977,0.000616265,0.00026920286,0.0044071893,0.000043657794,0.00007965468,0.00014814832,0.0007836681,0.9850606,0.0001834884],"about_ca_topic_score_codex":0.00033256534,"about_ca_topic_score_gemma":0.00031343222,"teacher_disagreement_score":0.10865681,"about_ca_system_score_codex":0.00021388607,"about_ca_system_score_gemma":0.00014763423,"threshold_uncertainty_score":0.9995114},"labels":[],"label_agreement":null},{"id":"W2890868314","doi":"10.1016/s2352-3026(18)30137-6","title":"Splanchnic vein thrombosis: what are the long-term risks?","year":2018,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Liver Disease and Transplantation","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; McMaster University","funders":"","keywords":"Medicine; Thrombosis; Population; Portal vein thrombosis; Internal medicine; Splanchnic; Incidence (geometry); Surgery; Radiology; Hemodynamics","score_opus":0.09497659565922568,"score_gpt":0.3454642917907541,"score_spread":0.25048769613152844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890868314","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17299296,0.005598353,0.000036936737,0.8176436,0.0016175506,0.00088163296,0.00010689313,0.00016156357,0.00096054486],"genre_scores_gemma":[0.25698036,0.00830874,0.000014983188,0.7201255,0.012778919,0.0001592154,0.0011129251,0.00007754397,0.00044183407],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9978835,0.00037749903,0.0003310974,0.00043784105,0.0003611897,0.00060885673],"domain_scores_gemma":[0.99783754,0.0003754142,0.00032057843,0.001322907,0.000089902285,0.00005365665],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002615994,0.00036872947,0.0012755471,0.000077281766,0.00020637547,0.00009889064,0.0006402388,0.00064605917,0.00040260566],"category_scores_gemma":[0.000013678489,0.00018803339,0.00021724703,0.00013207842,0.0005261646,0.00012418485,0.00006844263,0.0015398833,0.0013079237],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026958587,0.000038838683,0.041533753,0.0020096763,0.0011302745,0.003788832,0.0007679377,2.236573e-7,0.000008732941,0.00013132737,0.9502136,0.00010719287],"study_design_scores_gemma":[0.007026335,0.0007066992,0.740839,0.009796634,0.021019591,0.016199766,0.0007747258,0.000025095362,0.00091451633,0.0042112605,0.19701585,0.0014705372],"about_ca_topic_score_codex":0.000036192047,"about_ca_topic_score_gemma":0.000064773565,"teacher_disagreement_score":0.7531978,"about_ca_system_score_codex":0.00003809716,"about_ca_system_score_gemma":0.00009569548,"threshold_uncertainty_score":0.9994697},"labels":[],"label_agreement":null},{"id":"W2911409482","doi":"10.1016/s2352-3026(18)30224-2","title":"Outcomes and risk factors of massive and submassive pulmonary embolism in children: a retrospective cohort study","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Children's Hospital of Eastern Ontario; Hospital for Sick Children","funders":"","keywords":"Medicine; Pulmonary embolism; Retrospective cohort study; Internal medicine; Pediatrics","score_opus":0.014408017769814511,"score_gpt":0.2722228802423039,"score_spread":0.2578148624724894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911409482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99731183,0.00013624194,0.0000063613074,0.00063421886,0.000086214925,0.0013321817,0.000015532209,0.000023072273,0.00045433672],"genre_scores_gemma":[0.99960065,0.00014822022,0.000035573572,0.000106105465,0.00001889706,0.000022289969,0.0000062919376,0.000012587977,0.000049369046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989916,0.00017697034,0.00023471365,0.0002652501,0.00014573449,0.00018574261],"domain_scores_gemma":[0.9992713,0.00013066723,0.00018431095,0.00032792048,0.000043043463,0.000042759515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027658755,0.00014146633,0.001228287,0.000096261014,0.000038143993,0.000005226493,0.00007563819,0.00009066381,0.000047553967],"category_scores_gemma":[0.000085133135,0.000087347755,0.00003410753,0.00011803365,0.00011808409,0.00003827177,0.00008887612,0.00023738452,0.0000052163537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006545096,0.00015090151,0.99309856,0.000019466563,0.00024497256,0.000015143649,0.0011393899,9.465326e-7,0.00010892378,0.0050996924,0.000007638281,0.000048907776],"study_design_scores_gemma":[0.0021381506,0.00023892797,0.99354976,0.000020113737,0.00020261407,0.00012803805,0.0011818499,0.00007299082,0.00028914935,0.0020943831,0.0000015230906,0.000082497216],"about_ca_topic_score_codex":0.00032996893,"about_ca_topic_score_gemma":0.000053447344,"teacher_disagreement_score":0.003005309,"about_ca_system_score_codex":0.000016210503,"about_ca_system_score_gemma":0.00001658592,"threshold_uncertainty_score":0.3561938},"labels":[],"label_agreement":null},{"id":"W2914073197","doi":"10.1016/s2352-3026(19)30010-9","title":"Eltrombopag use in higher risk myeloid cancers: fitting a square “pag” into a round hole?","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Eltrombopag; Thrombopoietin; Medicine; Thrombopoietin receptor; Myeloid; Lenalidomide; Myelodysplastic syndromes; Internal medicine; Cancer research; Pharmacology; Haematopoiesis; Bone marrow; Immunology; Platelet; Stem cell; Biology; Cell biology; Multiple myeloma","score_opus":0.0568963901246791,"score_gpt":0.32652688668588453,"score_spread":0.2696304965612054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914073197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98154914,0.000725251,0.000033504,0.012844999,0.00035779495,0.0009312503,0.000015733269,0.00012363405,0.0034186912],"genre_scores_gemma":[0.9924672,0.00031927731,0.001069217,0.0025892453,0.00046797236,0.000112135785,0.000025730955,0.000061153405,0.0028880364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723047,0.00047437343,0.00045109805,0.0005372935,0.00035673875,0.00095],"domain_scores_gemma":[0.9974852,0.0008619103,0.00019826711,0.0012087215,0.000111614354,0.00013426482],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092455646,0.00027413,0.0013475806,0.00021471722,0.0001067776,0.000051972773,0.00050155073,0.00026561858,0.00078969967],"category_scores_gemma":[0.0005123482,0.0001883501,0.0001110794,0.00054035545,0.0002502939,0.00019550315,0.00027728322,0.001347122,0.0010102581],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014464542,0.00009174811,0.9677847,0.0006549932,0.00020407367,0.0010956354,0.0031229588,0.00017651138,0.002998567,0.0045438595,0.015812915,0.0020675769],"study_design_scores_gemma":[0.023576645,0.0011419138,0.8637417,0.0013313302,0.00033576987,0.0023578594,0.0032509472,0.0068198857,0.0023473606,0.0051690936,0.08880388,0.001123616],"about_ca_topic_score_codex":0.0057079718,"about_ca_topic_score_gemma":0.0017903295,"teacher_disagreement_score":0.10404301,"about_ca_system_score_codex":0.0007745048,"about_ca_system_score_gemma":0.0004120179,"threshold_uncertainty_score":0.99976754},"labels":[],"label_agreement":null},{"id":"W2934686121","doi":"10.1016/s2352-3026(19)30026-2","title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; BC Cancer Agency","funders":"Celgene; MorphoSys; Servier; Innovative Research Group Project of the National Natural Science Foundation of China; F. Hoffmann-La Roche; Genentech; AstraZeneca; Gilead Sciences; TG Therapeutics; Pfizer; Takeda Oncology; Amgen","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Rituximab; Refractory (planetary science); Lymphoma; Oncology; Phases of clinical research; Hodgkin lymphoma; Clinical trial","score_opus":0.029094146801748787,"score_gpt":0.30191791391980216,"score_spread":0.2728237671180534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2934686121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926148,0.00022307591,0.00000701686,0.0011479536,0.0003876488,0.004617763,0.00018640021,0.000107466396,0.0007078977],"genre_scores_gemma":[0.9973262,0.000042846703,0.000408879,0.00066970196,0.0001529421,0.00037377194,0.0003620755,0.00007091062,0.00059265195],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99615055,0.00054377294,0.0009886759,0.00093994796,0.0005561568,0.00082087755],"domain_scores_gemma":[0.99618495,0.001457421,0.0005147507,0.0015345146,0.00013423226,0.00017412801],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005114908,0.0005550603,0.0027653803,0.00020572437,0.00014783046,0.00003932495,0.0004476885,0.00025922304,0.00031395012],"category_scores_gemma":[0.0005014762,0.0002833656,0.00013701536,0.00044011208,0.0001663162,0.00012827465,0.00015899783,0.00037086074,0.00039991052],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79826856,0.029938655,0.14826559,0.00014448697,0.0008523407,0.005608637,0.006961841,0.000017063709,0.000035546844,0.00004973911,0.0030570407,0.006800527],"study_design_scores_gemma":[0.7009798,0.008991875,0.28622127,0.00039781252,0.00043480736,0.00016012175,0.0006756543,0.00042570735,0.00019483214,0.000032350446,0.0011457899,0.00033991484],"about_ca_topic_score_codex":0.0016431564,"about_ca_topic_score_gemma":0.0010195116,"teacher_disagreement_score":0.1379557,"about_ca_system_score_codex":0.00088604627,"about_ca_system_score_gemma":0.0011225363,"threshold_uncertainty_score":0.99996185},"labels":[],"label_agreement":null},{"id":"W2943259648","doi":"10.1016/s2352-3026(19)30029-8","title":"Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Agios Pharmaceuticals; European Hematology Association; Stand Up To Cancer; Entertainment Industry Foundation; Celgene; Astex Pharmaceuticals; Van Andel Research Institute; Pfizer; Amgen","keywords":"Decitabine; Medicine; Myelodysplastic syndromes; Hypomethylating agent; International Prognostic Scoring System; Azacitidine; Internal medicine; Clinical endpoint; Phases of clinical research; Clinical trial; Chronic myelomonocytic leukemia; Oncology; Bone marrow","score_opus":0.044043358952204334,"score_gpt":0.35056373520004225,"score_spread":0.3065203762478379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943259648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98751706,0.00008304627,0.00007571009,0.002260197,0.0007118981,0.008066001,0.00088689954,0.000090836525,0.00030836367],"genre_scores_gemma":[0.9954189,0.00017598696,0.0010619088,0.0008160183,0.00035252146,0.0003610163,0.0010006095,0.000089575784,0.0007234294],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99513185,0.0009548812,0.0012020384,0.0009515511,0.000629436,0.0011302674],"domain_scores_gemma":[0.99334604,0.0039000774,0.00061618735,0.0016310596,0.00020796289,0.00029865064],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012612259,0.00050312624,0.0029067916,0.0002978139,0.00011168881,0.00008182982,0.0012491305,0.00028842696,0.0007980852],"category_scores_gemma":[0.0038184114,0.00027295045,0.00006880235,0.0006155972,0.00038271482,0.00026624175,0.0005598853,0.0012428835,0.00083496555],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9790433,0.003864809,0.0048880684,0.00011833557,0.00048022007,0.0016868544,0.0009808642,0.000010452879,0.000120175886,0.000041149848,0.0060160235,0.0027497564],"study_design_scores_gemma":[0.9819606,0.008750103,0.0034601528,0.00048687393,0.00041394553,0.0001450223,0.00020451682,0.002895704,0.00018540192,0.00008791934,0.0010576982,0.0003520873],"about_ca_topic_score_codex":0.0009332674,"about_ca_topic_score_gemma":0.00040915536,"teacher_disagreement_score":0.0079018865,"about_ca_system_score_codex":0.00030232902,"about_ca_system_score_gemma":0.0005592273,"threshold_uncertainty_score":0.9999723},"labels":[],"label_agreement":null},{"id":"W2944123298","doi":"10.1016/s2352-3026(19)30080-8","title":"Revised international surveillance case definition of transfusion-associated circulatory overload: a classification agreement validation study","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood transfusion and management","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.06047060005823637,"score_gpt":0.30675337853288115,"score_spread":0.24628277847464478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944123298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98655397,0.00004874702,0.00025691846,0.004140843,0.00039506226,0.0014865386,0.000015429854,0.000052877876,0.0070496094],"genre_scores_gemma":[0.9989766,0.00016027264,0.0000824606,0.00048224922,0.000044014476,0.00005781258,0.00009051729,0.000011074099,0.000094999166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986518,0.00025869132,0.00040073457,0.00023827206,0.0002944055,0.00015607302],"domain_scores_gemma":[0.9990697,0.00010827232,0.00020013245,0.00044073543,0.00014862353,0.000032568332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078514876,0.00011220279,0.0005247715,0.00009528697,0.000053416643,0.000008389881,0.00012446866,0.000069754344,0.0005012989],"category_scores_gemma":[0.000064768465,0.00008404891,0.00007872636,0.00017340419,0.000044039698,0.000044533983,0.000026377247,0.00014367173,0.0000698442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011466148,0.0031011433,0.92732525,0.00061231764,0.00094866403,0.00062797667,0.003715407,0.000029978572,0.026267478,0.03131895,0.0022034927,0.0027027456],"study_design_scores_gemma":[0.015533068,0.0006968726,0.9736573,0.00020098605,0.00045634568,0.0015435129,0.0034367808,0.0008307696,0.0011423975,0.0008747141,0.0013671679,0.0002600755],"about_ca_topic_score_codex":0.000110257126,"about_ca_topic_score_gemma":0.00014697122,"teacher_disagreement_score":0.04633208,"about_ca_system_score_codex":0.00005402522,"about_ca_system_score_gemma":0.00003273947,"threshold_uncertainty_score":0.5488872},"labels":[],"label_agreement":null},{"id":"W2944405756","doi":"10.1016/s2352-3026(19)30081-x","title":"Building consensus: steps toward standardised haemovigilance reporting","year":2019,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Blood transfusion and management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"","keywords":"Medicine; Medical emergency; Intensive care medicine; Incidence (geometry)","score_opus":0.08805528011199608,"score_gpt":0.3442539045282208,"score_spread":0.2561986244162247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944405756","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007883362,0.00090081774,0.0011908545,0.96726227,0.001668141,0.0016006589,0.000056041234,0.00034073222,0.019097108],"genre_scores_gemma":[0.019821344,0.00027900215,0.0034136223,0.96738267,0.0036133952,0.000087266955,0.00012727815,0.00012092498,0.0051544914],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99633473,0.00024620479,0.0012843743,0.0007026614,0.00055345584,0.00087857986],"domain_scores_gemma":[0.99647874,0.00041926466,0.0013334937,0.0015637019,0.00014702234,0.000057799138],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011102569,0.00044859247,0.0029520753,0.00014840077,0.00012443236,0.000041533447,0.0004414607,0.00068331085,0.00024586014],"category_scores_gemma":[0.000510726,0.00029790658,0.00032936054,0.0001733973,0.00026380827,0.000020003465,0.00018515183,0.0024368847,0.00019049035],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018352104,0.000019223413,0.00095205894,0.002651205,0.00037009086,0.011347954,0.00016793651,0.0000033242172,0.0000876811,0.0015059267,0.9820021,0.00070899667],"study_design_scores_gemma":[0.0023034175,0.00008709823,0.0002888492,0.0006570526,0.00064626563,0.005752993,0.00007212998,0.000040277075,0.0002801525,0.0006496922,0.9888975,0.0003245576],"about_ca_topic_score_codex":0.000041763866,"about_ca_topic_score_gemma":0.0000072349944,"teacher_disagreement_score":0.013942616,"about_ca_system_score_codex":0.00007602887,"about_ca_system_score_gemma":0.00021386235,"threshold_uncertainty_score":0.9999473},"labels":[],"label_agreement":null},{"id":"W2951038309","doi":"10.1016/s2352-3026(19)30112-7","title":"The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia","year":2019,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Life expectancy; Imatinib; Myeloid leukemia; Population; Chronic myeloid leukaemia; Myeloid; Oncology; Internal medicine; Immunology","score_opus":0.04028012513636689,"score_gpt":0.30244136964268353,"score_spread":0.2621612445063166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951038309","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4538424,0.010050687,0.000009606929,0.5300012,0.0011099703,0.002030157,0.000061796825,0.00006685714,0.0028273228],"genre_scores_gemma":[0.48602527,0.019114574,0.00012846428,0.46105638,0.013971846,0.00071321527,0.0016172702,0.00029661163,0.017076345],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965749,0.00051751686,0.00091057376,0.0006337199,0.00046414524,0.00089915335],"domain_scores_gemma":[0.9958783,0.0012636062,0.0006379882,0.002074221,0.000106724474,0.00003917803],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00065882906,0.00056845095,0.002291528,0.0001652342,0.00015503044,0.000025722027,0.0008002711,0.0011232065,0.000708436],"category_scores_gemma":[0.0001727682,0.00031589545,0.000280398,0.00026732718,0.0004143443,0.000053450767,0.00013438262,0.0023139226,0.00045019208],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049678766,0.0000632538,0.0013319113,0.0010227977,0.0006728305,0.000952914,0.00054985326,0.0001797032,0.0010938103,0.0014641046,0.9892356,0.0029364834],"study_design_scores_gemma":[0.010680248,0.0010935419,0.0018553656,0.00045953057,0.00023313261,0.0026021842,0.000022471431,0.0012071162,0.0049100933,0.00095663447,0.97557116,0.00040855224],"about_ca_topic_score_codex":0.00043208545,"about_ca_topic_score_gemma":0.0016209817,"teacher_disagreement_score":0.06894481,"about_ca_system_score_codex":0.0017240086,"about_ca_system_score_gemma":0.0017893638,"threshold_uncertainty_score":0.9999878},"labels":[],"label_agreement":null},{"id":"W2956888684","doi":"10.1016/s2352-3026(19)30109-7","title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":242,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Merck Sharp and Dohme","keywords":"Medicine; Lenalidomide; Dexamethasone; Multiple myeloma; Clinical endpoint; Internal medicine; Interim analysis; Pembrolizumab; Adverse effect; Clinical trial; Oncology; Surgery; Cancer; Immunotherapy","score_opus":0.07617864432414798,"score_gpt":0.37293546761854046,"score_spread":0.29675682329439246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956888684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827675,0.00037263855,0.00018128469,0.0013166579,0.00016247088,0.014321632,0.0002068293,0.00005855868,0.0006124033],"genre_scores_gemma":[0.99346006,0.00013692898,0.0027193043,0.00031905144,0.00018756805,0.0019091332,0.000325384,0.00005967223,0.0008829238],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99759126,0.0003133435,0.0004062384,0.0006032133,0.00028259432,0.00080332375],"domain_scores_gemma":[0.9966329,0.001913061,0.00023399325,0.0007801412,0.00017744751,0.0002624742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034824817,0.00038458456,0.0020383375,0.000111208494,0.00021882431,0.000073074385,0.0003230142,0.00014865803,0.00012297035],"category_scores_gemma":[0.0005575231,0.00020565583,0.00009418201,0.00014655116,0.00025645053,0.00014538936,0.00014829183,0.00018879956,0.00008381254],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9577143,0.0022403586,0.027910914,0.00017520062,0.0009861686,0.00017893472,0.00039654475,0.0000017461435,0.0001985604,0.00029132096,0.000601546,0.009304404],"study_design_scores_gemma":[0.9773819,0.014162536,0.0027616867,0.0000934118,0.00045981008,0.0002759568,0.000078077195,0.0015705356,0.0007777246,0.00016170739,0.0020481704,0.00022850207],"about_ca_topic_score_codex":0.00023705488,"about_ca_topic_score_gemma":0.00011184105,"teacher_disagreement_score":0.025149226,"about_ca_system_score_codex":0.00016719363,"about_ca_system_score_gemma":0.00027290697,"threshold_uncertainty_score":0.83864015},"labels":[],"label_agreement":null},{"id":"W2966090323","doi":"10.1016/s2352-3026(19)30162-0","title":"Ironing out frequent blood donation","year":2019,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Blood donation and transfusion practices","field":"Business, Management and Accounting","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of British Columbia","funders":"","keywords":"Medicine; Blood donor; Donation; Intensive care medicine; Family medicine; Internal medicine; Immunology; Law","score_opus":0.047024923479655006,"score_gpt":0.2652828661624125,"score_spread":0.21825794268275747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966090323","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00209624,0.00030974043,0.00010537912,0.88190293,0.0024841249,0.00038976205,0.0000074892914,0.00022718268,0.11247713],"genre_scores_gemma":[0.020635549,0.00009286096,0.00009877417,0.9624981,0.012997818,0.000054844288,0.0003452454,0.00006402876,0.003212737],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828804,0.00007790592,0.0003756942,0.00041470223,0.00038151647,0.00046212497],"domain_scores_gemma":[0.99821717,0.00040239157,0.0006109916,0.0006237226,0.00014155122,0.0000041542903],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005442739,0.00030288368,0.0007910719,0.0002357784,0.00021398439,0.0003114402,0.00074997416,0.0005282604,0.0010724609],"category_scores_gemma":[0.00016099669,0.0002128448,0.00012851659,0.00017413357,0.00009424727,0.000579963,0.00015779395,0.0015489315,0.0044457465],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013338816,0.000027368053,0.0009858345,0.00053520687,0.00010823879,0.0002322666,0.000051171166,0.000004163214,0.000016010881,0.028943468,0.96868205,0.0004008738],"study_design_scores_gemma":[0.0008174835,0.000004824435,0.00016723727,0.00006126369,0.00041803712,0.00010921138,0.000025075657,0.00010747563,0.000017684159,0.005020856,0.9929818,0.00026904358],"about_ca_topic_score_codex":0.00018121049,"about_ca_topic_score_gemma":0.00012832263,"teacher_disagreement_score":0.10926439,"about_ca_system_score_codex":0.000012621602,"about_ca_system_score_gemma":0.000032909647,"threshold_uncertainty_score":0.9998407},"labels":[],"label_agreement":null},{"id":"W2968662162","doi":"10.1016/s2352-3026(19)30161-9","title":"Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Ottawa","funders":"Janssen Research and Development","keywords":"Medicine; Rivaroxaban; Fondaparinux; Vitamin K antagonist; Regimen; Dosing; Pediatrics; Venous thrombosis; Surgery; Venous thromboembolism; Internal medicine; Warfarin; Thrombosis","score_opus":0.08055790085093029,"score_gpt":0.32520847477519044,"score_spread":0.24465057392426015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968662162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98760945,0.001096713,0.0005545212,0.0063951304,0.00064719986,0.002340069,0.00019276424,0.00025386314,0.00091031013],"genre_scores_gemma":[0.99364775,0.00008622749,0.0031838054,0.001890019,0.00054648606,0.00007113769,0.00036795525,0.000063632484,0.00014296344],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978673,0.00012252829,0.0005133781,0.0005987401,0.00028710582,0.0006109833],"domain_scores_gemma":[0.9977108,0.0005049692,0.00035334736,0.0011056053,0.00020890518,0.0001163718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028660687,0.00035334835,0.0019663528,0.000086936336,0.00018808545,0.000025631616,0.00032525763,0.00019429876,0.0000987589],"category_scores_gemma":[0.00017074568,0.00021558793,0.00012863196,0.0001908943,0.00020362173,0.0000883131,0.0001049799,0.000290566,0.00019161422],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08858541,0.04980643,0.13429977,0.003382386,0.048315257,0.0012463562,0.07515947,0.0004721,0.1549693,0.33655155,0.056969114,0.05024286],"study_design_scores_gemma":[0.3984122,0.029542325,0.28673896,0.003037063,0.012656287,0.0034339658,0.0065292404,0.007974294,0.18107721,0.05453647,0.012471677,0.003590313],"about_ca_topic_score_codex":0.00009828717,"about_ca_topic_score_gemma":0.00034484145,"teacher_disagreement_score":0.3098268,"about_ca_system_score_codex":0.000049330632,"about_ca_system_score_gemma":0.00006698991,"threshold_uncertainty_score":0.87914205},"labels":[],"label_agreement":null},{"id":"W2987943866","doi":"10.1016/s2352-3026(19)30219-4","title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":315,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Alberta; McMaster Children's Hospital","funders":"Actelion Pharmaceuticals; Eli Lilly and Company; CSL Behring; AbbVie; Bristol-Myers Squibb Canada; Boehringer Ingelheim; Alnylam Pharmaceuticals; Bayer; Alexion Pharmaceuticals; Novartis; Pfizer; LEO Pharma Research Foundation","keywords":"Medicine; Rivaroxaban; Vitamin K antagonist; Venous thromboembolism; Randomized controlled trial; Venous thrombosis; Pulmonary embolism; Intention-to-treat analysis; Adverse effect; Surgery; Pediatrics; Internal medicine; Warfarin; Thrombosis","score_opus":0.03540028368779407,"score_gpt":0.33296245962491405,"score_spread":0.29756217593712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987943866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862964,0.0004106937,0.0007433955,0.00226411,0.0002662893,0.009719152,0.00008319424,0.000034544504,0.00018222284],"genre_scores_gemma":[0.99836546,0.00022655538,0.00029021388,0.00040298587,0.00016833899,0.00043386678,0.000042573767,0.000023351477,0.00004663257],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99863285,0.00016929404,0.00044265803,0.00022623377,0.00019659456,0.00033237122],"domain_scores_gemma":[0.9984885,0.00051851803,0.00027103044,0.0005836948,0.0000915942,0.000046680325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003810671,0.00020575132,0.0032150252,0.00006984613,0.000075733034,0.000011705768,0.00017764265,0.000091190144,0.000083702296],"category_scores_gemma":[0.00002893389,0.000091357855,0.0001985409,0.00012275467,0.00013870763,0.000025747382,0.000014004019,0.0001014328,0.000013245082],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97599995,0.0027402258,0.0043490627,0.00005739835,0.004190056,0.000028460885,0.002177404,0.000038068454,0.0015925651,0.0077641057,0.00022940378,0.0008332743],"study_design_scores_gemma":[0.9820227,0.006284486,0.0025095474,0.000058595644,0.0021704577,0.00038767903,0.00016141772,0.0012232995,0.0041965623,0.0006332309,0.00023226223,0.00011972857],"about_ca_topic_score_codex":0.000038938993,"about_ca_topic_score_gemma":0.000022955885,"teacher_disagreement_score":0.012069084,"about_ca_system_score_codex":0.000037677848,"about_ca_system_score_gemma":0.000105231644,"threshold_uncertainty_score":0.37254652},"labels":[],"label_agreement":null},{"id":"W2989004737","doi":"10.1016/s2352-3026(19)30202-9","title":"Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Institute for Research in Immunology and Cancer; Université de Montréal; Université Laval; Hôpital de l'Enfant-Jésus; Discovery Centre; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"Medicine; Cord blood; Transplantation; Stem cell; Hematopoietic stem cell transplantation; Haematopoiesis; Graft-versus-host disease; Surgery; Internal medicine","score_opus":0.07846348006498947,"score_gpt":0.3328566361871404,"score_spread":0.2543931561221509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989004737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99172616,0.000293024,0.002511592,0.00049593457,0.00023938982,0.0027161848,0.00004740899,0.00015423844,0.0018160413],"genre_scores_gemma":[0.9987104,0.00007548931,0.0006081578,0.00028110927,0.00007241443,0.000023231732,0.000055571603,0.00004857077,0.00012507857],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997191,0.0005553994,0.00074752426,0.0006105321,0.00036441875,0.0005311224],"domain_scores_gemma":[0.99810797,0.00058655994,0.0002646143,0.00079824287,0.00009715181,0.0001454651],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008971654,0.0003387517,0.0014203774,0.00011300905,0.00015453779,0.000037625887,0.00019318603,0.00018180946,0.000150517],"category_scores_gemma":[0.000017540196,0.000254355,0.000096600845,0.00025960393,0.00017794294,0.00011067156,0.000034056033,0.00032174302,0.000052010953],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024825852,0.022057166,0.3908387,0.013803934,0.00066299224,0.003042884,0.047267538,0.000086873,0.4931505,0.0015337539,0.00009314005,0.002636636],"study_design_scores_gemma":[0.21766596,0.03395465,0.05876258,0.0032591617,0.01390121,0.09936604,0.036505308,0.0058777956,0.52495533,0.0018904335,0.0005644024,0.003297149],"about_ca_topic_score_codex":0.000059164926,"about_ca_topic_score_gemma":0.000056040477,"teacher_disagreement_score":0.33207613,"about_ca_system_score_codex":0.00007153765,"about_ca_system_score_gemma":0.000077051125,"threshold_uncertainty_score":0.9999909},"labels":[],"label_agreement":null},{"id":"W2997806446","doi":"10.1016/s2352-3026(19)30206-6","title":"Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood disorders and treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Myelodysplastic syndromes; Retrospective cohort study; Myeloid leukaemia; Cohort; Myeloid leukemia; Myeloid; Cohort study; Internal medicine; Pediatrics; Bone marrow","score_opus":0.007303935844791967,"score_gpt":0.2659708146748395,"score_spread":0.2586668788300476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997806446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980685,0.0003962482,0.000004645432,0.00009333319,0.00011845053,0.0011412904,0.00006951321,0.000012376443,0.00009563607],"genre_scores_gemma":[0.99904644,0.00021753617,0.00016686354,0.00013653489,0.000010754456,0.000042045944,0.000050608433,0.000023447436,0.000305757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986209,0.0001440231,0.00029050806,0.00049961935,0.00015211648,0.0002928145],"domain_scores_gemma":[0.99906677,0.00010360832,0.00019116176,0.0005068504,0.00006395341,0.00006762763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016852135,0.00024120793,0.0010799567,0.00003456388,0.00006855542,0.000015281219,0.00018728268,0.00017104452,0.000016460643],"category_scores_gemma":[0.000064101216,0.00013169355,0.000048183454,0.00007234166,0.00026094768,0.00000805097,0.00020610656,0.00017135407,0.000005946029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077654613,0.0004912749,0.9969252,0.000042428182,0.0013085834,0.00012764713,0.000076054814,9.2745205e-7,0.000014348933,0.000040626914,0.00011719168,0.00007919019],"study_design_scores_gemma":[0.006804509,0.0024040414,0.98937863,0.000015500775,0.00046732492,0.00055093766,0.00010319529,0.0000035968374,0.000038058184,0.000048910224,0.000022175816,0.00016314567],"about_ca_topic_score_codex":0.000045590386,"about_ca_topic_score_gemma":0.0002665991,"teacher_disagreement_score":0.0075465757,"about_ca_system_score_codex":0.000007084937,"about_ca_system_score_gemma":0.000030356636,"threshold_uncertainty_score":0.5370307},"labels":[],"label_agreement":null},{"id":"W2998927302","doi":"10.1016/s2352-3026(19)30218-2","title":"Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; Canadian Centre for Applied Research in Cancer Control; University of Toronto","funders":"","keywords":"ABVD; Medicine; Procarbazine; Dacarbazine; Hodgkin's lymphoma; Vinblastine; Brentuximab vedotin; Oncology; Internal medicine; Vinorelbine; Vincristine; Chemotherapy; Hodgkin lymphoma; Lymphoma; Cyclophosphamide","score_opus":0.1019888536688762,"score_gpt":0.3400904008033418,"score_spread":0.2381015471344656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998927302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987448,0.0003050255,0.0053784074,0.0015283173,0.000048873262,0.0050124554,0.0001536453,0.000050139755,0.000075136886],"genre_scores_gemma":[0.9959906,0.0001195379,0.0015627985,0.00013317386,0.000050008955,0.0020104684,0.00009427134,0.000025089046,0.000014090384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895066,0.00011295738,0.00024087855,0.000303199,0.000130275,0.00026203628],"domain_scores_gemma":[0.99880236,0.00048743704,0.00013684665,0.00036224877,0.00012696077,0.00008412052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109868386,0.00020341048,0.0010560706,0.000032414213,0.000104648316,0.000005963006,0.000099318284,0.0000465795,0.000009037781],"category_scores_gemma":[0.000037525115,0.000109955065,0.000094858406,0.00013573698,0.000062458115,0.000036142024,0.00003249316,0.00003108471,0.0000063412117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01471621,0.012686937,0.9301867,0.0008417463,0.0012954185,0.00018542183,0.003394389,0.026888665,0.000012498627,0.0027826424,0.00005817632,0.0069512255],"study_design_scores_gemma":[0.35418773,0.084068164,0.4843725,0.0010016008,0.0054520615,0.00019460841,0.0029273527,0.047379505,0.007942338,0.0007400759,0.010681687,0.0010523917],"about_ca_topic_score_codex":0.00006795949,"about_ca_topic_score_gemma":0.000052168,"teacher_disagreement_score":0.44581416,"about_ca_system_score_codex":0.00016888589,"about_ca_system_score_gemma":0.00008237931,"threshold_uncertainty_score":0.44838372},"labels":[],"label_agreement":null},{"id":"W2999004039","doi":"10.1016/s2352-3026(19)30220-0","title":"Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University; BC Children's Hospital; Université Laval; Child and Family Research Institute; Hôtel-Dieu de Québec; CancerCare Manitoba; Capital District Health Authority; Royal Victoria Hospital; Centre hospitalier universitaire de Québec; Vancouver General Hospital; Princess Margaret Cancer Centre; University of British Columbia; Public Health Ontario; Dalhousie University; University of Toronto; McMaster University; Hôpital Maisonneuve-Rosemont; Juravinski Hospital","funders":"Canadian Institutes of Health Research; University of British Columbia; McMaster University; Sanofi","keywords":"Medicine; Anti-thymocyte globulin; Cumulative incidence; Internal medicine; Transplantation; Graft-versus-host disease; Hazard ratio; Surgery; Clinical endpoint; Tacrolimus; Randomized controlled trial; Gastroenterology; Confidence interval","score_opus":0.07633850075544721,"score_gpt":0.3329399635474426,"score_spread":0.25660146279199536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999004039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98852545,0.00013369585,0.003021775,0.0010395912,0.00012520685,0.004099295,0.0029720664,0.000042051226,0.000040853316],"genre_scores_gemma":[0.9954768,0.00032755284,0.001982997,0.000080509955,0.00003091565,0.00017658959,0.0019000913,0.00002290239,0.000001687743],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970556,0.0005551901,0.0009838423,0.00051559956,0.00052726833,0.00036253213],"domain_scores_gemma":[0.99730283,0.0014254123,0.00045696818,0.00038135797,0.00020956197,0.00022385879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030127176,0.00032293738,0.0024707275,0.00021856288,0.00007039943,0.000022522112,0.00024447445,0.00014509668,0.00014811207],"category_scores_gemma":[0.00037032462,0.00021286964,0.00013859772,0.0010144209,0.00018630589,0.00012148304,0.000031252162,0.0001576478,0.000006704431],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9727788,0.0011977511,0.018988058,0.00045900943,0.0018113634,0.00051396893,0.002795489,0.0006086414,0.0004217086,0.00015636937,0.000022589196,0.00024625644],"study_design_scores_gemma":[0.94851464,0.016899927,0.016966999,0.00063716964,0.008244813,0.0000060178486,0.00046116664,0.0010911723,0.0068578403,0.000022109236,0.000018062354,0.00028010533],"about_ca_topic_score_codex":0.00018443639,"about_ca_topic_score_gemma":0.0007589415,"teacher_disagreement_score":0.024264177,"about_ca_system_score_codex":0.00014835637,"about_ca_system_score_gemma":0.00029342785,"threshold_uncertainty_score":0.8680572},"labels":[],"label_agreement":null},{"id":"W3003963919","doi":"10.1016/s2352-3026(20)30001-6","title":"Idiopathic multicentric Castleman disease: bringing order to chaos","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Disease; Castleman disease; Scopus; Dermatology; Pathology; MEDLINE","score_opus":0.039026749861899204,"score_gpt":0.2993517674056224,"score_spread":0.2603250175437232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003963919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75825655,0.0035513153,0.0009881845,0.23355024,0.00025364495,0.0006624038,0.000013697199,0.00023609328,0.002487854],"genre_scores_gemma":[0.96964717,0.0001210006,0.00012774752,0.02957251,0.0003789143,0.000034159923,0.000007832692,0.000025801452,0.00008486266],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988244,0.00007287698,0.00019950607,0.00026503683,0.00017069503,0.00046745496],"domain_scores_gemma":[0.99923843,0.000039488088,0.00007145954,0.0002996237,0.000059709313,0.0002912856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012354432,0.00014276708,0.0006446458,0.000041784184,0.00010715314,0.000014615381,0.00018100243,0.00006289476,0.00009063316],"category_scores_gemma":[0.00064511073,0.00010077452,0.00006146487,0.00052257546,0.000055708926,0.00002806007,0.00008825178,0.00025227552,0.00032039313],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014521067,0.0009788942,0.5601664,0.007174841,0.0014302683,0.0148163205,0.04417796,0.003042658,0.011775399,0.06931012,0.23905623,0.03354981],"study_design_scores_gemma":[0.07541437,0.0034668432,0.3415697,0.002924014,0.0048373137,0.003170515,0.012020878,0.16789028,0.004169811,0.0035744037,0.37636477,0.004597099],"about_ca_topic_score_codex":0.000051119667,"about_ca_topic_score_gemma":0.00001923909,"teacher_disagreement_score":0.21859673,"about_ca_system_score_codex":0.00003264493,"about_ca_system_score_gemma":0.0001186349,"threshold_uncertainty_score":0.41181123},"labels":[],"label_agreement":null},{"id":"W3012570191","doi":"10.1016/s2352-3026(20)30070-3","title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":241,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre; Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Multiple myeloma; Internal medicine; Refractory (planetary science); Adverse effect; Clinical endpoint; Phases of clinical research; Proteasome inhibitor; Surgery; Clinical trial; Bortezomib","score_opus":0.08514856475611958,"score_gpt":0.35792034743549933,"score_spread":0.27277178267937974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012570191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880552,0.00009970782,0.000035390716,0.0020034015,0.0003508226,0.008337151,0.0000933162,0.000091386646,0.00093360926],"genre_scores_gemma":[0.99723184,0.00008559383,0.0010178611,0.00058532046,0.000262134,0.00043574566,0.00021570093,0.000065692206,0.00010008256],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966985,0.0004838539,0.0006520591,0.00067187275,0.0005100529,0.0009836688],"domain_scores_gemma":[0.9971873,0.0011187895,0.0002735598,0.0008047686,0.00016581295,0.00044972985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031303737,0.00040354067,0.0020050744,0.00010164166,0.00023080574,0.00008381738,0.00068748195,0.00021928185,0.00024531432],"category_scores_gemma":[0.0017731554,0.0002453966,0.00007095658,0.0004429582,0.00028348507,0.0001597715,0.00032666486,0.0007823974,0.0001795095],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96382713,0.004685221,0.013667307,0.00016813345,0.00043159563,0.008111784,0.0009775333,0.0000025646086,0.00011744396,0.000018040673,0.0008838661,0.007109374],"study_design_scores_gemma":[0.9666863,0.023045179,0.0058571445,0.00011517878,0.00023418946,0.00020913192,0.00014256685,0.0019488583,0.00015686842,0.0000070066567,0.0013053478,0.00029219623],"about_ca_topic_score_codex":0.00039022774,"about_ca_topic_score_gemma":0.0015652315,"teacher_disagreement_score":0.018359957,"about_ca_system_score_codex":0.00019395268,"about_ca_system_score_gemma":0.00043599657,"threshold_uncertainty_score":0.9999998},"labels":[],"label_agreement":null},{"id":"W3021441913","doi":"10.1016/s2352-3026(20)30113-7","title":"Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis – Authors' reply","year":2020,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Toronto; Public Health Ontario; McMaster University; Juravinski Hospital","funders":"","keywords":"Anti-thymocyte globulin; Medicine; Rituximab; Graft-versus-host disease; Transplantation; Internal medicine; Surgery; Immunology; Lymphoma","score_opus":0.04254126665838657,"score_gpt":0.30224978313135936,"score_spread":0.2597085164729728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021441913","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022231787,0.000413153,0.0016179685,0.96849304,0.0013703385,0.0021919608,0.002221223,0.0002566094,0.0012039423],"genre_scores_gemma":[0.20414868,0.00051918824,0.003284896,0.7799436,0.0065503526,0.0004173419,0.0041880575,0.00026009537,0.0006878147],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996479,0.00054115115,0.0008311763,0.00073314353,0.00078810996,0.00062744267],"domain_scores_gemma":[0.9971591,0.0006537262,0.00041865904,0.0012656805,0.00024114278,0.00026167827],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041130584,0.00046455424,0.0023286615,0.00018552707,0.00009788471,0.00002218423,0.00048218193,0.00049779017,0.0004585231],"category_scores_gemma":[0.00067401485,0.00034143453,0.00027295513,0.00043820025,0.0003077665,0.00004504474,0.00008991163,0.0014571784,0.00041601312],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005292477,0.000035549747,0.00056970626,0.0061929105,0.000259871,0.008531741,0.0006710185,0.000004247569,0.0004471577,0.0003920684,0.9774007,0.00020255346],"study_design_scores_gemma":[0.0053002005,0.0015604869,0.0020896865,0.0020415299,0.0017037753,0.00094435987,0.000102763195,0.000062196435,0.00512235,0.0006128975,0.979775,0.0006847363],"about_ca_topic_score_codex":0.000033155884,"about_ca_topic_score_gemma":0.0000075275234,"teacher_disagreement_score":0.18854944,"about_ca_system_score_codex":0.000101687125,"about_ca_system_score_gemma":0.00038114956,"threshold_uncertainty_score":0.99990374},"labels":[],"label_agreement":null},{"id":"W3032742617","doi":"10.1016/s2352-3026(20)30081-8","title":"Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Multiple myeloma; Sirius; Refractory (planetary science); Internal medicine; Oncology; Phases of clinical research; Clinical trial; Lenalidomide","score_opus":0.14371685728919703,"score_gpt":0.3637452154296498,"score_spread":0.2200283581404528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032742617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98400044,0.0006720248,0.000023863444,0.012645067,0.00005134092,0.0018380892,0.00055470533,0.000066634784,0.00014781942],"genre_scores_gemma":[0.9968877,0.00023546861,0.00049316575,0.0015533688,0.00017646598,0.00009871561,0.0004472374,0.000033342127,0.00007452876],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99720836,0.00091907114,0.00058730633,0.00048597762,0.00031838182,0.00048092342],"domain_scores_gemma":[0.99637103,0.0024733024,0.00025767754,0.00062478567,0.00008543187,0.00018779836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053857977,0.00027063,0.0013872079,0.000050065657,0.00015137118,0.000030454297,0.00024146581,0.00014010302,0.00007883874],"category_scores_gemma":[0.0024897666,0.00011507366,0.00006178452,0.00027641267,0.00026341667,0.00007384466,0.000066154,0.00047744153,0.000031710304],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49580628,0.0014103106,0.4631036,0.000082218554,0.0008630125,0.0020889135,0.0051193805,0.000006840308,0.00067496963,0.000031652013,0.009378064,0.021434756],"study_design_scores_gemma":[0.27509278,0.005623862,0.7106761,0.00020729839,0.0002272088,0.00009597184,0.00024500757,0.0013284379,0.0011942176,0.00008538656,0.0049557067,0.00026802195],"about_ca_topic_score_codex":0.00051286677,"about_ca_topic_score_gemma":0.00051917555,"teacher_disagreement_score":0.2475725,"about_ca_system_score_codex":0.000055974237,"about_ca_system_score_gemma":0.00014112583,"threshold_uncertainty_score":0.46925676},"labels":[],"label_agreement":null},{"id":"W3036451283","doi":"10.1016/s2352-3026(20)30205-2","title":"Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts","year":2020,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; National Institutes of Health; Sierra Oncology; National Institute for Health and Care Research; Omeros Corporation; Argenx; Pfizer; Incyte; CTI Biopharma; Astellas Pharma; Eisai; Celltrion; Agios Pharmaceuticals; MEI Pharma; Syndax Pharmaceuticals; Acceleron; Astex Pharmaceuticals; Celgene; PTC Therapeutics; Arog Pharmaceuticals; National Center for Advancing Translational Sciences; Medical Research Council; Teva Pharmaceutical Industries; Helsinn; Jazz Pharmaceuticals; Array BioPharma; University of Toronto; Apellis Pharmaceuticals; Alexion Pharmaceuticals; Bristol-Myers Squibb; AstraZeneca; TG Therapeutics; MacroGenics; Celldex Therapeutics; Cardinal Health; Amgen","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Intensive care medicine; 2019-20 coronavirus outbreak; Myeloid leukemia; Oncology; Internal medicine; Virology; Disease; Outbreak","score_opus":0.15019995941805153,"score_gpt":0.4148418345378975,"score_spread":0.264641875119846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036451283","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022929996,0.40469122,0.00017029009,0.5563277,0.001149292,0.009349439,0.0021730121,0.000047508944,0.0031615235],"genre_scores_gemma":[0.011017854,0.96869475,0.000551477,0.01832902,0.000467191,0.0002835044,0.00062691915,0.00001941601,0.000009887641],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980028,0.0005560075,0.0007030231,0.00025952145,0.00027627245,0.00020232452],"domain_scores_gemma":[0.99702865,0.001957275,0.00043243179,0.00044802052,0.00007456443,0.000059039616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033343848,0.00021474161,0.0015321976,0.00014248457,0.00007120889,0.000016625552,0.00033843803,0.00013024396,0.00009784561],"category_scores_gemma":[0.0003344663,0.00010142339,0.00008213198,0.00027187116,0.00018993275,0.00003839682,0.00010025755,0.00045563528,0.0000035501],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025176147,0.0018430693,0.050503977,0.04337719,0.004764895,0.0051032994,0.12715666,0.000011162658,6.015813e-7,0.11857548,0.22044204,0.425704],"study_design_scores_gemma":[0.004505711,0.0002547773,0.008047822,0.0046497113,0.0011005251,0.0009562828,0.0027965156,0.000009312309,4.638245e-7,0.0017272477,0.9757562,0.0001953739],"about_ca_topic_score_codex":0.000599753,"about_ca_topic_score_gemma":0.0027851812,"teacher_disagreement_score":0.75531423,"about_ca_system_score_codex":0.00011850419,"about_ca_system_score_gemma":0.0005571367,"threshold_uncertainty_score":0.4135926},"labels":[],"label_agreement":null},{"id":"W3037937011","doi":"10.1016/s2352-3026(20)30179-4","title":"Hyper-CVAD: a regimen for all seasons","year":2020,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Oncology; Transplantation; Regimen; Hematopoietic stem cell transplantation; Acute lymphocytic leukemia; Chemotherapy regimen; Internal medicine; Leukemia; Chemotherapy; Pediatrics; Immunology; Lymphoblastic Leukemia","score_opus":0.07289611587682732,"score_gpt":0.3215748360427885,"score_spread":0.2486787201659612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037937011","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014043255,0.0016846308,0.000026032978,0.98966116,0.0004003387,0.0013628702,0.00018553634,0.00015828261,0.0051167975],"genre_scores_gemma":[0.004271767,0.00028231414,0.00095907436,0.98355633,0.005831737,0.000950382,0.0009144633,0.000077199045,0.0031567547],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837714,0.000112386486,0.000226378,0.00047282694,0.00019184755,0.0006194285],"domain_scores_gemma":[0.99819285,0.00063436717,0.00017519397,0.0008542871,0.00005888119,0.00008441481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008952878,0.00034444654,0.0018662269,0.000044575507,0.00008766013,0.000021444273,0.0003273024,0.0004858569,0.00011261914],"category_scores_gemma":[0.00012724685,0.00020107203,0.0003104118,0.00007241094,0.00014569877,0.00001574236,0.000094909774,0.0006183884,0.0004406859],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015990976,0.00005257446,0.0010389113,0.0005771039,0.0005980959,0.003956394,0.00019404995,9.861098e-8,0.000005588563,0.0011506153,0.99177796,0.00048868393],"study_design_scores_gemma":[0.003037658,0.00028239354,0.00019726017,0.00012487579,0.001234021,0.0031606483,0.000014529061,0.000023009226,0.000120504286,0.0013669817,0.9902489,0.00018919303],"about_ca_topic_score_codex":0.000030581676,"about_ca_topic_score_gemma":0.000008595966,"teacher_disagreement_score":0.006104877,"about_ca_system_score_codex":0.00013015316,"about_ca_system_score_gemma":0.00024313988,"threshold_uncertainty_score":0.81994796},"labels":[],"label_agreement":null},{"id":"W3039544106","doi":"10.1016/s2352-3026(20)30186-1","title":"Effects of the COVID-19 pandemic on supply and use of blood for transfusion","year":2020,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Blood donation and transfusion practices","field":"Business, Management and Accounting","cited_by":332,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University Health Network; University of Toronto; Canadian Blood Services; Héma-Québec","funders":"NHS Blood and Transplant","keywords":"Pandemic; Contingency plan; Economic shortage; Transfusion medicine; Blood transfusion; Coronavirus disease 2019 (COVID-19); Medicine; Business; Intensive care medicine; Public health; Medical emergency; Disease; Infectious disease (medical specialty); Immunology; Computer science; Nursing; Computer security","score_opus":0.10732169656124362,"score_gpt":0.3333454154482485,"score_spread":0.2260237188870049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039544106","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023297034,0.9822097,0.00023597713,0.010937342,0.0005268058,0.0032916237,0.00006924927,0.00008055084,0.0003190847],"genre_scores_gemma":[0.0026210824,0.9921768,0.00005157358,0.0047281636,0.00022475135,0.000120985605,0.000020180112,0.000028903878,0.00002757031],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99885786,0.0001534436,0.00042986023,0.00024968124,0.00014881237,0.00016036764],"domain_scores_gemma":[0.99593127,0.0030438697,0.0006756922,0.0002865121,0.000049184117,0.000013462016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003973237,0.00022127148,0.0016348003,0.00010334554,0.00012866574,0.000036773305,0.0004033204,0.00018358995,0.000031857027],"category_scores_gemma":[0.000920885,0.000113095295,0.0002499549,0.00029184626,0.00015917383,0.00014583206,0.00009006006,0.00027779874,0.0000064815176],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005056583,0.0003890815,0.0025536346,0.31523043,0.0009226618,0.00004270355,0.0003089787,0.000004345995,0.0000576991,0.23122519,0.007276618,0.441483],"study_design_scores_gemma":[0.0011259345,0.00002256262,0.00003736486,0.0012060099,0.002957956,0.00009022601,0.000008195227,0.000010388968,0.000013437808,0.00092813245,0.99348634,0.00011345484],"about_ca_topic_score_codex":0.00011016807,"about_ca_topic_score_gemma":0.00011062636,"teacher_disagreement_score":0.9862097,"about_ca_system_score_codex":0.0000043993286,"about_ca_system_score_gemma":0.00006642859,"threshold_uncertainty_score":0.4611892},"labels":[],"label_agreement":null},{"id":"W3045883965","doi":"10.1016/s2352-3026(20)30219-2","title":"Is venous thromboembolism a preventable cause of death?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; McMaster University","funders":"","keywords":"Medicine; Pulmonary embolism; Deep vein; Venous thrombosis; Perioperative; Surgeon general; Orthopedic surgery; Thrombosis; Randomized controlled trial; Surgery; Intensive care medicine; Public health; Pathology","score_opus":0.0816195909306139,"score_gpt":0.3254530608087744,"score_spread":0.2438334698781605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045883965","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012683824,0.002187982,0.00004069053,0.9724691,0.00069156557,0.001426459,0.00012641956,0.00014728511,0.010226661],"genre_scores_gemma":[0.032795943,0.0020205716,0.00033917793,0.95916635,0.0038843805,0.00017909706,0.0002071334,0.0001233329,0.0012840305],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973226,0.0002069934,0.0006373139,0.0005803959,0.00045977955,0.00079288613],"domain_scores_gemma":[0.99769235,0.00020526713,0.00047690506,0.0014411248,0.000100268095,0.00008408027],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019095601,0.00045572966,0.004570879,0.00012313348,0.00011043662,0.000020286127,0.0006962593,0.0005660086,0.00080179534],"category_scores_gemma":[0.00007712067,0.00031609356,0.0003455635,0.00021506658,0.00025788142,0.000037604244,0.00035631406,0.0015798844,0.0004227225],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004056804,0.00023759692,0.00051218545,0.002914118,0.0012797029,0.0034518575,0.0010855532,8.68002e-7,0.000028937451,0.0019479776,0.98832333,0.00017731574],"study_design_scores_gemma":[0.0011961792,0.0005107425,0.0027114267,0.0005168611,0.0030007653,0.0012913478,0.000061348204,0.00001844455,0.0006869392,0.005119546,0.9845456,0.00034082087],"about_ca_topic_score_codex":0.00028426867,"about_ca_topic_score_gemma":0.000011985214,"teacher_disagreement_score":0.020112121,"about_ca_system_score_codex":0.00006344421,"about_ca_system_score_gemma":0.00018028676,"threshold_uncertainty_score":0.99992913},"labels":[],"label_agreement":null},{"id":"W3081462523","doi":"10.1016/s2352-3026(20)30227-1","title":"Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Alberta; Université de Montréal; University of Toronto; McGill University; Western University; McGill University Health Centre; University of Waterloo; McMaster University; Canadian Blood Services","funders":"Health Canada; Government of Canada; Canadian Blood Services; Australian Government; Pfizer; McMaster University; GlaxoSmithKline; Novartis","keywords":"Medicine; Eltrombopag; Perioperative; Surgery; Internal medicine; Platelet; Immune thrombocytopenia","score_opus":0.027490315801281955,"score_gpt":0.2823031305319179,"score_spread":0.25481281473063594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081462523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161196,0.00022383084,0.000025093195,0.0037043805,0.00022243941,0.003101095,0.000019720863,0.00004894898,0.0010425142],"genre_scores_gemma":[0.99856645,0.00007425031,0.00035173746,0.0006523787,0.000088040644,0.000118613374,0.00010235739,0.000028970877,0.00001717571],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998309,0.0001961313,0.00042609492,0.00034630473,0.0002135323,0.0005088936],"domain_scores_gemma":[0.99913937,0.0001665177,0.0001466226,0.00036383205,0.000079505946,0.00010413888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014526346,0.0002905569,0.002288241,0.000041221185,0.000114331415,0.000028953711,0.00023104549,0.00012751551,0.00015050564],"category_scores_gemma":[0.00017685401,0.00017188951,0.00010073152,0.00023082833,0.00018417487,0.000083197556,0.00009493988,0.0004125213,0.00012185192],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96286374,0.0012333225,0.027355459,0.00008188139,0.0006751409,0.0020502955,0.004368217,0.000016809394,0.00019753349,0.00015300792,0.00012758552,0.0008770025],"study_design_scores_gemma":[0.9006562,0.0043916376,0.093098894,0.00006028514,0.00035186557,0.000089539564,0.0003812013,0.00022946144,0.00029831118,0.000017068907,0.00019688238,0.00022861185],"about_ca_topic_score_codex":0.00019579071,"about_ca_topic_score_gemma":0.00015906361,"teacher_disagreement_score":0.06574343,"about_ca_system_score_codex":0.00007531388,"about_ca_system_score_gemma":0.00014483102,"threshold_uncertainty_score":0.700945},"labels":[],"label_agreement":null},{"id":"W3081481587","doi":"10.1016/s2352-3026(20)30258-1","title":"A survey in Nepalese patients with acute leukaemia: a starting point for defining financial toxicity of cancer care in low-income and middle-income countries","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Commission; Cancer; High income countries; Developing country; Family medicine; Economic growth; Finance; Business; Internal medicine; Economics","score_opus":0.033968601225190534,"score_gpt":0.253959741878639,"score_spread":0.2199911406534485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081481587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932218,0.0032623145,0.00015915603,0.0012386943,0.00011364086,0.00048434827,0.0013629458,0.0000123980835,0.00014468274],"genre_scores_gemma":[0.99834836,0.0003056681,0.00024810203,0.0009111071,0.000051693252,0.000088276785,0.000021268626,0.000021920026,0.000003627261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983941,0.00003938891,0.00073040585,0.0003503813,0.000030803218,0.00045493388],"domain_scores_gemma":[0.9988948,0.00025495308,0.00052796805,0.00019504849,0.00006760424,0.000059595885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005154196,0.00018320729,0.0012935809,0.00010984516,0.00006109304,0.000023543695,0.000237112,0.00013959373,0.000017720862],"category_scores_gemma":[0.0004342894,0.00016252545,0.00004557967,0.0002163939,0.00016709989,0.00019433825,0.00009150677,0.00022201064,0.000005911431],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010398652,0.0000151836375,0.98184407,0.00045219203,0.00002333288,0.000008385852,0.0029802527,0.00015881119,4.452206e-7,0.013344841,0.00002046951,0.00011213443],"study_design_scores_gemma":[0.0035724996,0.00024378988,0.99162966,0.00027354615,0.000010442142,0.0000016604031,0.000092850314,0.00051854167,0.0000553234,0.0032569089,0.000116017465,0.00022878403],"about_ca_topic_score_codex":0.0014688225,"about_ca_topic_score_gemma":0.022400057,"teacher_disagreement_score":0.020931235,"about_ca_system_score_codex":0.00013262787,"about_ca_system_score_gemma":0.00012417625,"threshold_uncertainty_score":0.9954386},"labels":[],"label_agreement":null},{"id":"W3088801289","doi":"10.1016/s2352-3026(20)30293-3","title":"Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis","year":2020,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Ontario Clinical Oncology Group; Western University; University of Ottawa; McMaster University; Impact; St. Joseph’s Healthcare Hamilton; Cochrane","funders":"Universidad de Navarra; Charité – Universitätsmedizin Berlin; Canadian Institutes of Health Research; Sunnybrook Research Institute; Cancer Research UK; GlaxoSmithKline; Marie Curie; Mayo Clinic","keywords":"Medicine; Meta-analysis; Cochrane Library; Randomized controlled trial; Placebo; MEDLINE; Ambulatory; Internal medicine; Relative risk; Intensive care medicine; Confidence interval; Alternative medicine","score_opus":0.49517208088843384,"score_gpt":0.46917878031642946,"score_spread":0.025993300572004385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088801289","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008945121,0.9903202,0.0000055869095,0.0013285037,0.000025777364,0.008044738,0.00011774291,0.000039518098,0.000028478384],"genre_scores_gemma":[0.0025606663,0.9914902,0.00032485207,0.0028737576,0.000046524983,0.002114038,0.00051831186,0.000058721496,0.000012915631],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99478304,0.001648096,0.0015504145,0.00089469086,0.00058237324,0.0005413988],"domain_scores_gemma":[0.995562,0.0005164282,0.0013381937,0.0023699868,0.00008032682,0.00013307629],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0028678773,0.00057052,0.024368057,0.00020001161,0.00007826391,0.000051184994,0.0008708863,0.00011690628,0.00007152724],"category_scores_gemma":[0.00076408207,0.00026981434,0.0006425214,0.00090492057,0.00014023363,0.00008013248,0.0008636116,0.0005873807,0.00004341276],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008842268,0.00021019956,0.00008963425,0.8327382,0.16495524,0.00014193098,0.00020008397,0.0000017384642,1.9642314e-9,0.00009502682,0.00043067074,0.0011284094],"study_design_scores_gemma":[0.00041723487,0.00020466618,0.0001922226,0.046702366,0.948128,0.00012424451,0.000027543401,0.00007346823,1.6645476e-8,0.000009855394,0.0038583153,0.00026209303],"about_ca_topic_score_codex":0.000046170633,"about_ca_topic_score_gemma":0.00010415587,"teacher_disagreement_score":0.78603584,"about_ca_system_score_codex":0.000036978345,"about_ca_system_score_gemma":0.00022405123,"threshold_uncertainty_score":0.9999754},"labels":[],"label_agreement":null},{"id":"W3089833778","doi":"10.1016/s2352-3026(20)30321-5","title":"Immunotherapy for older patients with classic Hodgkin lymphoma","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Lymphoma; Immunotherapy; Hodgkin lymphoma; Oncology; Internal medicine; Intensive care medicine; Cancer","score_opus":0.027256223858852145,"score_gpt":0.27264843305991515,"score_spread":0.245392209201063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089833778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95700884,0.00048943196,0.0002801502,0.04019217,0.000083846775,0.00093693094,0.000023105118,0.00007610108,0.00090945314],"genre_scores_gemma":[0.9843873,0.000048391677,0.00086675765,0.014144116,0.00017154943,0.00024203114,0.000049815837,0.00002578801,0.000064284766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921066,0.000037690974,0.00015255265,0.00021116465,0.0001114303,0.00027649823],"domain_scores_gemma":[0.9993515,0.00014293508,0.00007994947,0.0002996449,0.000058103622,0.000067838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048176513,0.0001424585,0.0006391276,0.000016544838,0.000074893105,0.000010951794,0.000118954515,0.00006119551,0.000074740994],"category_scores_gemma":[0.000024781368,0.00007180769,0.00007384023,0.000085368796,0.000086920634,0.000024508738,0.000021114012,0.0000383597,0.00006692726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004450626,0.0009603405,0.8909519,0.00023145165,0.00067378354,0.00014703796,0.0020562042,0.0000024443218,0.00006204179,0.009051535,0.0409748,0.05043784],"study_design_scores_gemma":[0.036843643,0.0014981161,0.88364047,0.0000712099,0.00023009286,0.00016304359,0.000073689145,0.00009669929,0.0017166821,0.00032688436,0.07515612,0.00018337475],"about_ca_topic_score_codex":0.0000099562385,"about_ca_topic_score_gemma":0.0000042344477,"teacher_disagreement_score":0.050254468,"about_ca_system_score_codex":0.00004984708,"about_ca_system_score_gemma":0.000081860984,"threshold_uncertainty_score":0.29282328},"labels":[],"label_agreement":null},{"id":"W3093752978","doi":"10.1016/s2352-3026(20)30285-4","title":"Mortality benefits of thromboprophylaxis","year":2020,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Venous thromboembolism; Pulmonary embolism; Scopus; Overdiagnosis; MEDLINE; Intensive care medicine; Meta-analysis; Surgery; Internal medicine; Thrombosis","score_opus":0.08385518034055514,"score_gpt":0.31413435795413247,"score_spread":0.23027917761357733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093752978","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04820858,0.0012993112,0.00001618089,0.9384664,0.0005896258,0.0008592856,0.00011750773,0.00011034362,0.010332726],"genre_scores_gemma":[0.07672166,0.0011063282,0.00018110128,0.9169651,0.004323112,0.000088000656,0.0002873935,0.0000687882,0.00025851233],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99801344,0.00014393927,0.00050850015,0.0004360933,0.00040752205,0.0004904824],"domain_scores_gemma":[0.99809605,0.00015161074,0.0003714329,0.0012355599,0.00009434415,0.000050996074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017451648,0.00031887053,0.0033659188,0.000073964824,0.00006394335,0.000010637583,0.0005213148,0.00042827957,0.00040845637],"category_scores_gemma":[0.00009941459,0.00020417392,0.0002646246,0.0001895073,0.00034054782,0.000020284373,0.00026014782,0.0012770661,0.00028459026],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020648753,0.000074668314,0.0014199789,0.002598556,0.00060556823,0.00095818785,0.00020440119,0.0000022232334,0.000015693233,0.0033046943,0.9904126,0.00038276872],"study_design_scores_gemma":[0.0009320376,0.00047032165,0.034503557,0.00035469254,0.001653526,0.0003765978,0.00003486779,0.000012811235,0.00045972122,0.0028293312,0.95805025,0.00032227958],"about_ca_topic_score_codex":0.00018131104,"about_ca_topic_score_gemma":0.000020401327,"teacher_disagreement_score":0.033083577,"about_ca_system_score_codex":0.000028076473,"about_ca_system_score_gemma":0.00007636047,"threshold_uncertainty_score":0.8325971},"labels":[],"label_agreement":null},{"id":"W3111617049","doi":"10.1016/s2352-3026(20)30368-9","title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Children's Hospital of Eastern Ontario; Hospital for Sick Children; University of Ottawa","funders":"","keywords":"Dabigatran; Venous thromboembolism; Medicine; Open label; Randomized controlled trial; Intensive care medicine; Internal medicine; Atrial fibrillation; Warfarin; Thrombosis","score_opus":0.09972071038314155,"score_gpt":0.36821511905063026,"score_spread":0.2684944086674887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111617049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97271025,0.00036245605,0.0007452044,0.014397202,0.00029039133,0.011074392,0.00009100069,0.00003867636,0.00029042346],"genre_scores_gemma":[0.99620855,0.000587102,0.00028630797,0.00207306,0.0003313927,0.0004308552,0.000038989387,0.000020195708,0.000023554627],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985196,0.00020286195,0.0004893302,0.00029525984,0.00015490671,0.00033803392],"domain_scores_gemma":[0.99868083,0.00043100983,0.00026445117,0.00046343557,0.000062785,0.00009746916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043066233,0.00022417493,0.00278286,0.000046555517,0.00023000232,0.000022572764,0.00048585125,0.00013734888,0.00006198947],"category_scores_gemma":[0.00006974766,0.000121079705,0.00020623418,0.00018414257,0.00015800874,0.000056054352,0.00013749563,0.00015891317,0.000011802166],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9533117,0.006737483,0.0013150288,0.00010044974,0.005839806,0.00010908872,0.007902532,0.000015786583,0.008319452,0.011608206,0.00065662694,0.0040838607],"study_design_scores_gemma":[0.9814395,0.0065149325,0.000925042,0.00002463357,0.0030027444,0.0001276829,0.00008418183,0.0018957609,0.004309039,0.0012586917,0.00028120866,0.00013663474],"about_ca_topic_score_codex":0.00012406403,"about_ca_topic_score_gemma":0.000029695742,"teacher_disagreement_score":0.028127767,"about_ca_system_score_codex":0.000029088056,"about_ca_system_score_gemma":0.00011125388,"threshold_uncertainty_score":0.49374872},"labels":[],"label_agreement":null},{"id":"W3116889989","doi":"10.1016/s2352-3026(20)30375-6","title":"PARP inhibitors—understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia","year":2020,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Oncology; Veliparib; Internal medicine; Ovarian cancer; Cancer research; Carboplatin; Cancer; Chemotherapy; Poly ADP ribose polymerase; Polymerase; Biology; Genetics","score_opus":0.05215419540124464,"score_gpt":0.28976288000656997,"score_spread":0.23760868460532533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116889989","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043801513,0.0026575606,0.0016654959,0.94781715,0.0011399002,0.0010233376,0.00029867102,0.000165406,0.0014309982],"genre_scores_gemma":[0.46693048,0.003844031,0.00024264952,0.52386576,0.0044057807,0.00015617453,0.00013679659,0.0001384132,0.00027994905],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99699694,0.00070738647,0.0006738978,0.0005347076,0.0004729789,0.0006140823],"domain_scores_gemma":[0.99608886,0.0020499474,0.0007597031,0.0009576343,0.00006183492,0.0000819898],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0004804945,0.00047046313,0.002231299,0.00013205287,0.00028282,0.00003309749,0.00048148556,0.0006760855,0.00016356702],"category_scores_gemma":[0.00020330453,0.00026606675,0.00022423426,0.00030873634,0.0017771804,0.000058697027,0.0001854521,0.0034288738,0.00006652143],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040851574,0.00001262567,0.002487166,0.0009573541,0.0012585681,0.0037145165,0.00094596145,0.0000047726157,0.0003035529,0.0014202627,0.98843384,0.000052848314],"study_design_scores_gemma":[0.014856674,0.0020432824,0.0037054687,0.003935597,0.01047679,0.11071223,0.0012037838,0.00053510925,0.0029165666,0.1336787,0.71399975,0.0019360773],"about_ca_topic_score_codex":0.000032812906,"about_ca_topic_score_gemma":0.0000051768416,"teacher_disagreement_score":0.4239514,"about_ca_system_score_codex":0.00020603927,"about_ca_system_score_gemma":0.00019796373,"threshold_uncertainty_score":0.99997914},"labels":[],"label_agreement":null},{"id":"W3135992090","doi":"10.1016/s2352-3026(21)00067-3","title":"A century between pandemics and poisonings","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Hepatic veno-occlusive disease; Hematopoietic stem cell transplantation; Chemotherapy; Disease; Haematopoiesis; Liver transplantation; Pandemic; Intensive care medicine; Transplantation; Stem cell; Internal medicine; Coronavirus disease 2019 (COVID-19)","score_opus":0.040178080253992526,"score_gpt":0.30416510258695245,"score_spread":0.2639870223329599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135992090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781163,0.0012412675,0.001251768,0.014649058,0.00009211825,0.00013174822,0.000008117105,0.00006177757,0.0044478574],"genre_scores_gemma":[0.9953397,0.0008298379,0.0016990051,0.0017446075,0.0001771288,0.000007661312,0.000034872843,0.000012205678,0.00015497292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992758,0.000099003766,0.00016422573,0.00015726846,0.00009167549,0.00021203123],"domain_scores_gemma":[0.9992603,0.00035356358,0.000043489155,0.0002444189,0.00004086022,0.000057334386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002287757,0.0000803889,0.00051451917,0.00002014325,0.00005232729,0.000008423848,0.00005503279,0.00009253736,0.000036315218],"category_scores_gemma":[0.000091560396,0.000054815617,0.000029250441,0.00009232219,0.0000945789,0.000018440109,0.000027990533,0.00018213506,0.000028252978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009820859,0.000030850708,0.9588645,0.00090375403,0.00013750001,0.001150976,0.003286121,4.0757504e-7,0.003860867,0.02475871,0.00185981,0.005048268],"study_design_scores_gemma":[0.012482104,0.00025872458,0.6859077,0.0012490873,0.0018856965,0.08919745,0.0037853757,0.00024754702,0.060579855,0.014472041,0.12917206,0.0007623292],"about_ca_topic_score_codex":0.000007884747,"about_ca_topic_score_gemma":0.00000754563,"teacher_disagreement_score":0.2729568,"about_ca_system_score_codex":0.00000882985,"about_ca_system_score_gemma":0.00004690873,"threshold_uncertainty_score":0.22353159},"labels":[],"label_agreement":null},{"id":"W3143101252","doi":"10.1016/s2352-3026(17)30177-1","title":"Erythropoietin on cycling performance","year":2017,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Erythropoietin; Placebo; Cycling; Double blind; Internal medicine; Physical therapy; Alternative medicine; Pathology","score_opus":0.06843412221406373,"score_gpt":0.32916519119568516,"score_spread":0.26073106898162146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143101252","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041651063,0.00053777464,0.0000028939824,0.89983016,0.0010715169,0.00045872567,0.000017261986,0.00016228508,0.05626833],"genre_scores_gemma":[0.060508188,0.0017654271,0.00048126397,0.89765257,0.014434363,0.00011312442,0.00031810734,0.00012970845,0.02459724],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978694,0.00013255198,0.00034686265,0.00052805775,0.00034964603,0.0007735145],"domain_scores_gemma":[0.99711,0.00028898785,0.00037450317,0.0021101693,0.000059079808,0.000057261896],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027130017,0.0004584542,0.0018459113,0.000084583844,0.00044827536,0.000041808045,0.0005944745,0.0008603907,0.00042090827],"category_scores_gemma":[0.00011733097,0.0002636085,0.00023434011,0.000043771928,0.00064503454,0.000026390846,0.00012524905,0.0028345748,0.0020539623],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115826704,0.000045680656,0.0016657191,0.0007771615,0.0001348438,0.0055283657,0.00009987345,8.644112e-7,0.000008808035,0.00014927002,0.9903957,0.0010778419],"study_design_scores_gemma":[0.0016836495,0.00041987738,0.0008016855,0.001051077,0.0003162555,0.0072322744,0.000021025695,0.000023080209,0.0005321071,0.00020122681,0.987424,0.00029373312],"about_ca_topic_score_codex":0.000027477223,"about_ca_topic_score_gemma":0.0000032153819,"teacher_disagreement_score":0.03167109,"about_ca_system_score_codex":0.00008862798,"about_ca_system_score_gemma":0.00011536716,"threshold_uncertainty_score":0.99998164},"labels":[],"label_agreement":null},{"id":"W3155195921","doi":"10.1016/s2352-3026(21)00060-0","title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Canada Research Chairs; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Intensive care; Intensive care unit; Cytokine release syndrome; Cohort study; Cohort; Observational study; Proportional hazards model; Internal medicine; Retrospective cohort study; Emergency medicine; Chimeric antigen receptor; Pediatrics; Intensive care medicine; Confidence interval; Immunotherapy","score_opus":0.05996188039825393,"score_gpt":0.35537644755280046,"score_spread":0.2954145671545465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155195921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993148,0.00011569032,0.0000026088212,0.0034847255,0.00017973113,0.0022765934,0.000053139796,0.000057334484,0.00068216276],"genre_scores_gemma":[0.9939078,0.00015306052,0.00019074394,0.0036248341,0.000090033434,0.00017815683,0.00065851933,0.00004612545,0.0011507324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778336,0.00041767076,0.0003554387,0.00051119545,0.0005179028,0.00041442426],"domain_scores_gemma":[0.9973433,0.00017990188,0.00010731052,0.0007509675,0.0014902415,0.00012830588],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018631862,0.00024284457,0.0010487039,0.00015251554,0.0000738412,0.000031279535,0.0003514657,0.0000870403,0.0012724983],"category_scores_gemma":[0.00022000464,0.00015712697,0.000062865554,0.00045446763,0.000082861436,0.00009193867,0.00010554155,0.0003363021,0.000061939274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028296572,0.0008739643,0.9875934,0.000018235267,0.00036862039,0.00020426801,0.0054554804,0.000013070122,0.0010806794,0.000011146158,0.0006834619,0.00086803176],"study_design_scores_gemma":[0.009593734,0.0010029307,0.97834086,0.000043463708,0.000035738416,0.000029667739,0.0059760404,0.000051318475,0.0024010981,0.0000026202633,0.0023580415,0.00016448497],"about_ca_topic_score_codex":0.0003150926,"about_ca_topic_score_gemma":0.00063367176,"teacher_disagreement_score":0.009252523,"about_ca_system_score_codex":0.00014479808,"about_ca_system_score_gemma":0.00015194135,"threshold_uncertainty_score":0.99964046},"labels":[],"label_agreement":null},{"id":"W3155992812","doi":"10.1016/s2352-3026(21)00056-9","title":"Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management","year":2021,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"IgG4-Related and Inflammatory Diseases","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Medicine; Polyclonal antibodies; Hypergammaglobulinemia; Immunology; Plasmacytosis; Immune dysregulation; Castleman disease; Pathology; Disease; Antibody; Multiple myeloma","score_opus":0.09329584682208628,"score_gpt":0.456191901175889,"score_spread":0.3628960543538027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155992812","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016176712,0.9859376,0.00006140608,0.0015178616,0.00062922196,0.0007462363,0.000026795571,0.00008606853,0.01083303],"genre_scores_gemma":[0.00010773889,0.99617386,0.000643156,0.0012655531,0.0005821527,0.00011870739,0.0002572479,0.00004437706,0.00080718583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973858,0.0006238943,0.00095960184,0.0004903747,0.00018242544,0.0003579001],"domain_scores_gemma":[0.9982765,0.0004308549,0.00036634816,0.0007178067,0.00006728516,0.00014121961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053665205,0.0003527045,0.0038256014,0.00009522283,0.00010176986,0.00003331875,0.00026005635,0.00042591142,0.0002036915],"category_scores_gemma":[0.00011805281,0.00021503103,0.00045484558,0.00017671552,0.000332115,0.000038574886,0.0002708057,0.00089320337,0.00012766682],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007099334,0.00016396979,0.0018711424,0.03432493,0.0018977284,0.004114596,0.000033740365,1.3777634e-7,2.8155698e-8,0.041832462,0.050994117,0.86469615],"study_design_scores_gemma":[0.000751374,0.00006057764,0.00077707006,0.00973922,0.004399577,0.0050421115,0.000034029184,0.000013777673,6.1833504e-8,0.00018172635,0.97879857,0.00020189851],"about_ca_topic_score_codex":0.0000016575918,"about_ca_topic_score_gemma":0.0000017588584,"teacher_disagreement_score":0.92780447,"about_ca_system_score_codex":0.000046997546,"about_ca_system_score_gemma":0.0003226759,"threshold_uncertainty_score":0.8768711},"labels":[],"label_agreement":null},{"id":"W3165566500","doi":"10.1016/s2352-3026(21)00102-2","title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Pharmacyclics; Genentech; Bayer Fund; Seattle Genetics; Janssen Pharmaceuticals; Gilead Sciences; Roche; Johnson and Johnson; AbbVie; Merck; Celgene; Bristol-Myers Squibb; AstraZeneca; Takeda Pharmaceuticals U.S.A.; Pfizer","keywords":"Medicine; Brentuximab vedotin; Open label; Oncology; Internal medicine; Chemotherapy; Hodgkin lymphoma; Phases of clinical research; Lymphoma; Randomized controlled trial","score_opus":0.07474879554476967,"score_gpt":0.39146995681349683,"score_spread":0.3167211612687272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165566500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98003185,0.00014887887,0.00031245535,0.015895184,0.00031633108,0.0021234974,0.00015284622,0.00004060031,0.0009783343],"genre_scores_gemma":[0.9860933,0.0004831722,0.0076085716,0.0029334405,0.00047164317,0.0007945247,0.00040868533,0.000050308176,0.0011563716],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99843246,0.00018200219,0.00045199276,0.00039766406,0.00021680846,0.00031905712],"domain_scores_gemma":[0.998346,0.00044748533,0.00026773402,0.00066767086,0.0001699277,0.00010121471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040272286,0.0002156483,0.0014257606,0.00004675907,0.00007817923,0.00005087268,0.00042204367,0.000115195355,0.00050081825],"category_scores_gemma":[0.0001495727,0.00011803059,0.000087697335,0.00013527484,0.00017747321,0.00010580026,0.000100028235,0.000073400115,0.000013452312],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94331616,0.011885564,0.00064065953,0.000117587304,0.0012050617,0.001038655,0.0004240872,0.0000012802195,0.0007593516,0.012760467,0.0057066493,0.02214448],"study_design_scores_gemma":[0.9313973,0.003425915,0.00023715931,0.000096332034,0.0003092886,0.0008200096,0.00016775321,0.00044740678,0.026948556,0.00022694375,0.035769694,0.00015364467],"about_ca_topic_score_codex":0.0000328657,"about_ca_topic_score_gemma":0.00007657053,"teacher_disagreement_score":0.030063046,"about_ca_system_score_codex":0.00009371566,"about_ca_system_score_gemma":0.00064081355,"threshold_uncertainty_score":0.5483608},"labels":[],"label_agreement":null},{"id":"W3176370909","doi":"10.1016/s2352-3026(21)00134-4","title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":211,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"Celator Pharmaceuticals; Jazz Pharmaceuticals","keywords":"Medicine; Cytarabine; Daunorubicin; Internal medicine; Myeloid leukemia; Chemotherapy; Myeloid leukaemia; Chemotherapy regimen; Oncology; Pediatrics","score_opus":0.03108454719582305,"score_gpt":0.33817549234273164,"score_spread":0.3070909451469086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176370909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98455125,0.0007347346,0.000038118393,0.009053932,0.00023593615,0.004319117,0.00027092226,0.000052000283,0.0007439591],"genre_scores_gemma":[0.984178,0.0071468726,0.005405994,0.0013100967,0.0003956526,0.0003935263,0.0003293854,0.00009687276,0.00074357516],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961975,0.00082637015,0.00092978444,0.0008186714,0.00040523225,0.00082242774],"domain_scores_gemma":[0.9951868,0.002656147,0.0004648045,0.0012087413,0.0002634085,0.00022008269],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001192342,0.00041342675,0.0025633895,0.00017838879,0.000117605065,0.00004622597,0.00059784995,0.0003245366,0.0003095677],"category_scores_gemma":[0.0015269654,0.00024998642,0.00006826344,0.000695057,0.0005087961,0.00017072435,0.00033833573,0.0011850173,0.000021412767],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97005886,0.0014551174,0.00056859874,0.00028780356,0.0007537687,0.0056165047,0.0025900446,0.0000048718366,0.0014037138,0.00012678184,0.008086095,0.0090478705],"study_design_scores_gemma":[0.9788458,0.0039469837,0.0014154232,0.0004374757,0.00045219663,0.0008407798,0.0012926498,0.00043339178,0.011082037,0.000040835814,0.0009293876,0.0002830784],"about_ca_topic_score_codex":0.0012669608,"about_ca_topic_score_gemma":0.0021254367,"teacher_disagreement_score":0.009678324,"about_ca_system_score_codex":0.00016954698,"about_ca_system_score_gemma":0.001238521,"threshold_uncertainty_score":0.99999523},"labels":[],"label_agreement":null},{"id":"W3199497677","doi":"10.1016/s2352-3026(21)00269-6","title":"All-trans retinoic acid for treating immune thrombocytopenia: new purpose for an old drug?","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Thrombopoietin; Eltrombopag; Thrombopoietin receptor; Immune system; Internal medicine; Thrombocytopenic purpura; Antibody; Hematology; Immunology; Immune thrombocytopenia","score_opus":0.05526540880039474,"score_gpt":0.3396319064009549,"score_spread":0.2843664976005602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199497677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9618138,0.0026619204,0.0015685457,0.030426184,0.00021710033,0.0013418187,0.000065923814,0.00010506822,0.001799607],"genre_scores_gemma":[0.9840039,0.00030220003,0.008632552,0.003076927,0.00029373626,0.0002523206,0.0004904592,0.000052527266,0.0028953576],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99873453,0.00006687107,0.00028543096,0.00033045028,0.00008489902,0.0004978385],"domain_scores_gemma":[0.99895203,0.00022309448,0.00009602088,0.0005567706,0.00007520863,0.00009686773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018918703,0.00019338167,0.0013503769,0.000028591117,0.00015509421,0.000022072072,0.0001707844,0.00011519733,0.000083200975],"category_scores_gemma":[0.00011232386,0.00013150554,0.0001733772,0.00009260107,0.00006527597,0.000064199805,0.000031068004,0.00013212537,0.000017094155],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019920792,0.005761906,0.038836114,0.0059377705,0.008163685,0.01340948,0.034065332,0.000057933186,0.402153,0.12904821,0.23538461,0.107261166],"study_design_scores_gemma":[0.08535873,0.0032818175,0.009817567,0.0007031856,0.0052042017,0.02678884,0.0036996712,0.0018350482,0.63253266,0.07388532,0.15546985,0.0014230883],"about_ca_topic_score_codex":0.000113577225,"about_ca_topic_score_gemma":0.0004067907,"teacher_disagreement_score":0.23037969,"about_ca_system_score_codex":0.000025257124,"about_ca_system_score_gemma":0.00012481,"threshold_uncertainty_score":0.53626406},"labels":[],"label_agreement":null},{"id":"W3204272926","doi":"10.1016/s2352-3026(21)00271-4","title":"Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"Medicine; Mycosis fungoides; Refractory (planetary science); Internal medicine; Cohort; Adverse effect; Gastroenterology; Surgery; Dermatology; Lymphoma","score_opus":0.04827010800737181,"score_gpt":0.3387986010248302,"score_spread":0.2905284930174584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204272926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247223,0.00091303635,0.00002658372,0.004137565,0.0001067829,0.0021611024,0.00004664008,0.0000599749,0.00007609319],"genre_scores_gemma":[0.99730265,0.000212451,0.0005769348,0.00097069796,0.000055112294,0.000279843,0.00013616237,0.00004737802,0.00041874198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99651706,0.0008926166,0.0007108624,0.0005951034,0.00048448207,0.00079989486],"domain_scores_gemma":[0.9973001,0.0011638219,0.00025166708,0.0008234999,0.0003600647,0.00010084984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009733809,0.0003423683,0.0013009077,0.00014934098,0.00026321047,0.000034649398,0.00043590376,0.00015196105,0.00051421556],"category_scores_gemma":[0.0029301853,0.00015104552,0.00008972969,0.00069817726,0.0004151969,0.0000638424,0.0003695086,0.00080077234,0.000041304087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057451006,0.015795156,0.8877351,0.0004936292,0.0010161578,0.013625815,0.008385384,0.00004293592,0.01257184,0.00009919602,0.00090241665,0.0018813616],"study_design_scores_gemma":[0.10265248,0.012943686,0.8346498,0.0010056815,0.00047582152,0.018049506,0.02192831,0.0015821386,0.0042308015,0.00014304522,0.0013622135,0.0009765082],"about_ca_topic_score_codex":0.00012166666,"about_ca_topic_score_gemma":0.00062043895,"teacher_disagreement_score":0.0530853,"about_ca_system_score_codex":0.0001606724,"about_ca_system_score_gemma":0.0005578239,"threshold_uncertainty_score":0.61594576},"labels":[],"label_agreement":null},{"id":"W3211623336","doi":"10.1016/s2352-3026(21)00306-9","title":"Vaccine-induced immune thrombotic thrombocytopenia","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Heparin-Induced Thrombocytopenia and Thrombosis","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Bayer; Bristol-Myers Squibb","keywords":"Immune thrombocytopenia; Antibody; Immune system; Vaccination; Thrombosis; Venous thrombosis; Immunization; Intravenous Immunoglobulins","score_opus":0.07505048938255585,"score_gpt":0.3375881821335542,"score_spread":0.26253769275099836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211623336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9306212,0.0008975613,0.00007991904,0.038397886,0.0008900724,0.0005290486,0.0000070217584,0.0002732945,0.028303958],"genre_scores_gemma":[0.99290246,0.0003478965,0.0009259335,0.004365827,0.00054975704,0.000056612782,0.000051362622,0.00007669914,0.0007234331],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969403,0.0003799175,0.00070046016,0.00066855596,0.00031730195,0.0009934785],"domain_scores_gemma":[0.99699646,0.00032788573,0.00019881896,0.0020013857,0.00025901245,0.00021643254],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00051530026,0.00041328606,0.002888586,0.00008913576,0.0003367904,0.00006461243,0.0005443687,0.00032754202,0.0019008814],"category_scores_gemma":[0.0003965245,0.00028670457,0.00030788378,0.00064745994,0.00014190243,0.00013889605,0.0004069691,0.000851822,0.0016700343],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005009514,0.0009833326,0.05448091,0.00073752366,0.0016185674,0.005266843,0.0019041497,0.000006144356,0.795938,0.1221794,0.013754244,0.0026299092],"study_design_scores_gemma":[0.008918521,0.00048813096,0.55318385,0.00036098014,0.0012644667,0.025802225,0.0009184359,0.00014911534,0.38404545,0.008355981,0.01562261,0.00089025515],"about_ca_topic_score_codex":0.00012623619,"about_ca_topic_score_gemma":0.00018728287,"teacher_disagreement_score":0.4987029,"about_ca_system_score_codex":0.00010147308,"about_ca_system_score_gemma":0.00044873095,"threshold_uncertainty_score":0.9999585},"labels":[],"label_agreement":null},{"id":"W3217353697","doi":"10.1016/s2352-3026(21)00311-2","title":"Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; Roche","keywords":"Lenalidomide; Medicine; Follicular lymphoma; Obinutuzumab; Internal medicine; Rituximab; Oncology; Lymphoma; Cohort; Neutropenia; Tolerability; Brentuximab vedotin; Gastroenterology; Chemotherapy; Adverse effect; Multiple myeloma; CD30","score_opus":0.02440419732320716,"score_gpt":0.28496713509118393,"score_spread":0.2605629377679768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217353697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659747,0.0012694965,0.0000042845995,0.00036911646,0.00008585846,0.0014095893,0.000020228352,0.00003215959,0.00021177848],"genre_scores_gemma":[0.99896747,0.00009030586,0.00031163852,0.00032363948,0.000033973287,0.00012063031,0.000054543536,0.000029185207,0.000068627254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980791,0.00031387105,0.00048598496,0.00044034675,0.00029752892,0.0003831641],"domain_scores_gemma":[0.99846077,0.00037450128,0.00023973851,0.0006745996,0.00014935793,0.00010104273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018244372,0.00025851835,0.0015075454,0.000092242866,0.0000660467,0.000014462835,0.00011290777,0.000106246756,0.000044702625],"category_scores_gemma":[0.00024923615,0.0001461561,0.00006538376,0.00028520316,0.00015412914,0.000058134654,0.00010145132,0.00011566047,0.0000073378087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016392142,0.021150269,0.9487895,0.00021999881,0.0008882716,0.0060883113,0.0040636766,0.000009740443,0.00010058435,0.0001717457,0.00020422434,0.0019215407],"study_design_scores_gemma":[0.2769307,0.0066466695,0.70853925,0.00046064288,0.0012303671,0.0008901538,0.0021793954,0.00024507623,0.0019444991,0.000037982034,0.0006139514,0.0002813347],"about_ca_topic_score_codex":0.0004195524,"about_ca_topic_score_gemma":0.0006066536,"teacher_disagreement_score":0.26053855,"about_ca_system_score_codex":0.000795779,"about_ca_system_score_gemma":0.0007502466,"threshold_uncertainty_score":0.5960073},"labels":[],"label_agreement":null},{"id":"W4200016924","doi":"10.1016/s2352-3026(21)00351-3","title":"Sex specific definitions of anaemia contribute to health inequity and sociomedical injustice","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Public health; Pregnancy; Injustice; Anemia; Pathological; Epidemiology","score_opus":0.05165800612500909,"score_gpt":0.32285333895385526,"score_spread":0.27119533282884617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200016924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7800273,0.008267503,0.0017058237,0.2056672,0.00022350383,0.00029031953,0.00007489279,0.000049135062,0.0036943303],"genre_scores_gemma":[0.9820954,0.007567403,0.0008694395,0.009219798,0.00011312913,0.000009164315,0.000046097637,0.000009489912,0.00007008658],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989772,0.0001483499,0.00027791725,0.0001658408,0.00012342074,0.00030730772],"domain_scores_gemma":[0.9991803,0.00022944553,0.00007012372,0.0002815669,0.000080627826,0.00015790832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003830564,0.00008380429,0.00077568495,0.000039656694,0.000104807244,0.000004616115,0.00007028577,0.00011955706,0.000094969226],"category_scores_gemma":[0.00029177262,0.000057002366,0.00003956937,0.0002356659,0.00026699578,0.000011344281,0.00009569986,0.0003008208,0.000025723511],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006943277,0.0007703259,0.03829104,0.0028180783,0.00049139984,0.0019352492,0.0113758715,0.000018102804,0.003122169,0.58228093,0.33591858,0.02228391],"study_design_scores_gemma":[0.037031915,0.0037527187,0.16112317,0.002772638,0.0014773309,0.043572247,0.041937523,0.000742905,0.009418024,0.1277898,0.5688471,0.001534638],"about_ca_topic_score_codex":0.000037192676,"about_ca_topic_score_gemma":0.00003252365,"teacher_disagreement_score":0.45449117,"about_ca_system_score_codex":0.000025276016,"about_ca_system_score_gemma":0.0002155419,"threshold_uncertainty_score":0.23244889},"labels":[],"label_agreement":null},{"id":"W4200347843","doi":"10.1016/s2352-3026(21)00349-5","title":"Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Lymphoma Research Foundation; Children’s Oncology Group; Irving Medical Center, Columbia University; St. Baldrick's Foundation","keywords":"Pooled analysis; Lymphoma; Meta-analysis; Retrospective cohort study; Survival analysis; Hodgkin lymphoma; MEDLINE; Clinical trial","score_opus":0.019518349032160386,"score_gpt":0.28792850178472795,"score_spread":0.2684101527525676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200347843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952618,0.0021640249,0.000018522653,0.0015299662,0.00007273518,0.00053242524,0.0001231197,0.000016556547,0.00028084638],"genre_scores_gemma":[0.99824065,0.0006278552,0.00015622153,0.000513953,0.00005484818,0.000058925994,0.00031933343,0.000012716808,0.000015483647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778247,0.000818083,0.00050718145,0.00037212923,0.00021655305,0.00030356704],"domain_scores_gemma":[0.99854183,0.0005788145,0.00033182482,0.00038789856,0.00008726273,0.00007235529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006380045,0.00018720714,0.0028438955,0.00019292292,0.000037093083,0.000008651501,0.00008799253,0.00013611055,0.000037377995],"category_scores_gemma":[0.0003115954,0.00010893645,0.00015291045,0.0008766921,0.00015764036,0.00002382868,0.00008171962,0.000098287506,0.0000020676584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009568815,0.0020229407,0.98987305,0.00003758486,0.0024571747,0.00045961599,0.00029599844,0.000001989179,0.0000293008,0.0006178447,0.00070051115,0.002547102],"study_design_scores_gemma":[0.017458776,0.0005245255,0.9764385,0.000037337213,0.0048153475,0.00007702885,0.0000761222,0.000011051975,0.00027415474,0.00010561072,0.0000813802,0.000100125806],"about_ca_topic_score_codex":0.00018623605,"about_ca_topic_score_gemma":0.0007500176,"teacher_disagreement_score":0.016501894,"about_ca_system_score_codex":0.00028362658,"about_ca_system_score_gemma":0.00014059867,"threshold_uncertainty_score":0.44422996},"labels":[],"label_agreement":null},{"id":"W4210632919","doi":"10.1016/s2352-3026(21)00283-0","title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","year":2022,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Intensive care medicine; Context (archaeology); Vaccination; Disease; Immunology; Internal medicine","score_opus":0.33242502555324743,"score_gpt":0.45737459681764064,"score_spread":0.12494957126439321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210632919","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036051192,0.96915674,0.00029464645,0.020279791,0.0013076636,0.0045389025,0.00027922352,0.00009303721,0.0004448932],"genre_scores_gemma":[0.0014979952,0.9883793,0.0025674463,0.00029040573,0.000609828,0.0024088074,0.003916624,0.00004345016,0.0002861588],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99767226,0.00048536208,0.0008561758,0.00044861773,0.00021994385,0.00031762666],"domain_scores_gemma":[0.9957097,0.0031127725,0.0005177567,0.00053044973,0.000078273224,0.000051027808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011754418,0.0002557464,0.0014323365,0.0001545739,0.0002676166,0.000039573748,0.00023928806,0.00016292222,0.00017162203],"category_scores_gemma":[0.0026312727,0.00014846004,0.00023710355,0.00021827068,0.000116687894,0.000027830809,0.00025578652,0.0005204139,0.0000090636095],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025359407,0.00012376717,0.012614837,0.0008994149,0.00065257243,0.0005417993,0.00008501957,6.21205e-7,9.2623657e-7,0.00038271796,0.016377106,0.96806765],"study_design_scores_gemma":[0.002093728,0.00006568331,0.0025096976,0.0020574215,0.00043732152,0.005335067,0.00005446137,0.00025722614,5.2846457e-7,0.0007861315,0.9862812,0.00012149284],"about_ca_topic_score_codex":0.00056899275,"about_ca_topic_score_gemma":0.0018694199,"teacher_disagreement_score":0.9699041,"about_ca_system_score_codex":0.00018849784,"about_ca_system_score_gemma":0.00018836222,"threshold_uncertainty_score":0.60540247},"labels":[],"label_agreement":null},{"id":"W4210694747","doi":"10.1016/s2352-3026(21)00366-5","title":"Malignancy-associated haemophagocytic lymphohistiocytosis","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Vancouver Hospital and Health Sciences Centre; BC Children's Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Macrophage activation syndrome; Hemophagocytic lymphohistiocytosis; Cytokine storm; Immune system; Cytokine; Chemokine; Lymphoma; Cancer","score_opus":0.04493415929046922,"score_gpt":0.3097292743034708,"score_spread":0.26479511501300157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210694747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9503644,0.003153885,0.00004196308,0.019083308,0.00028481864,0.0005381477,0.000025222917,0.00021853807,0.026289705],"genre_scores_gemma":[0.9915591,0.00011986305,0.000033157565,0.0037041763,0.000066676956,0.00023511644,0.000047397352,0.000028314395,0.004206188],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820584,0.0003546455,0.00031212776,0.00022755074,0.00036507714,0.00053476304],"domain_scores_gemma":[0.9990048,0.00014093667,0.0001233302,0.00061648164,0.000058303023,0.000056186054],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006832525,0.00013393546,0.0008362289,0.00009512957,0.000565712,0.000011433711,0.00039317692,0.000062731415,0.0025024319],"category_scores_gemma":[0.00022683323,0.000098571276,0.00011659081,0.00037813553,0.00020504121,0.000032746255,0.00032408212,0.00043440264,0.00025893282],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003564427,0.0017391383,0.20311345,0.0008594982,0.001319825,0.008428215,0.005398183,0.000317174,0.007676548,0.097253956,0.65478575,0.015543854],"study_design_scores_gemma":[0.030888334,0.0024115562,0.1935122,0.00020722277,0.0008253361,0.022558635,0.0057414537,0.006810855,0.0063148467,0.01921689,0.7101106,0.0014020673],"about_ca_topic_score_codex":0.000065853805,"about_ca_topic_score_gemma":0.000008477469,"teacher_disagreement_score":0.07803707,"about_ca_system_score_codex":0.00021148723,"about_ca_system_score_gemma":0.000300377,"threshold_uncertainty_score":0.9984094},"labels":[],"label_agreement":null},{"id":"W4221022237","doi":"10.1016/s2352-3026(22)00053-9","title":"Sex specific definitions of anaemia reflect androgen production – Authors' reply","year":2022,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Erythropoiesis; Medicine; Androgen; Testosterone (patch); Androgen deficiency; Endocrinology; Internal medicine; Anemia; Physiology; Hormone","score_opus":0.11654895895473834,"score_gpt":0.3203843541744941,"score_spread":0.2038353952197558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221022237","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022530857,0.0057986905,0.0000066370435,0.951042,0.0013212224,0.00072848174,0.00010139613,0.00012135991,0.018349348],"genre_scores_gemma":[0.13635176,0.027660895,0.0022003958,0.7312312,0.06070706,0.0014296426,0.0031957345,0.0004326849,0.03679062],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976065,0.00041443095,0.00048175766,0.0006878847,0.00037232102,0.00043707414],"domain_scores_gemma":[0.99803007,0.00016826218,0.00033976012,0.0012662385,0.00016681521,0.000028827852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062252313,0.0002833249,0.0018117878,0.00017603699,0.00028745286,0.0000053050594,0.0002680163,0.0002605147,0.00034926072],"category_scores_gemma":[0.0002783312,0.000179412,0.00021075735,0.00038253228,0.00061122305,0.000022755023,0.0001939426,0.0020456929,0.000053289332],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021077717,0.000049811075,0.0007595084,0.00051787857,0.00038759087,0.00092803827,0.00069665856,0.000001530102,0.00033851896,0.0013408796,0.9944978,0.0002710178],"study_design_scores_gemma":[0.00033304121,0.00029499122,0.0006352384,0.00007058643,0.00032561657,0.0053901975,0.00028863468,4.238009e-7,0.0018697303,0.007156725,0.983445,0.0001897975],"about_ca_topic_score_codex":0.000032351418,"about_ca_topic_score_gemma":0.0000054416128,"teacher_disagreement_score":0.2198108,"about_ca_system_score_codex":0.00007647368,"about_ca_system_score_gemma":0.00010842183,"threshold_uncertainty_score":0.8887631},"labels":[],"label_agreement":null},{"id":"W4224529699","doi":"10.1016/s2352-3026(22)00045-x","title":"Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Princess Margaret Cancer Centre","funders":"National Center for Research Resources; National Heart, Lung, and Blood Institute; Genentech; Center for Clinical and Translational Science, Mayo Clinic; U.S. Food and Drug Administration; Medac; Swedish Orphan Biovitrum; Daiichi-Sankyo; Energy Market Authority of Singapore; Pfizer; Incyte; Yorkshire Cancer Research; Bayer Fund; TG Therapeutics; MorphoSys; UCB; National Institutes of Health; Regeneron Pharmaceuticals; Breast Cancer Now; Kræftens Bekæmpelse; Takeda Pharmaceuticals U.S.A.; Novartis; Celgene; Alnylam Pharmaceuticals; Sanofi; National Center for Advancing Translational Sciences; Teva Pharmaceutical Industries; Astellas Pharma; Georgia Clinical and Translational Science Alliance; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Bristol-Myers Squibb; Roche; Astellas Pharma US; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences","keywords":"Adverse effect; Context (archaeology); Clinical trial; Cancer; Hematology; Patient safety","score_opus":0.06402545302891255,"score_gpt":0.3630694404143654,"score_spread":0.29904398738545285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224529699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97165334,0.0018382686,0.00022952551,0.025066858,0.000143813,0.0008687505,0.000010552213,0.000041558906,0.00014731183],"genre_scores_gemma":[0.99567324,0.00019071781,0.0034074518,0.00040484016,0.000074015545,0.00020418769,0.000008912255,0.000016930824,0.000019728306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837875,0.00027136496,0.00064787024,0.0002567823,0.0001704821,0.00027472165],"domain_scores_gemma":[0.9986304,0.00031893686,0.0006809962,0.00030692466,0.000032022253,0.00003072608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015796745,0.0001325262,0.00083242723,0.0000634413,0.0003709258,0.0000031119566,0.00011834547,0.000083959894,0.000010886753],"category_scores_gemma":[0.00014684422,0.00007832192,0.00006395819,0.00015333257,0.00023766943,0.00003573863,0.00016170106,0.000505992,7.1768035e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005585319,0.00035798462,0.96440035,0.00063331943,0.00020978965,0.00034274894,0.008617945,0.00007712601,0.0021601862,0.015628567,0.00025781753,0.006755622],"study_design_scores_gemma":[0.009846047,0.0007383064,0.81053597,0.0004744459,0.00056857325,0.04840452,0.014435935,0.013112236,0.0027087359,0.08924947,0.009342477,0.0005832768],"about_ca_topic_score_codex":0.000026780097,"about_ca_topic_score_gemma":0.00003232496,"teacher_disagreement_score":0.15386438,"about_ca_system_score_codex":0.000057687765,"about_ca_system_score_gemma":0.00005145247,"threshold_uncertainty_score":0.31938753},"labels":[],"label_agreement":null},{"id":"W4229458082","doi":"10.1016/s2352-3026(22)00103-x","title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Princess Margaret Cancer Centre; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary","funders":"Celgene; European Hematology Association; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Clinical endpoint; Transplantation; Autologous stem-cell transplantation; Oncology; Surgery; Clinical trial","score_opus":0.062251826724128344,"score_gpt":0.36570004295411734,"score_spread":0.303448216229989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229458082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876368,0.000116440155,0.000917935,0.0007316548,0.00009920194,0.009351031,0.0010370439,0.000034169978,0.000075719356],"genre_scores_gemma":[0.9876275,0.000085032094,0.0063994676,0.00036624324,0.00007536919,0.0037379735,0.0016275225,0.00003574935,0.000045156834],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979463,0.000460124,0.0004129523,0.00039467425,0.00033958192,0.00044633696],"domain_scores_gemma":[0.99776506,0.0012696362,0.00021123285,0.00040370872,0.00014036905,0.00021001158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052120164,0.00020398157,0.00096575957,0.00015027235,0.00028748866,0.000028771157,0.00028083852,0.000052271003,0.00014227707],"category_scores_gemma":[0.00039865746,0.00013741493,0.000038583934,0.00020643073,0.00010484798,0.00014073924,0.00010436786,0.00016484245,0.0000041275557],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9679289,0.0044972724,0.008685218,0.00024214505,0.00032077602,0.00017968466,0.0012853366,0.000043844102,0.000739986,0.00026143633,0.0008559143,0.01495949],"study_design_scores_gemma":[0.9783733,0.011007799,0.005724841,0.0000679585,0.00036568617,0.00014423582,0.00033614112,0.0011239373,0.0015984407,0.00008632469,0.000997043,0.00017429666],"about_ca_topic_score_codex":0.00039574175,"about_ca_topic_score_gemma":0.00025982675,"teacher_disagreement_score":0.014785194,"about_ca_system_score_codex":0.00007542881,"about_ca_system_score_gemma":0.00012272975,"threshold_uncertainty_score":0.5603618},"labels":[],"label_agreement":null},{"id":"W4280594357","doi":"10.1016/s2352-3026(22)00102-8","title":"Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"Novartis Pharmaceuticals Corporation; Novartis","keywords":"Ruxolitinib; Medicine; Polycythaemia; Clinical endpoint; Internal medicine; Phlebotomy; Myelofibrosis; Polycythemia vera; Clinical trial; Randomized controlled trial; Pediatrics; Surgery; Bone marrow","score_opus":0.08405562557028219,"score_gpt":0.35526130428884,"score_spread":0.27120567871855783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280594357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869192,0.0012691626,0.0000031321015,0.0040841126,0.00043356078,0.0048103905,0.000081747596,0.00004469843,0.0023539695],"genre_scores_gemma":[0.99502504,0.00032283104,0.00007706755,0.00054353714,0.000102751765,0.0028542199,0.00003309102,0.00004317455,0.0009982677],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960715,0.0016831205,0.0007735683,0.00046158605,0.00043283566,0.0005773871],"domain_scores_gemma":[0.996712,0.0019814898,0.00036253937,0.000743754,0.00009227395,0.00010789857],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018028829,0.00033951266,0.002819989,0.00024269425,0.0002463966,0.0000127147905,0.0003181986,0.0000792102,0.0015979465],"category_scores_gemma":[0.00045833224,0.00022485925,0.00023552145,0.00035058922,0.00015361693,0.000046421355,0.00012074798,0.00047261966,0.00009207233],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86730206,0.004748012,0.117960855,0.00003802914,0.0011194696,0.0010336905,0.003957473,0.000026237632,0.0005437927,0.0011660433,0.0017116292,0.0003926802],"study_design_scores_gemma":[0.9655591,0.016280118,0.004872672,0.00004816578,0.0005099179,0.0003856628,0.0038413492,0.00021601352,0.0021899184,0.00011108754,0.005705856,0.00028013403],"about_ca_topic_score_codex":0.000486632,"about_ca_topic_score_gemma":0.00018386525,"teacher_disagreement_score":0.11308818,"about_ca_system_score_codex":0.00017964869,"about_ca_system_score_gemma":0.00039045146,"threshold_uncertainty_score":0.9993147},"labels":[],"label_agreement":null},{"id":"W4281792225","doi":"10.1016/s2352-3026(22)00174-0","title":"Climate change and haematology: perspectives from the Philippines","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Climate Change and Health Impacts","field":"Environmental Science","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hematology; Internal medicine; Intensive care medicine","score_opus":0.11915282715021121,"score_gpt":0.3209336407305177,"score_spread":0.20178081358030653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281792225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83887994,0.0029972247,0.0000016057804,0.15446071,0.00023941643,0.00037329056,0.00011341816,0.00006111736,0.0028732507],"genre_scores_gemma":[0.98361224,0.0019225818,0.00005045174,0.013770789,0.00032914933,0.00025261092,0.000014362345,0.000015951291,0.00003188006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984675,0.0003415042,0.00016823382,0.00030070194,0.00016523128,0.0005568088],"domain_scores_gemma":[0.9989332,0.00042023344,0.00011457198,0.0004628438,0.0000044453186,0.00006469538],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00051864603,0.00014058119,0.0004548577,0.000015964917,0.001078844,0.000020229949,0.00048173484,0.000043879885,0.0038426984],"category_scores_gemma":[0.000060151026,0.000080740756,0.00003392321,0.0001575544,0.00051279325,0.00008088518,0.0010562934,0.0003077436,0.00021052042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004955918,0.00024125945,0.6043988,0.00010874558,0.00005328308,0.00059773866,0.15140626,0.000024765906,0.000548531,0.058810588,0.17069067,0.012623752],"study_design_scores_gemma":[0.0026059179,0.0004076067,0.6886536,0.00006293364,0.00016573783,0.0064070965,0.06250696,0.0009524708,0.00011916906,0.059070334,0.17827019,0.0007780051],"about_ca_topic_score_codex":0.0006834667,"about_ca_topic_score_gemma":0.0007793168,"teacher_disagreement_score":0.14473227,"about_ca_system_score_codex":0.000051127572,"about_ca_system_score_gemma":0.0000045136926,"threshold_uncertainty_score":0.9970679},"labels":[],"label_agreement":null},{"id":"W4283658919","doi":"10.1016/s2352-3026(22)00037-0","title":"Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Heart, Lung, and Blood Institute; VGH and UBC Hospital Foundation","keywords":"Medicine; Disease; Pathology","score_opus":0.016508713768927985,"score_gpt":0.25100828575868805,"score_spread":0.23449957198976007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283658919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97594,0.010504502,0.000041658255,0.011747881,0.00014446449,0.00046708056,0.00007127164,0.00009183998,0.0009912925],"genre_scores_gemma":[0.99357206,0.00034191474,0.000053805292,0.005591695,0.000097375894,0.00015823255,0.000017953515,0.00003082167,0.00013617278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986277,0.00023072303,0.00019749746,0.00029886863,0.00022057831,0.0004246052],"domain_scores_gemma":[0.9992259,0.000056916542,0.0001300589,0.00040514796,0.000030521627,0.00015144752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030044667,0.00017128423,0.0006963027,0.00008588779,0.00040179165,0.000017431596,0.0001533431,0.000039196184,0.00028827327],"category_scores_gemma":[0.00005019014,0.00011494514,0.000059604536,0.00022953136,0.00015133004,0.00004548536,0.00013092688,0.0004687968,0.000017308037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029446773,0.0016185781,0.84012693,0.0035073021,0.0013793713,0.030562093,0.017803099,0.00042412287,0.0045413803,0.016132224,0.025563622,0.028894497],"study_design_scores_gemma":[0.119699016,0.008890041,0.6242606,0.0008060035,0.00572994,0.04673885,0.027698591,0.008669126,0.0020380537,0.011175645,0.14095828,0.0033358652],"about_ca_topic_score_codex":0.00007099454,"about_ca_topic_score_gemma":0.000040761734,"teacher_disagreement_score":0.21586634,"about_ca_system_score_codex":0.00007500443,"about_ca_system_score_gemma":0.00020110408,"threshold_uncertainty_score":0.46873268},"labels":[],"label_agreement":null},{"id":"W4283744395","doi":"10.1016/s2352-3026(22)00173-9","title":"Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Heparin-Induced Thrombocytopenia and Thrombosis","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"LEO Pharma; Daiichi Sankyo Europe; Sanofi; Bayer HealthCare; University of Oxford; National Institute for Health and Care Research; Norgine; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Low molecular weight heparin; Population; Clinical endpoint; Randomized controlled trial; Adverse effect; Internal medicine; Clinical trial; Surgery; Pediatrics; Heparin","score_opus":0.06402574084759774,"score_gpt":0.3857780231439044,"score_spread":0.3217522822963067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283744395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98542523,0.000591674,0.000052441454,0.0020653696,0.0007361506,0.009377181,0.00024303238,0.000079656,0.0014292818],"genre_scores_gemma":[0.9969244,0.00015388809,0.0003454951,0.000989877,0.00007905335,0.001158563,0.00022895826,0.00008070582,0.000039048766],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993859,0.0026665288,0.0010803974,0.0008259908,0.0007301607,0.0008379099],"domain_scores_gemma":[0.9958327,0.0012188368,0.0008829825,0.0014265667,0.00024634216,0.0003926189],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015530795,0.00048729582,0.0042159185,0.00023554686,0.0005472272,0.000042749158,0.0010351944,0.00022376564,0.00075101125],"category_scores_gemma":[0.0013910922,0.00033223355,0.0001451784,0.00061660644,0.00031904402,0.00016421365,0.000770337,0.0011224288,0.00002035467],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9827758,0.0026123552,0.004213128,0.00037951986,0.0007866165,0.0011582358,0.004500104,0.00013941398,0.001571843,0.0013136577,0.00016630141,0.00038300376],"study_design_scores_gemma":[0.96651095,0.024355065,0.00018946,0.00006658506,0.001311014,0.00023180048,0.0019953067,0.00035204724,0.0033640056,0.00020813342,0.0010220322,0.0003936127],"about_ca_topic_score_codex":0.0011401991,"about_ca_topic_score_gemma":0.003242694,"teacher_disagreement_score":0.021742709,"about_ca_system_score_codex":0.00088746264,"about_ca_system_score_gemma":0.0012277372,"threshold_uncertainty_score":0.999913},"labels":[],"label_agreement":null},{"id":"W4286264839","doi":"10.1016/s2352-3026(22)00240-x","title":"Reducing toxic waste: improving toxicity capture in childhood cancer","year":2022,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Toxicity; Childhood cancer; Oncology; Intensive care medicine; Cancer; Environmental health; Internal medicine","score_opus":0.0343898653313362,"score_gpt":0.30899161107644463,"score_spread":0.2746017457451084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286264839","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18962446,0.0060320054,0.000012803272,0.7985329,0.0022171424,0.0012548271,0.00020987524,0.0002180442,0.0018979559],"genre_scores_gemma":[0.09495309,0.00042690977,0.00018495787,0.88854223,0.013120655,0.0005816982,0.00037280732,0.0002101336,0.0016074999],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99430066,0.0010900134,0.0011019199,0.0011728,0.00088656397,0.001448036],"domain_scores_gemma":[0.9963857,0.00067153905,0.0007381925,0.0020196883,0.00007103964,0.00011381915],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013308448,0.00072090357,0.0034971137,0.0003491267,0.00026644432,0.00004355004,0.0011374084,0.0010893147,0.0018763822],"category_scores_gemma":[0.0004823418,0.00057027,0.0003556357,0.0005934775,0.000287015,0.00008383926,0.0006166426,0.00835086,0.00004272925],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020593923,0.00011954605,0.001795584,0.0021977213,0.00024054825,0.0029861336,0.007039128,0.00006586194,0.00013225489,0.00008865918,0.9843435,0.00078507484],"study_design_scores_gemma":[0.009129284,0.00063631876,0.0057208952,0.0033384622,0.0012956643,0.012848793,0.0040990617,0.00024132714,0.0015562082,0.001463747,0.9570549,0.0026153235],"about_ca_topic_score_codex":0.006982916,"about_ca_topic_score_gemma":0.0022881452,"teacher_disagreement_score":0.094671376,"about_ca_system_score_codex":0.0006370245,"about_ca_system_score_gemma":0.00090203714,"threshold_uncertainty_score":0.99967486},"labels":[],"label_agreement":null},{"id":"W4293708357","doi":"10.1016/s2352-3026(22)00215-0","title":"Development of an international standard set of outcome measures for patients with venous thromboembolism: an International Consortium for Health Outcomes Measurement consensus recommendation","year":2022,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; McMaster University; Queen's University; Ottawa Hospital; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Leids Universitair Medisch Centrum; LEO Pharma; Boston Scientific Corporation; Universiteit Leiden; King's College London; National Institute for Health and Care Research","keywords":"Medicine; Benchmarking; Venous thromboembolism; Outcome (game theory); Outcomes research; Set (abstract data type); Intensive care medicine; Health care; MEDLINE; Inclusion (mineral); Alternative medicine; Surgery","score_opus":0.22475972025404756,"score_gpt":0.429903519425277,"score_spread":0.20514379917122944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293708357","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16905896,0.4910434,0.030012686,0.05634796,0.03793655,0.14854991,0.05974413,0.0012789926,0.006027417],"genre_scores_gemma":[0.019471275,0.88455045,0.06546173,0.0027390046,0.0007082107,0.006603508,0.020060968,0.0003668798,0.00003796234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996355,0.00031202714,0.0016527075,0.00048534296,0.00080189446,0.00039302098],"domain_scores_gemma":[0.996486,0.00031150604,0.0018822963,0.00059542875,0.00062567845,0.0000991],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024078898,0.00038951167,0.004852287,0.00026762957,0.00019274057,0.000017953782,0.00062552665,0.000117476535,0.00014080245],"category_scores_gemma":[0.00036504975,0.000256217,0.00026727823,0.00009972249,0.00013710988,0.00006879152,0.00014337938,0.00021444798,0.0000010325988],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011996254,0.002523767,0.004785991,0.016454585,0.0050401143,0.0000046334794,0.0016750175,0.000009192989,3.7349906e-7,0.004186518,0.001976002,0.9621442],"study_design_scores_gemma":[0.003666341,0.0016112291,0.005825906,0.0010009406,0.0011459572,0.000033143857,0.00025512173,0.000011036729,0.0000059005392,0.00007819412,0.9861111,0.00025511612],"about_ca_topic_score_codex":0.00003639635,"about_ca_topic_score_gemma":0.00021263903,"teacher_disagreement_score":0.9841351,"about_ca_system_score_codex":0.0005628888,"about_ca_system_score_gemma":0.00078617776,"threshold_uncertainty_score":0.99998903},"labels":[],"label_agreement":null},{"id":"W4293708402","doi":"10.1016/s2352-3026(22)00209-5","title":"Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years","year":2022,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; McMaster University; Population Health Research Institute; Canadian Hemophilia Society","funders":"Novo Nordisk; National Institutes of Health; World Federation of Hemophilia; CSL Behring; Roche; Bayer; Takeda Pharmaceutical Company; Women's Fund of Hawaii","keywords":"Medicine; Haemophilia; Middle income; Low and middle income countries; Family medicine; Economic growth; Pediatrics; Developing country; Demographic economics","score_opus":0.06779054807722965,"score_gpt":0.3846574054554025,"score_spread":0.3168668573781729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293708402","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31941792,0.67204285,4.4515164e-7,0.0015748309,0.00040447558,0.005758043,0.000107847496,0.000046591016,0.000647018],"genre_scores_gemma":[0.30595377,0.69066775,0.00012531738,0.00023664605,0.00032213135,0.0018439258,0.000105831416,0.00011158966,0.0006330546],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969293,0.00057685806,0.0009273683,0.00049811974,0.00052181387,0.00054654566],"domain_scores_gemma":[0.9978461,0.00047797276,0.00038936522,0.0010915697,0.000095421514,0.00009951531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060499937,0.00040905547,0.0032510331,0.00047613998,0.00016877067,0.00005825368,0.00080489053,0.00024076227,0.0002507503],"category_scores_gemma":[0.0001670133,0.00023696119,0.00031344555,0.00089962943,0.00040422438,0.00008084185,0.00084030477,0.0008458832,0.000011049915],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00449601,0.0014186649,0.2500992,0.40329447,0.001822048,0.0038507942,0.011227853,0.00001234294,0.0000049402342,0.0031984414,0.00045847555,0.32011676],"study_design_scores_gemma":[0.0068204915,0.002448396,0.062945135,0.11294669,0.0025328614,0.0017045224,0.00071392575,0.000015231998,0.000081664,0.0004621361,0.80803037,0.001298575],"about_ca_topic_score_codex":0.00007354947,"about_ca_topic_score_gemma":0.0015589742,"teacher_disagreement_score":0.8075719,"about_ca_system_score_codex":0.00025581577,"about_ca_system_score_gemma":0.0004191949,"threshold_uncertainty_score":0.96629965},"labels":[],"label_agreement":null},{"id":"W4296817009","doi":"10.1016/s2352-3026(22)00317-9","title":"Blueprint for greater security of immunoglobulins for patients in Canada","year":2022,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Blood donation and transfusion practices","field":"Business, Management and Accounting","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Blood Services","funders":"","keywords":"Medicine; Blueprint; Interim; Political science; Law","score_opus":0.028063324179270523,"score_gpt":0.24185357750828582,"score_spread":0.2137902533290153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296817009","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16224587,0.000080254635,0.000045482015,0.83062935,0.001967308,0.0018019247,0.00035751646,0.00003158841,0.0028407346],"genre_scores_gemma":[0.42300546,0.000027508568,0.00007437284,0.574119,0.0012306044,0.0005982561,0.0008162726,0.00004223956,0.00008630468],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881226,0.000039046765,0.0003954016,0.0002467514,0.00019207672,0.00031448828],"domain_scores_gemma":[0.99864775,0.00040888353,0.0004723068,0.00032251325,0.00014556498,0.0000029900345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031955264,0.00016938028,0.00070410786,0.00011687355,0.00011236221,0.000028628867,0.0005289302,0.0001319972,0.00047447794],"category_scores_gemma":[0.00013184837,0.0001291722,0.00009125179,0.00013608322,0.000037130816,0.00012741357,0.00014157267,0.00050200464,0.000005239756],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033382818,0.00005899324,0.02965805,0.0017075199,0.000086803404,0.000032077354,0.00008293476,0.000011854904,4.3927344e-7,0.0073385686,0.96035755,0.00033140206],"study_design_scores_gemma":[0.0016559996,0.000012523932,0.0024015103,0.000022172808,0.00009853535,0.0000046622877,0.0000683093,0.00017470751,0.000008010223,0.00567437,0.9897247,0.00015449002],"about_ca_topic_score_codex":0.39300495,"about_ca_topic_score_gemma":0.48794454,"teacher_disagreement_score":0.2607596,"about_ca_system_score_codex":0.000060180955,"about_ca_system_score_gemma":0.0001504999,"threshold_uncertainty_score":0.6110371},"labels":[],"label_agreement":null},{"id":"W4296901367","doi":"10.1016/s2352-3026(22)00297-6","title":"Prioritising health equity alongside donation safety","year":2022,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stem Cell Network","funders":"","keywords":"Medicine; Scopus; Family medicine; Donation; MEDLINE; Political science","score_opus":0.0733045916659028,"score_gpt":0.3590316530727404,"score_spread":0.28572706140683757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296901367","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011106132,0.0011454463,0.0019388614,0.97956806,0.00113659,0.0011704935,0.00014789325,0.00023687433,0.013545187],"genre_scores_gemma":[0.007863326,0.0007961647,0.0014125174,0.98204124,0.0034263441,0.00012676178,0.0029346116,0.00010691156,0.0012921182],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996352,0.0009204902,0.0007453452,0.00049646525,0.0006989212,0.00078678044],"domain_scores_gemma":[0.9977154,0.00081727724,0.00046008543,0.0008716576,0.000067238056,0.000068328336],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001649899,0.00031277753,0.0018534444,0.00014839132,0.00034584562,0.00002591079,0.00040476036,0.00046250742,0.001104911],"category_scores_gemma":[0.00008984015,0.0002456523,0.0001611347,0.00022305029,0.00016338573,0.000041135838,0.00015621867,0.0025590383,0.00012815456],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020283059,0.000026683892,0.0003526906,0.0040332577,0.00011906699,0.005452595,0.0009009024,0.000003946836,0.00001490472,0.002386458,0.9836492,0.0028574613],"study_design_scores_gemma":[0.0016527243,0.00017481614,0.0011098407,0.00050037826,0.00023470029,0.03411113,0.000106055406,0.00004822231,0.000066708315,0.0015416436,0.9601831,0.00027069586],"about_ca_topic_score_codex":0.00022887764,"about_ca_topic_score_gemma":0.000059688053,"teacher_disagreement_score":0.028658535,"about_ca_system_score_codex":0.00044533267,"about_ca_system_score_gemma":0.0005353644,"threshold_uncertainty_score":0.9999996},"labels":[],"label_agreement":null},{"id":"W4296932772","doi":"10.1016/s2352-3026(22)00214-9","title":"Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Agios Pharmaceuticals","keywords":"Medicine; Open label; Pyruvate kinase; Clinical trial; Internal medicine; Pediatrics; Surgery","score_opus":0.05312475385225649,"score_gpt":0.3087857028299263,"score_spread":0.2556609489776698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296932772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99070317,0.00010077558,0.000078095545,0.004739569,0.0006996458,0.002208181,0.000046484016,0.00008519949,0.0013389137],"genre_scores_gemma":[0.99536765,0.00005553606,0.00052381674,0.003157257,0.00010835167,0.00037140152,0.00012536047,0.000040559866,0.00025007426],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99738675,0.0007053358,0.00048225632,0.00053540297,0.00028373877,0.0006065377],"domain_scores_gemma":[0.9985158,0.00034273058,0.00021993087,0.0006922171,0.000121047226,0.000108298336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038301077,0.00025324934,0.0010640984,0.00016726679,0.00043210838,0.000020012201,0.00045305814,0.00010178055,0.0006744033],"category_scores_gemma":[0.0003102516,0.0001728796,0.0000555056,0.0006367934,0.00020457385,0.000109383654,0.00024423585,0.0006970083,0.000026459567],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.795585,0.061860044,0.031349886,0.00054203515,0.00029031554,0.002322108,0.01029934,0.00028215218,0.06301005,0.0073480653,0.008518109,0.01859292],"study_design_scores_gemma":[0.93729246,0.02790451,0.007707933,0.00036170325,0.00045640764,0.000666154,0.003502486,0.0011555854,0.0032227836,0.0009685178,0.015835395,0.00092607597],"about_ca_topic_score_codex":0.00013676904,"about_ca_topic_score_gemma":0.00016964809,"teacher_disagreement_score":0.14170747,"about_ca_system_score_codex":0.0001321392,"about_ca_system_score_gemma":0.00012729048,"threshold_uncertainty_score":0.73842424},"labels":[],"label_agreement":null},{"id":"W4303473194","doi":"10.1016/s2352-3026(22)00284-8","title":"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Research and Development","keywords":"Medicine; Internal medicine; Multiple myeloma; Quality of life (healthcare); Refractory (planetary science); Clinical trial; Cancer; Chimeric antigen receptor; Oncology; Immunotherapy","score_opus":0.19861245780340173,"score_gpt":0.447965213090437,"score_spread":0.2493527552870353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303473194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98550344,0.00039563893,0.000018613011,0.006620649,0.00025683246,0.006700232,0.00021645181,0.00006325227,0.00022489387],"genre_scores_gemma":[0.9956942,0.00003194056,0.00027000596,0.0012535392,0.00004727379,0.0011792668,0.00015359843,0.000056073783,0.0013141058],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994648,0.002147683,0.0013817217,0.00053289003,0.00058990525,0.00069983426],"domain_scores_gemma":[0.996647,0.0012239711,0.00063793693,0.0011386399,0.00017609748,0.00017633062],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0040401174,0.00023247232,0.0023770572,0.00020546335,0.00028099612,0.000014047588,0.0008973071,0.00010748322,0.0009167936],"category_scores_gemma":[0.0014758764,0.00017149161,0.00008639788,0.0005957645,0.00017600757,0.00007278468,0.0007010577,0.0007616857,0.0000116075125],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2542171,0.099208914,0.54782844,0.0019275409,0.0015026473,0.00042886936,0.024513498,0.00006556751,0.012056339,0.0008441198,0.030895956,0.026511047],"study_design_scores_gemma":[0.65644735,0.04339799,0.2684587,0.00017801543,0.00016778019,0.00015786107,0.005820594,0.0029465226,0.0006801172,0.000592676,0.02041736,0.00073501235],"about_ca_topic_score_codex":0.0019027983,"about_ca_topic_score_gemma":0.0014481434,"teacher_disagreement_score":0.4022303,"about_ca_system_score_codex":0.00032321017,"about_ca_system_score_gemma":0.00069824274,"threshold_uncertainty_score":0.9999965},"labels":[],"label_agreement":null},{"id":"W4310121312","doi":"10.1016/s2352-3026(22)00247-2","title":"25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Compression stockings; Post-thrombotic syndrome; Deep vein; Thrombosis; Intention-to-treat analysis; Randomized controlled trial; Venous thrombosis; Confidence interval; Adverse effect; Internal medicine; Surgery","score_opus":0.045653173306074456,"score_gpt":0.32720634785827124,"score_spread":0.2815531745521968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310121312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783875,0.00040592402,0.00041956353,0.00921648,0.0030277416,0.0074756397,0.000037822494,0.00018863058,0.00084073254],"genre_scores_gemma":[0.99271226,0.00012586357,0.00030101804,0.0030405028,0.00045345287,0.0030596792,0.00008866794,0.000089961024,0.00012861076],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957914,0.00057038857,0.0008936327,0.0008468117,0.0007939109,0.0011038686],"domain_scores_gemma":[0.99720556,0.00065196154,0.000369921,0.0013431058,0.00011824413,0.00031123948],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010946804,0.00053809956,0.0030532614,0.000287027,0.00058315526,0.00007219811,0.00079050695,0.00018476008,0.0017238203],"category_scores_gemma":[0.00017380605,0.00040953184,0.0003996524,0.00048802927,0.00020012324,0.0001121857,0.0011585074,0.0008438257,0.00029369115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94716686,0.0077506714,0.002102525,0.0014361595,0.002617553,0.0024718286,0.00811891,0.0018618219,0.0014604087,0.0036408517,0.020585008,0.00078741676],"study_design_scores_gemma":[0.9112158,0.0127738165,0.049707074,0.0006950895,0.004509656,0.0015432407,0.0017962704,0.00083658035,0.0005912349,0.0005605063,0.01437025,0.0014004761],"about_ca_topic_score_codex":0.00040100215,"about_ca_topic_score_gemma":0.00023802569,"teacher_disagreement_score":0.04760455,"about_ca_system_score_codex":0.0003244791,"about_ca_system_score_gemma":0.00017625222,"threshold_uncertainty_score":0.99983567},"labels":[],"label_agreement":null},{"id":"W4312211847","doi":"10.1016/s2352-3026(22)00373-8","title":"Towards reparatory measures: blood donation, health systems, and men who have sex with men","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood donation and transfusion practices","field":"Business, Management and Accounting","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Medicine; Blood donor; Internal medicine; Gerontology; Intensive care medicine; Immunology","score_opus":0.03326485270114383,"score_gpt":0.2728790389968272,"score_spread":0.23961418629568337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312211847","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16775079,0.007752134,0.00094098377,0.21231622,0.00038674867,0.0021000851,0.000043379332,0.0006600183,0.60804963],"genre_scores_gemma":[0.9886397,0.00018568893,0.00004440868,0.008903325,0.00036549373,0.00018350472,0.000027165077,0.000025502739,0.0016252039],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861425,0.00019267079,0.00027220655,0.0002827463,0.00037427308,0.00026386735],"domain_scores_gemma":[0.9991309,0.00009323694,0.00034525755,0.00030963175,0.00010445317,0.000016514436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016190881,0.00014031422,0.00049174734,0.00012472773,0.0007356108,0.00015165516,0.00027854263,0.000034742196,0.00015179656],"category_scores_gemma":[0.00004478783,0.00009684578,0.000019067016,0.00022830065,0.0000878384,0.00037244268,0.00014984923,0.0002486354,0.000015902799],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044447405,0.0002869066,0.04642453,0.0009932144,0.00047501622,0.00015915647,0.0026770353,0.00046674817,0.000028740618,0.59589154,0.34841466,0.0037379859],"study_design_scores_gemma":[0.0036199936,0.000086764885,0.0059428615,0.00003564275,0.00025597296,0.00088389043,0.010393369,0.0068132947,0.000021527003,0.0025542183,0.96904314,0.00034931785],"about_ca_topic_score_codex":0.0015357304,"about_ca_topic_score_gemma":0.00032890166,"teacher_disagreement_score":0.82088894,"about_ca_system_score_codex":0.000017377162,"about_ca_system_score_gemma":0.00007868659,"threshold_uncertainty_score":0.56577975},"labels":[],"label_agreement":null},{"id":"W4318302179","doi":"10.1016/s2352-3026(22)00377-5","title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Hospices Civils de Lyon; F. Hoffmann-La Roche","keywords":"Medicine; Open label; Haemophilia; Physical therapy; Pediatrics; Internal medicine; Clinical trial","score_opus":0.18999977330478884,"score_gpt":0.4239973036752933,"score_spread":0.23399753037050447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318302179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769554,0.00013974773,0.000005628193,0.018103331,0.000081140446,0.0033234856,0.000018807872,0.00015553541,0.0012169129],"genre_scores_gemma":[0.9944611,0.00012324369,0.00025378313,0.0005139896,0.00010842186,0.00040660592,0.000055719778,0.000051198735,0.0040259287],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975637,0.00034852407,0.00037200187,0.0005070497,0.00033593667,0.00087273924],"domain_scores_gemma":[0.99846405,0.00039811427,0.00008702744,0.0008142623,0.0000881654,0.00014840816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058631593,0.00027245673,0.0013840232,0.00023465238,0.00018378439,0.00006079615,0.0005368147,0.000112235146,0.00019018674],"category_scores_gemma":[0.00017596087,0.00013916705,0.000030730604,0.0010761024,0.00016503914,0.00009694045,0.00035647076,0.00043931903,0.00036332614],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19872661,0.09189394,0.45786902,0.001905498,0.002675481,0.105375364,0.07071621,0.00022289446,0.0044251094,0.0012389912,0.049396742,0.015554156],"study_design_scores_gemma":[0.73059034,0.05782423,0.054972883,0.0023149112,0.0019141348,0.012318799,0.035756536,0.08450024,0.009168643,0.0024477537,0.0058216746,0.0023698395],"about_ca_topic_score_codex":0.0003750812,"about_ca_topic_score_gemma":0.0040245443,"teacher_disagreement_score":0.53186375,"about_ca_system_score_codex":0.000108646935,"about_ca_system_score_gemma":0.00023776382,"threshold_uncertainty_score":0.5675068},"labels":[],"label_agreement":null},{"id":"W4318922870","doi":"10.1016/s2352-3026(22)00371-4","title":"Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation","funders":"National Institutes of Health; National Cancer Institute; St. Baldrick's Foundation","keywords":"Medicine; Ethnic group; Cohort; Racial differences; Cohort study; Childhood leukaemia; Internal medicine; Acute lymphocytic leukemia; Demography; Oncology; Pediatrics; Gerontology; Leukemia; Lymphoblastic Leukemia","score_opus":0.0638022391813319,"score_gpt":0.39692676790558484,"score_spread":0.3331245287242529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318922870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992381,0.0022743328,0.00003137853,0.0032517419,0.00018205798,0.00092850224,0.00011286572,0.00007305079,0.00076507125],"genre_scores_gemma":[0.9904646,0.007862967,0.00018593585,0.00077936926,0.0002727647,0.00012627964,0.00015207943,0.000033455766,0.00012250921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682856,0.0008688243,0.00084622734,0.0004612494,0.00031169952,0.0006834524],"domain_scores_gemma":[0.9969206,0.0021064342,0.00027977326,0.0004742659,0.00008629199,0.00013263745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019931842,0.0002660514,0.0028279298,0.00040104057,0.00010092871,0.000015955353,0.0002641433,0.0003921684,0.00005299086],"category_scores_gemma":[0.0014778891,0.00017412819,0.000112497786,0.00064043654,0.0009966736,0.00009605091,0.0003539819,0.00059064524,0.000019068262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005905333,0.0003413924,0.9315643,0.0014413105,0.0042240964,0.003925589,0.006856515,0.000015502206,0.005118238,0.008072516,0.017817417,0.014717827],"study_design_scores_gemma":[0.016622161,0.0005941071,0.9678809,0.00016741983,0.0009822107,0.008365915,0.00034629155,0.00082562404,0.0014449791,0.00249809,0.000053955144,0.00021834364],"about_ca_topic_score_codex":0.0014455139,"about_ca_topic_score_gemma":0.00062309956,"teacher_disagreement_score":0.03631664,"about_ca_system_score_codex":0.00038226656,"about_ca_system_score_gemma":0.00084824086,"threshold_uncertainty_score":0.7100741},"labels":[],"label_agreement":null},{"id":"W4360821291","doi":"10.1016/s2352-3026(23)00036-4","title":"Superficial vein thrombosis in pregnancy: what we did not know could hurt our patients","year":2023,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Thrombosis; Venous thrombosis; Deep vein; Population; Internal medicine; Surgery","score_opus":0.07184835124389331,"score_gpt":0.32752685008460647,"score_spread":0.25567849884071314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360821291","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04704359,0.0021428703,0.0000035815842,0.94303,0.00438355,0.0020479031,0.000086597596,0.00025906897,0.0010028653],"genre_scores_gemma":[0.08270507,0.046329685,0.00006694123,0.857997,0.007192533,0.0011945373,0.0012832383,0.0003694873,0.0028615],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960156,0.00037909148,0.0007921263,0.00086157344,0.0006632284,0.0012883457],"domain_scores_gemma":[0.99780846,0.00029282956,0.00031341257,0.0013919808,0.0001175795,0.000075718024],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038245216,0.00062012224,0.003657129,0.00036657767,0.00013997211,0.00010217204,0.00080830586,0.0011093711,0.00014920808],"category_scores_gemma":[0.00016924,0.00044636938,0.00028472563,0.00041939135,0.00015411049,0.00015626449,0.0004809427,0.002298726,0.0012254248],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051860767,0.00035804295,0.006090837,0.0016736954,0.00031934716,0.0014680164,0.00097345584,0.0000036241397,0.0000067559236,0.00039190747,0.98670846,0.0019539653],"study_design_scores_gemma":[0.00400468,0.00057540834,0.038853593,0.00877623,0.0009881872,0.00007567233,0.00074181496,0.00003942662,0.00010446554,0.0011014101,0.94390404,0.00083507155],"about_ca_topic_score_codex":0.0002720726,"about_ca_topic_score_gemma":0.000434229,"teacher_disagreement_score":0.08503296,"about_ca_system_score_codex":0.00017663834,"about_ca_system_score_gemma":0.00012702784,"threshold_uncertainty_score":0.99979883},"labels":[],"label_agreement":null},{"id":"W4361027080","doi":"10.1016/s2352-3026(23)00069-8","title":"Global representation among journal editors in haematology: are we diverse, equitable, and inclusive?","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Diversity and Career in Medicine","field":"Social Sciences","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Context (archaeology); Inclusion (mineral); Paragraph; Medicine; Diversity (politics); Sentence; Psychology; Political science; Law; Social psychology; History; Computer science","score_opus":0.06796460172463388,"score_gpt":0.37329474496606785,"score_spread":0.305330143241434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361027080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9016871,0.00035286244,0.000045422537,0.084936105,0.0035985147,0.00017850033,0.000011213009,0.00009104907,0.009099258],"genre_scores_gemma":[0.99533176,0.0017028255,0.000028556064,0.00065887964,0.001957718,0.0000066172433,0.0000047096582,0.0000042457177,0.00030466673],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9980483,0.00054697035,0.00018647211,0.00018516406,0.00043331215,0.00059974665],"domain_scores_gemma":[0.9991787,0.0003259007,0.00015756144,0.00016199623,0.00007894374,0.00009690067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022492765,0.00008906178,0.00048720068,0.00010655286,0.00086606026,0.000069637805,0.00057835615,0.00015656438,0.000080233214],"category_scores_gemma":[0.0006422752,0.00006904891,0.000035526737,0.00074565824,0.0010465599,0.00022464922,0.0005574623,0.00025464979,0.00004662293],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032940203,0.000010234729,0.68048185,0.000024890203,0.000018279265,0.001232983,0.010369416,0.0000326418,7.6378836e-7,0.021198064,0.28595957,0.0006383609],"study_design_scores_gemma":[0.002438808,0.000061992105,0.3758797,0.00023832971,0.000106332605,0.0007258916,0.43606958,0.00014213652,0.00000859489,0.11483092,0.069198266,0.00029943848],"about_ca_topic_score_codex":0.0012705026,"about_ca_topic_score_gemma":0.007708029,"teacher_disagreement_score":0.42570016,"about_ca_system_score_codex":0.00008263234,"about_ca_system_score_gemma":0.00007920344,"threshold_uncertainty_score":0.66611224},"labels":[],"label_agreement":null},{"id":"W4362510065","doi":"10.1016/s2352-3026(23)00061-3","title":"A long-awaited benchmark in lymphomatoid granulomatosis","year":2023,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Mononucleosis; Lymphomatoid granulomatosis; Immunology; Dermatology; Virus; Lymphoma","score_opus":0.0285397734106393,"score_gpt":0.28640031190840426,"score_spread":0.25786053849776497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362510065","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.062847905,0.002202259,0.0000088321585,0.92452306,0.0010018048,0.0008544141,0.000091698486,0.00043394777,0.008036082],"genre_scores_gemma":[0.041173477,0.002310524,0.000039863502,0.949168,0.0022434935,0.0004138456,0.0012796122,0.00021044348,0.003160707],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99681133,0.0003238362,0.0006304268,0.00060779246,0.000439222,0.0011873962],"domain_scores_gemma":[0.9980834,0.00041439632,0.00032881976,0.0010360368,0.00006925771,0.000068061105],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0004233944,0.00048836577,0.0025869815,0.00040995752,0.00011170798,0.000032483567,0.0005578066,0.0014104929,0.00027491455],"category_scores_gemma":[0.0002144604,0.0003488453,0.00030460485,0.0008976992,0.00028392812,0.000039929633,0.0001410747,0.0019633716,0.0006948515],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015203202,0.000036545338,0.028837036,0.00076201383,0.00019222363,0.0068688844,0.00026255965,0.0000022177219,0.0000052506853,0.00015750069,0.9624113,0.00031247005],"study_design_scores_gemma":[0.015927235,0.0003149075,0.04568639,0.0019511578,0.00088236807,0.004634072,0.0003908453,0.00027153577,0.000064110085,0.008753804,0.91975665,0.0013669096],"about_ca_topic_score_codex":0.00078220514,"about_ca_topic_score_gemma":0.00067121105,"teacher_disagreement_score":0.0426546,"about_ca_system_score_codex":0.00025115648,"about_ca_system_score_gemma":0.00028470124,"threshold_uncertainty_score":0.99989635},"labels":[],"label_agreement":null},{"id":"W4366607155","doi":"10.1016/s2352-3026(23)00062-5","title":"Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Cancer Research UK; National Institutes of Health; Medical Research Council; National Institute for Health and Care Research; F. Hoffmann-La Roche","keywords":"Medicine; Rituximab; Internal medicine; Population; Lymphoma; Oncology; Chemotherapy; Immunology; Immune system","score_opus":0.010968648447637177,"score_gpt":0.27560009410366065,"score_spread":0.2646314456560235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366607155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955188,0.00045540082,0.0000016381452,0.0010921309,0.00019006117,0.001467596,0.00012001699,0.00003241647,0.0011219507],"genre_scores_gemma":[0.99919623,0.00013722495,0.000023506907,0.000120189405,0.000063047475,0.00017676917,0.00009851067,0.00002216337,0.00016234719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810547,0.00045846254,0.0004730111,0.0003096582,0.0002505,0.00040292213],"domain_scores_gemma":[0.997858,0.0006978183,0.00032519805,0.0010361177,0.00003745573,0.00004541453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056575524,0.00024499212,0.0020658944,0.00031742427,0.000047068257,0.00000813007,0.00031501177,0.00016131974,0.000072148425],"category_scores_gemma":[0.000075997275,0.00011214173,0.00032002944,0.0011284656,0.00022566483,0.00002420631,0.0001333605,0.00021792318,0.000026013362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13245943,0.004385311,0.83754444,0.0005626609,0.006629628,0.00034722275,0.0023360958,0.000110181994,0.0007248777,0.0005204817,0.0051445793,0.009235095],"study_design_scores_gemma":[0.14204985,0.0023502049,0.8331971,0.00017706002,0.0021138198,0.00010026675,0.000062092695,0.000117246425,0.019576717,0.000029931474,0.00011764052,0.00010805442],"about_ca_topic_score_codex":0.00061672734,"about_ca_topic_score_gemma":0.0002812736,"teacher_disagreement_score":0.018851839,"about_ca_system_score_codex":0.00008729172,"about_ca_system_score_gemma":0.00015725155,"threshold_uncertainty_score":0.4573007},"labels":[],"label_agreement":null},{"id":"W4367673623","doi":"10.1016/s2352-3026(23)00030-3","title":"European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours","year":2023,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Ministero della Salute; Regeneron Pharmaceuticals; Associazione Italiana per la Ricerca sul Cancro; Celgene; Society of Nuclear Medicine and Molecular Imaging; Gilead Sciences; Sanofi; Siemens Healthineers; Bristol-Myers Squibb; Amgen","keywords":"Appropriate Use Criteria; Medicine; Delphi method; Medical physics; Evidence-based medicine; MEDLINE; Interim; Expert opinion; Consensus conference; Family medicine; Alternative medicine; Artificial intelligence; Computer science; Pathology; Political science; Intensive care medicine; Internal medicine","score_opus":0.09752737482974728,"score_gpt":0.374843280926998,"score_spread":0.2773159060972507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367673623","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025971697,0.94707197,0.0000010473035,0.047235064,0.00014933568,0.00093405065,0.000027544032,0.000084762745,0.0018990772],"genre_scores_gemma":[0.005933754,0.9927461,0.000109585744,0.00089562667,0.00008932977,0.00006702162,0.00007339819,0.000057600715,0.000027541633],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99710953,0.001185134,0.0008263306,0.00035772394,0.00018131486,0.0003399344],"domain_scores_gemma":[0.9973322,0.0014284936,0.0006779006,0.00043689637,0.00006314522,0.00006137743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011825889,0.00030810133,0.0034855148,0.00021010077,0.00005551362,0.0000100948155,0.00018262528,0.00015503235,0.000050862887],"category_scores_gemma":[0.00062181376,0.00017227518,0.0001709921,0.00031303233,0.00022157675,0.000012675513,0.00010738107,0.0003189879,0.00007082567],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013512542,0.000440263,0.016618408,0.008667587,0.0011782043,0.008534837,0.0009810342,3.2204508e-7,0.0000045523225,0.021388918,0.05231503,0.8897357],"study_design_scores_gemma":[0.006350443,0.0003434959,0.0026830202,0.019879619,0.0017749381,0.0061228815,0.00029106482,0.000017352524,0.0000068874824,0.0024440351,0.9597183,0.0003679741],"about_ca_topic_score_codex":0.00008928248,"about_ca_topic_score_gemma":0.000015328791,"teacher_disagreement_score":0.90740323,"about_ca_system_score_codex":0.00016806518,"about_ca_system_score_gemma":0.000093634204,"threshold_uncertainty_score":0.7025178},"labels":[],"label_agreement":null},{"id":"W4378979009","doi":"10.1016/s2352-3026(23)00094-7","title":"Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; University of California, San Francisco; Centers for Disease Control and Prevention; Dana-Farber/Harvard Cancer Center; University of Southern California; California Department of Public Health; American Society of Hematology","keywords":"Medicine; Lymphoma; Diffuse large B-cell lymphoma; Mental health; Gerontology; Internal medicine; Pediatrics; Oncology; Psychiatry","score_opus":0.015844687599885176,"score_gpt":0.28512575649984684,"score_spread":0.2692810688999617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378979009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914953,0.00006493435,0.0000016219694,0.0068106037,0.00007430429,0.0014111691,0.000027200154,0.000034858145,0.00008001454],"genre_scores_gemma":[0.9984586,0.000034199173,0.0000095663445,0.0011102929,0.000019833462,0.00018051,0.00015069087,0.000014681111,0.000021612599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987399,0.00028218393,0.00018784268,0.00022035446,0.00022148919,0.00034823723],"domain_scores_gemma":[0.9993043,0.0002241813,0.000086592445,0.0003261491,0.000012076998,0.000046724817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031367847,0.00014174634,0.0005099406,0.0000660046,0.00017404823,0.000014904186,0.00009889783,0.000033521414,0.000009647823],"category_scores_gemma":[0.000015520249,0.00006718525,0.00002811621,0.00024150028,0.000051673473,0.000027171855,0.000039160535,0.000057518962,0.000015009036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014152052,0.005220438,0.9906481,0.00004531812,0.000033679335,0.00004623514,0.002982296,0.0000018283458,5.1241717e-8,0.00015273865,0.0003777641,0.00035006017],"study_design_scores_gemma":[0.03417934,0.00042008742,0.96390235,0.0000340234,0.00003743266,0.0000063577786,0.0011179465,0.0001142998,9.1318947e-7,0.000026010026,0.00009376622,0.00006749352],"about_ca_topic_score_codex":0.0019422871,"about_ca_topic_score_gemma":0.018347347,"teacher_disagreement_score":0.03403782,"about_ca_system_score_codex":0.000075641175,"about_ca_system_score_gemma":0.000055011904,"threshold_uncertainty_score":0.99956524},"labels":[],"label_agreement":null},{"id":"W4380986318","doi":"10.1016/s2352-3026(23)00118-7","title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":666,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sistema Nacional de Investigadores; Warwick Medical School; National Health and Medical Research Council; Medical Research Council; Universidad Autónoma de Sinaloa; Secretaría Nacional de Ciencia, Tecnología e Innovación; Shahid Beheshti University of Medical Sciences; Universidad Nacional Autónoma de México; University of Jordan; Universitetet i Bergen; Jawaharlal Institute Of Postgraduate Medical Education and Research; Ahvaz Jundishapur University of Medical Sciences; Tehran University of Medical Sciences and Health Services; Sultan Qaboos University; Shiraz University of Medical Sciences; Shiraz University; Uniwersytet Łódzki; King Abdulaziz University; Manipal Academy of Higher Education; Isfahan University of Medical Sciences; Banaras Hindu University; Department of Sport and Recreation, Government of Western Australia; University of Sydney; Ministero della Salute; Southern Cross University; University Grants Commission; Indian Council of Medical Research; National Institute for Health and Care Research; Ministry of Health and Medical Education; University of Pretoria; Babol University of Medical Sciences; Cleveland Clinic; York University; Science and Technology Development Fund; University of Toronto; Macquarie University; Imperial College London; Philadelphia University; University of Technology Sydney; University of Warwick; Høgskulen på Vestlandet; University of Central Punjab; University of Aberdeen; Universidade de São Paulo; South Eastern Sydney Local Health District; Cleveland Clinic Foundation; Florida International University; Ain Shams University; King Abdulaziz City for Science and Technology; Academy of Scientific Research and Technology; Shaqra University; Tulane University; Iran University of Medical Sciences; Chandigarh University; Trường Đại học Duy Tân; Alfaisal University; Kasturba Medical College, Manipal; University of New South Wales; Yale University; Karolinska Institutet; Bill and Melinda Gates Foundation","keywords":"Medicine; Disease; Epidemiology; Population; Incidence (geometry); Disease burden; Mortality rate; Pediatrics; Acute chest syndrome; Sickle cell anemia; Demography; Environmental health; Internal medicine","score_opus":0.026363326781828348,"score_gpt":0.3061564235177414,"score_spread":0.27979309673591307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380986318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97720945,0.014759426,0.000016465994,0.0061488254,0.00005430445,0.0009345526,0.00062593265,0.000020495352,0.00023055774],"genre_scores_gemma":[0.99774694,0.0018014731,0.000013676853,0.00012588913,0.00008707128,0.00004894197,0.000058352663,0.0000064464034,0.0001111991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980186,0.0004359944,0.00048177503,0.00032937198,0.00050508743,0.00022913427],"domain_scores_gemma":[0.9983509,0.00045360991,0.00027543577,0.0006170564,0.00015597265,0.00014703508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005745129,0.0001678757,0.0010427763,0.00004649273,0.0000998942,0.000013810026,0.00025146792,0.00006917228,0.00008190258],"category_scores_gemma":[0.00039885024,0.00009441806,0.00013287937,0.0009320294,0.00044362227,0.000035145866,0.00017740927,0.0001006101,0.000010498107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040977265,0.00018934504,0.98508817,0.006650757,0.0016338036,0.00013555816,0.0015530466,0.00089417765,0.0000064414908,0.0012326929,0.0021841128,0.000022097438],"study_design_scores_gemma":[0.001909987,0.00009462398,0.968968,0.0010426396,0.007817834,0.000024436204,0.0054213395,0.00897804,0.0000012841332,0.0055326386,0.000058605885,0.00015057766],"about_ca_topic_score_codex":0.0012439693,"about_ca_topic_score_gemma":0.000109823886,"teacher_disagreement_score":0.02053751,"about_ca_system_score_codex":0.000036356865,"about_ca_system_score_gemma":0.00021018651,"threshold_uncertainty_score":0.38502568},"labels":[],"label_agreement":null},{"id":"W4382934820","doi":"10.1016/s2352-3026(23)00088-1","title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Dasatinib; Internal medicine; Chemotherapy; Minimal residual disease; Clinical endpoint; Acute lymphocytic leukemia; Imatinib; Induction chemotherapy; Hematopoietic stem cell transplantation; Oncology; Chemotherapy regimen; Transplantation; Surgery; Pediatrics; Clinical trial; Leukemia; Lymphoblastic Leukemia","score_opus":0.035050732731479066,"score_gpt":0.3213202882339479,"score_spread":0.28626955550246885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382934820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982882,0.0004243204,0.00009826247,0.01298544,0.00035229692,0.0023638487,0.00009114051,0.00032539322,0.00047727145],"genre_scores_gemma":[0.9934078,0.0006149993,0.0005080928,0.0037870097,0.0008170437,0.00033558192,0.00025207154,0.00011173334,0.00016569959],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99662274,0.00031250864,0.00065819215,0.0007175381,0.00040444836,0.0012845523],"domain_scores_gemma":[0.99719125,0.0011817459,0.00035371064,0.00083660934,0.00021183449,0.00022484371],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037992137,0.0005321504,0.0018400013,0.00037010567,0.0001284595,0.000030931984,0.0003968504,0.00031032736,0.00017278809],"category_scores_gemma":[0.00052493985,0.00036036447,0.00016145385,0.0012783924,0.00041066305,0.00009635086,0.00013548326,0.0006031118,0.00029433265],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7091217,0.012574469,0.028119707,0.0015036253,0.0085379165,0.12716196,0.03811001,0.00068288087,0.024642477,0.001947858,0.03195296,0.01564446],"study_design_scores_gemma":[0.9318027,0.010280217,0.0071556447,0.0010272167,0.0027443352,0.022442102,0.0022497622,0.00828899,0.010615669,0.00079067494,0.0014435214,0.0011592018],"about_ca_topic_score_codex":0.00014785708,"about_ca_topic_score_gemma":0.00021097677,"teacher_disagreement_score":0.22268099,"about_ca_system_score_codex":0.0013382189,"about_ca_system_score_gemma":0.000928292,"threshold_uncertainty_score":0.99988484},"labels":[],"label_agreement":null},{"id":"W4383873996","doi":"10.1016/s2352-3026(23)00158-8","title":"Public health and programme development in sickle cell disease in Ghana: the legacy of Kwaku Ohene-Frempong","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Disease; Psychological intervention; Public health; Quality of life (healthcare); Gerontology; Pediatrics; Intensive care medicine; Family medicine; Internal medicine; Psychiatry; Pathology; Nursing","score_opus":0.06994973778607058,"score_gpt":0.29291467049328573,"score_spread":0.22296493270721515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383873996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.899411,0.0036128336,0.000006563138,0.09580055,0.00006326098,0.0005338039,0.0000014750004,0.000041891395,0.0005285804],"genre_scores_gemma":[0.9975448,0.0006856387,0.000110422414,0.0014356743,0.000020088813,0.000061521685,0.000019983965,0.000012437618,0.000109402645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864316,0.00018391527,0.00033978955,0.00017348687,0.00012489666,0.0005347525],"domain_scores_gemma":[0.999331,0.00012985716,0.0000917178,0.00028913908,0.000022248618,0.00013602739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008690827,0.00010570029,0.0005295163,0.00013183204,0.0000690465,0.000011002096,0.00015106468,0.000056100824,0.000008758483],"category_scores_gemma":[0.00016552272,0.000057317524,0.000027251375,0.00055089174,0.00019755446,0.00003564217,0.0001060371,0.0002682961,0.000018553481],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004452264,0.00062038575,0.91345716,0.002361344,0.000069833535,0.0007504854,0.028046265,0.000039524275,0.000055485714,0.0112138055,0.005215008,0.03772549],"study_design_scores_gemma":[0.01614361,0.00044857035,0.8606444,0.0010365713,0.000073389165,0.00043191164,0.03899466,0.0033748602,0.00035634253,0.00469865,0.07317658,0.00062045513],"about_ca_topic_score_codex":0.00026008807,"about_ca_topic_score_gemma":0.0005010207,"teacher_disagreement_score":0.09813379,"about_ca_system_score_codex":0.000036733574,"about_ca_system_score_gemma":0.0004466525,"threshold_uncertainty_score":0.23373407},"labels":[],"label_agreement":null},{"id":"W4383874164","doi":"10.1016/s2352-3026(23)00096-0","title":"Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission","year":2023,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Medical Research Council; Fondation Pierre Fabre; TauRx Pharmaceuticals; bluebird bio; Sangamo Therapeutics; Les Laboratories Pierre Fabre; Vertex Pharmaceuticals; National Institute for Health and Care Excellence; European Hematology Association; European Commission; World Health Organization; GlaxoSmithKline; National Heart, Lung, and Blood Institute; Pfizer; Northwestern University; Doris Duke Charitable Foundation; American Society of Hematology; HORIZON EUROPE Framework Programme; Health Resources and Services Administration; Agios Pharmaceuticals; Wellcome Trust","keywords":"Medicine; Hematology; Intensive care medicine; Disease; Internal medicine","score_opus":0.04810619309733443,"score_gpt":0.37523118629591523,"score_spread":0.3271249931985808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383874164","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009039156,0.9792512,0.000041658095,0.008348213,0.0008964376,0.0019530762,0.0003114432,0.00037690302,0.007917158],"genre_scores_gemma":[0.0011995272,0.9955479,0.00023253962,0.0010997045,0.00017832316,0.00040706742,0.00021382222,0.00011209067,0.0010090518],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996032,0.00054420525,0.0011328467,0.0007687365,0.00029213782,0.0012301031],"domain_scores_gemma":[0.9972267,0.00063550717,0.00041878253,0.0013251776,0.00005488433,0.00033895706],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057130854,0.00072575005,0.007830311,0.00023595015,0.00014670493,0.000052225812,0.0007875273,0.00080311275,0.000059864462],"category_scores_gemma":[0.0004269492,0.000427589,0.0005036558,0.000831198,0.00025737402,0.00005216924,0.00048546187,0.0012744837,0.0013410603],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015042338,0.0014014734,0.021878395,0.2952533,0.0020236801,0.03614186,0.0019389127,0.000093542694,0.0000032448368,0.19814149,0.1284468,0.3131731],"study_design_scores_gemma":[0.0023672373,0.00019184165,0.0004641763,0.011687082,0.0015198609,0.0017612588,0.0007391214,0.000034552184,8.4746216e-7,0.003332772,0.9772101,0.00069115154],"about_ca_topic_score_codex":0.0001821376,"about_ca_topic_score_gemma":0.00020215556,"teacher_disagreement_score":0.8487633,"about_ca_system_score_codex":0.00016495443,"about_ca_system_score_gemma":0.00091025815,"threshold_uncertainty_score":0.9998176},"labels":[],"label_agreement":null},{"id":"W4385297552","doi":"10.1016/s2352-3026(23)00174-6","title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Danazol; Clinical endpoint; Ruxolitinib; Anemia; Post-hoc analysis; Randomized controlled trial; Intention-to-treat analysis; Adverse effect; Placebo; Gastroenterology; Surgery; Bone marrow; Endometriosis","score_opus":0.04147677945176609,"score_gpt":0.34679700797642826,"score_spread":0.3053202285246622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385297552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99603105,0.00001902653,0.0000030983579,0.00038593033,0.00004154422,0.0032765088,0.00006554041,0.00008824688,0.0000890565],"genre_scores_gemma":[0.99752325,0.000042456788,0.000096807205,0.000049103848,0.000026331094,0.00072298903,0.0014935537,0.00002927123,0.000016218128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796575,0.000286492,0.0005372072,0.0004938186,0.00036839768,0.00034831185],"domain_scores_gemma":[0.99853873,0.00024034668,0.00030261872,0.00058945926,0.00018743095,0.00014138677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035875663,0.00029409898,0.0016686575,0.0006743823,0.00007893373,0.00003340013,0.00018537529,0.0000753467,0.0000735849],"category_scores_gemma":[0.000037341837,0.00016396934,0.000056673893,0.0015646848,0.0001431413,0.00016991433,0.000053028834,0.0001347899,0.000004785885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15224214,0.003554035,0.8361516,0.00004896504,0.0043506883,0.00021677578,0.0027617372,0.00011835331,0.00003673295,0.00006263991,0.000041602758,0.0004147319],"study_design_scores_gemma":[0.4475587,0.0083770435,0.53403753,0.00010642411,0.0042388616,0.000019697685,0.0012707207,0.0032321557,0.0009332219,0.0000045398624,0.0000130289645,0.00020805618],"about_ca_topic_score_codex":0.00023342765,"about_ca_topic_score_gemma":0.0013985552,"teacher_disagreement_score":0.30211407,"about_ca_system_score_codex":0.000082694474,"about_ca_system_score_gemma":0.000063817264,"threshold_uncertainty_score":0.6686475},"labels":[],"label_agreement":null},{"id":"W4385412860","doi":"10.1016/s2352-3026(23)00160-6","title":"Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":551,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fundação para a Ciência e a Tecnologia; National Health and Medical Research Council; Directorate for Biological Sciences; Uniwersytet Opolski; George Institute for Global Health; Madda Walabu University; Sydney Medical School; Minderoo Foundation; ARC Centre of Excellence for Children and Families over the Life Course; Shahid Sadoughi University of Medical Sciences; Lingnan University; Kurdistan University Of Medical Sciences; Lorestan University of Medical Sciences; University of Thessaly; Alexandria University; University of Colombo; National Institute of Pharmaceutical Education and Research, Raebareli; Jawaharlal Institute Of Postgraduate Medical Education and Research; University of Peradeniya; Xiamen University; University of the Ryukyus; Dire Dawa University; Zanjan University of Medical Sciences; Tarbiat Modares University; National Research, Development and Innovation Office; National Nutrition and Food Technology Research Institute; Alfaisal University; University of Gondar; Ilam University; Universitatea de Medicină şi Farmacie \"Carol Davila\" Bucureşti; University of Sulaimani; Majmaah University; Savitribai Phule Pune University; Shaqra University; Pomorski Uniwersytet Medyczny W Szczecinie; Universidade Federal de Minas Gerais; Universitatea din București; Arak University of Medical Sciences; University of Cape Town; University of California, San Diego; Universidade Federal de Santa Catarina; Technische Universität Berlin; Direktorat Jenderal Pendidikan Tinggi; University of South Carolina; Cooperativa de Ensino Superior Politécnico e Universitário; University of Hail; Universidade do Porto; Centre Hospitalier Universitaire Vaudois; Emory University; United Arab Emirates University; Sabzevar University of Medical Sciences; Bangladesh University of Health Sciences; Cancer Institute NSW; Shahid Beheshti University of Medical Sciences; Gonabad University of Medical Sciences; University of the Philippines; Universidad Nacional Autónoma de México; Universidade de São Paulo; National and Kapodistrian University of Athens; University of Veterinary and Animal Sciences; Chinese University of Hong Kong; Cleveland Clinic; Taipei Medical University; Inyuvesi Yakwazulu-Natali; Universiti Sains Malaysia; Oulun Yliopisto; Isfahan University of Medical Sciences; Universiti Malaya; Ain Shams University; Shiraz University of Medical Sciences; Rajiv Gandhi University of Health Sciences; Uniwersytet Łódzki; King Abdulaziz University; Ilam University of Medical Sciences; Universitas Padjadjaran; University of the Western Cape; Universidad Autónoma de Sinaloa; Università di Catania; Bundesministerium für Gesundheit; Gachon University; Adigrat University; Universitetet i Bergen; King Saud University; Universitas Syiah Kuala; Shiraz University; National Natural Science Foundation of China; Hamadan University of Medical Sciences; Semmelweis Egyetem; Deakin University; Public Health Agency; Wollega University; Universiteit Stellenbosch; University of Leeds; Public Health Foundation of India; Indian Council of Medical Research; Masarykova Univerzita; Guilan University of Medical Sciences; Qazvin University of Medical Sciences; University of Queensland; National Institute for Health and Care Research; University of Toronto; Stanford Cardiovascular Institute, School of Medicine, Stanford University; Macquarie University; Kasturba Medical College, Manipal; Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education; Universiteit Utrecht; Nankai University; Banaras Hindu University; Høgskulen på Vestlandet; Coventry University; Babol University of Medical Sciences; Universidad de Colima; Karolinska Institutet; United Nations Population Fund; Universitas Indonesia; University of Technology Sydney; Salahaddin University-Erbil; Uppsala Universitet; University of Embu; Samara University; Jordan University of Science and Technology; McMaster University; Morehouse School of Medicine; Tabriz University of Medical Sciences; Addis Ababa University; Sultan Qaboos University; Canadian Institutes of Health Research; University of Tabriz; Ahmadu Bello University; South Eastern Sydney Local Health District; Nazarbayev University; Charles Sturt University; Student Research Committee, Tabriz University of Medical Sciences; Bahir Dar University; Sheffield Hallam University; New Mexico State University; Trường Đại học Duy Tân; Applied Molecular Biosciences Unit; Iran University of Medical Sciences; University of Zanjan; Florida International University; Amity University; Mazandaran University of Medical Sciences; Zahedan University of Medical Sciences; Harvard University; University of Aberdeen; Case Western Reserve University; International Centre for Diarrhoeal Disease Research, Bangladesh; Washington University in St. Louis; University of New South Wales; Dongguk University; Jazan University; U.S. Department of Veterans Affairs; Akademiska Sjukhuset; Ekiti State University; Public Health Agency of Canada; Anglia Ruskin University; University of Canberra; Dilla University; Universität Basel; Central Taiwan University of Science and Technology; Bill and Melinda Gates Foundation","keywords":"Medicine; Burden of disease; Disease burden; Demography; Population; Disease; Demographics; Global health; Environmental health; Pediatrics; Public health; Internal medicine; Pathology","score_opus":0.02196993615495434,"score_gpt":0.30235018863455443,"score_spread":0.2803802524796001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385412860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908662,0.0016519597,9.458038e-7,0.0066481493,0.00004578996,0.00039784255,0.00022048777,0.00001938563,0.00014927746],"genre_scores_gemma":[0.9988682,0.0007005481,0.000019500376,0.00011308822,0.0000889566,0.000030804098,0.000046531604,0.000009537766,0.00012277793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987682,0.0002474447,0.00020646409,0.00031906957,0.00019029154,0.00026850376],"domain_scores_gemma":[0.9991364,0.0002188477,0.000061677805,0.00048045046,0.000017001381,0.00008562647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032880087,0.00014431676,0.0006180103,0.00003134902,0.000054482745,0.000013900873,0.00018401045,0.00005979998,0.00012839849],"category_scores_gemma":[0.00011238359,0.00008317309,0.000026643527,0.00043063873,0.0006288694,0.000041891893,0.00018846898,0.00016580177,0.000006272059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007010664,0.00007887788,0.9906258,0.00010888463,0.00004373508,0.000101438774,0.0036780518,0.0000039648585,0.000011590443,0.00012934903,0.0028532862,0.0016639637],"study_design_scores_gemma":[0.002574833,0.00010178461,0.99116194,0.000050087714,0.00027867348,0.000017838072,0.0048475596,0.00007100413,0.0000028513912,0.00059108884,0.00021080421,0.000091518814],"about_ca_topic_score_codex":0.0034356434,"about_ca_topic_score_gemma":0.00096836436,"teacher_disagreement_score":0.008002094,"about_ca_system_score_codex":0.000013146851,"about_ca_system_score_gemma":0.000029704728,"threshold_uncertainty_score":0.5193688},"labels":[],"label_agreement":null},{"id":"W4385689290","doi":"10.1016/s2352-3026(23)00159-x","title":"Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts","year":2023,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK","keywords":"Medicine; Myeloid leukaemia; Perspective (graphical); Intensive care medicine; Disease; Drug response; Health care; Clinical trial; Risk analysis (engineering); Drug; Computer science; Immunology; Artificial intelligence; Pathology; Psychiatry","score_opus":0.23415766790350245,"score_gpt":0.4443996815337133,"score_spread":0.21024201363021083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385689290","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004856026,0.98962057,0.00042075093,0.0024650884,0.0008811601,0.0017362107,0.000964216,0.00019324257,0.0032331548],"genre_scores_gemma":[0.00071817834,0.9958097,0.00022317207,0.00008040308,0.0011854869,0.0004250511,0.00065345893,0.00011678146,0.0007878126],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965452,0.0006282377,0.0009829135,0.00066304073,0.00067039597,0.00051021733],"domain_scores_gemma":[0.9961921,0.001194027,0.0007894438,0.0012375257,0.00048243994,0.00010444089],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077159674,0.00042251614,0.0045999256,0.00038907747,0.00009384419,0.000044783323,0.00094818335,0.0005536996,0.00007961668],"category_scores_gemma":[0.00069353735,0.00026414916,0.0004487668,0.0005039021,0.00042163915,0.00006423774,0.0003603516,0.0009319188,0.00023367451],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038747264,0.0005779669,0.0006505452,0.10248161,0.046908785,0.01086221,0.019744722,0.000013819805,0.00045024368,0.1766322,0.28624797,0.35155523],"study_design_scores_gemma":[0.0020584222,0.00012283494,0.000084254265,0.023769077,0.0035801635,0.0048173107,0.0055091153,0.0005122263,0.000013508243,0.0010193725,0.95804346,0.00047026825],"about_ca_topic_score_codex":0.0005473209,"about_ca_topic_score_gemma":0.000021512937,"teacher_disagreement_score":0.6717955,"about_ca_system_score_codex":0.0016708117,"about_ca_system_score_gemma":0.0013700568,"threshold_uncertainty_score":0.99998105},"labels":[],"label_agreement":null},{"id":"W4388736571","doi":"10.1016/s2352-3026(23)00339-3","title":"Thromboprophylaxis in paediatric acute lymphoblastic leukaemia","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Impact; McMaster Children's Hospital","funders":"","keywords":"Medicine; Pediatrics; Venous thromboembolism; Lymphoblastic Leukemia; Internal medicine; Low molecular weight heparin; Thrombosis; Leukemia","score_opus":0.032990869520327475,"score_gpt":0.3218957363652994,"score_spread":0.2889048668449719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388736571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981706,0.00025419297,0.00012660817,0.012469558,0.0003495513,0.0005507736,0.000015992375,0.00034311158,0.004184196],"genre_scores_gemma":[0.99618274,0.0005780557,0.00023331307,0.0012712615,0.0004982158,0.00012108462,0.000037559883,0.000050060757,0.0010277275],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9974984,0.00019705818,0.00040202937,0.00041822693,0.00043858014,0.0010457002],"domain_scores_gemma":[0.9979368,0.00092425465,0.00008302305,0.0008467284,0.000072417206,0.00013679973],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069076236,0.00022485013,0.0011091455,0.00042796045,0.00009991107,0.000019033985,0.0004997278,0.00022374904,0.00018517123],"category_scores_gemma":[0.0005986422,0.00014395613,0.00010361815,0.0020164726,0.00034748754,0.00005726574,0.00035311969,0.0005051088,0.0036174646],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046839993,0.0005748513,0.37013605,0.0024461078,0.0011622643,0.056998134,0.0051746387,0.0005714446,0.014430152,0.034171533,0.49508432,0.014566502],"study_design_scores_gemma":[0.044821024,0.0021446133,0.7941689,0.0005499872,0.0009864148,0.035856977,0.0014823431,0.06028122,0.0064227586,0.030870887,0.02074164,0.001673215],"about_ca_topic_score_codex":0.00009505969,"about_ca_topic_score_gemma":0.00004436343,"teacher_disagreement_score":0.47434267,"about_ca_system_score_codex":0.00042105722,"about_ca_system_score_gemma":0.0005764571,"threshold_uncertainty_score":0.99715835},"labels":[],"label_agreement":null},{"id":"W4388736594","doi":"10.1016/s2352-3026(23)00314-9","title":"Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Bristol-Myers Squibb","keywords":"Medicine; Apixaban; Population; Internal medicine; Surgery; Pediatrics; Warfarin; Rivaroxaban","score_opus":0.06430429640012142,"score_gpt":0.36798972023862675,"score_spread":0.30368542383850533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388736594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751034,0.00026798958,0.000540773,0.0021823533,0.0006989716,0.020820145,0.000033955475,0.00009865365,0.0002537538],"genre_scores_gemma":[0.99252266,0.0012119367,0.000318104,0.0005206862,0.0004155855,0.0046266736,0.00016558383,0.000060358983,0.00015842395],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997455,0.00034428897,0.0008064963,0.00044375152,0.00032285633,0.0006276185],"domain_scores_gemma":[0.99618757,0.0022711393,0.0005619634,0.00077304046,0.00013232922,0.00007393561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012970282,0.00032646023,0.0030313581,0.00017814801,0.00020200836,0.000058204125,0.0006355014,0.00015547733,0.00006536333],"category_scores_gemma":[0.00069252227,0.00016839815,0.0001651058,0.00048587847,0.00022585214,0.00012852326,0.00019137746,0.00012716468,0.000040066683],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9726104,0.004669368,0.0002576163,0.00022877086,0.0043586823,0.00012568815,0.0009188315,0.00030078492,0.00033131122,0.0033414036,0.0066137207,0.006243399],"study_design_scores_gemma":[0.9735627,0.007101031,0.008313827,0.00023035638,0.004104342,0.00013018167,0.00013702521,0.005347892,0.00015270042,0.00043427802,0.00027269,0.00021293959],"about_ca_topic_score_codex":0.00021801073,"about_ca_topic_score_gemma":0.00022788247,"teacher_disagreement_score":0.017419241,"about_ca_system_score_codex":0.000097567354,"about_ca_system_score_gemma":0.00032126092,"threshold_uncertainty_score":0.68670774},"labels":[],"label_agreement":null},{"id":"W4389068167","doi":"10.1016/s2352-3026(23)00306-x","title":"Life after sickle cell disease, is it really uhuru?","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health; University of Toronto; bluebird bio; Alexion Pharmaceuticals; Vertex Pharmaceuticals; Novo Nordisk; Teva Pharmaceutical Industries; Andrew W. Mellon Foundation; National Heart, Lung, and Blood Institute; Pfizer; Health Resources and Services Administration; Agios Pharmaceuticals; Patient-Centered Outcomes Research Institute; Bristol-Myers Squibb; Doris Duke Charitable Foundation","keywords":"Medicine; Disease; Health care; Transplantation; Intensive care medicine; Family medicine; Internal medicine; Political science; Law","score_opus":0.02586312662935763,"score_gpt":0.28567142537998336,"score_spread":0.2598082987506257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389068167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6399216,0.0022546838,0.000025263413,0.32616255,0.00037193263,0.00037109814,0.00003102141,0.00027708797,0.0305848],"genre_scores_gemma":[0.93534845,0.0017348031,0.000042236406,0.05379999,0.00024199157,0.000060839713,0.00003197894,0.000031935615,0.008707747],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987915,0.00007328007,0.0002274246,0.00024265796,0.00016966766,0.0004954475],"domain_scores_gemma":[0.99895567,0.000101411875,0.000057115747,0.00057307334,0.000040277555,0.0002724524],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019631849,0.000148355,0.00056350266,0.000067084955,0.00008912976,0.000011089171,0.00018019114,0.00014359938,0.00082063855],"category_scores_gemma":[0.00015711659,0.00009052848,0.000110690584,0.00030886018,0.00017340494,0.00002545623,0.000103128485,0.00029606075,0.003921063],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062099495,0.00008021089,0.02009879,0.00041212112,0.00006703193,0.0015203493,0.001491203,0.000012199563,0.00008097729,0.0015959367,0.97367215,0.00034804308],"study_design_scores_gemma":[0.005861664,0.0002537755,0.06947245,0.0003103874,0.0006672049,0.0005410186,0.0023408805,0.0017693706,0.00039248058,0.0056934953,0.91213036,0.0005669426],"about_ca_topic_score_codex":0.000026607784,"about_ca_topic_score_gemma":0.000007647409,"teacher_disagreement_score":0.2954269,"about_ca_system_score_codex":0.00001178467,"about_ca_system_score_gemma":0.00015710072,"threshold_uncertainty_score":0.9968545},"labels":[],"label_agreement":null},{"id":"W4389304091","doi":"10.1016/s2352-3026(23)00305-8","title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group","year":2023,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; International Prognostic Scoring System; Transplantation; Hematopoietic stem cell transplantation; Internal medicine; Disease; Oncology; Intensive care medicine; Bone marrow; Myelodysplastic syndromes","score_opus":0.0847614625065938,"score_gpt":0.356447509342724,"score_spread":0.2716860468361302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389304091","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006188285,0.9797915,0.00014609113,0.009052019,0.00036136393,0.0032143798,0.0001817817,0.00007014314,0.0009944419],"genre_scores_gemma":[0.008038856,0.9884518,0.00022978938,0.00018652009,0.000047933958,0.0011955026,0.0016322323,0.00003875037,0.00017865737],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979761,0.00040508824,0.0007868649,0.00037314708,0.00020949134,0.00024930554],"domain_scores_gemma":[0.9985741,0.00043936798,0.00052949565,0.0003880457,0.00003072709,0.000038294453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052756385,0.00028911763,0.0015307099,0.0002008641,0.00009629644,0.000024821291,0.00030016003,0.00018233551,0.000055524717],"category_scores_gemma":[0.0000053911954,0.00016554556,0.00012498282,0.00038260373,0.0001233123,0.000033919285,0.00008463143,0.00029350942,0.000050178776],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026897067,0.0009756515,0.010506365,0.056447513,0.0036997504,0.00046620026,0.0027401487,0.000006162136,0.000009122101,0.03310112,0.015903518,0.8758755],"study_design_scores_gemma":[0.0060725203,0.00033418898,0.0076351375,0.051219057,0.008438146,0.002586988,0.0011179814,0.000086048436,0.00012702234,0.001014629,0.92060256,0.0007657199],"about_ca_topic_score_codex":0.000026099618,"about_ca_topic_score_gemma":0.00008157297,"teacher_disagreement_score":0.904699,"about_ca_system_score_codex":0.000087125736,"about_ca_system_score_gemma":0.000039981624,"threshold_uncertainty_score":0.6750752},"labels":[],"label_agreement":null},{"id":"W4390021910","doi":"10.1016/s2352-3026(23)00338-1","title":"Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa","funders":"Astex Pharmaceuticals","keywords":"Decitabine; Medicine; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Azacitidine; Internal medicine; International Prognostic Scoring System; Adverse effect; Oncology; Pharmacology; Bone marrow","score_opus":0.09378879086140673,"score_gpt":0.4066840908216205,"score_spread":0.31289529996021376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390021910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843653,0.0013255718,0.00070058985,0.00790766,0.00054172915,0.0044526733,0.00011274311,0.00030361512,0.0002901339],"genre_scores_gemma":[0.99536216,0.00093543564,0.00044736217,0.00029927393,0.00086247944,0.0010002875,0.0002644621,0.00009865654,0.00072985323],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964586,0.00028439923,0.0007522846,0.00076789403,0.00049909175,0.0012377374],"domain_scores_gemma":[0.99480563,0.0034704925,0.00022522265,0.0008621403,0.00034419724,0.00029233433],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013721391,0.00047085184,0.0018146784,0.00031728428,0.00042223439,0.00009114875,0.0005231801,0.00018939377,0.00015788994],"category_scores_gemma":[0.0025508432,0.00034380803,0.00015009395,0.0008291274,0.00068885117,0.000114588256,0.00025455636,0.0006314144,0.00013827755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59516555,0.004354703,0.0055198674,0.006113825,0.008833014,0.017418718,0.0061809826,0.002176213,0.026961794,0.01893115,0.27642795,0.03191625],"study_design_scores_gemma":[0.8679723,0.013551996,0.005296642,0.00028074096,0.003006905,0.008903063,0.0020575884,0.07182059,0.004175074,0.0018313435,0.019886417,0.0012173166],"about_ca_topic_score_codex":0.000065147935,"about_ca_topic_score_gemma":0.00011366728,"teacher_disagreement_score":0.2728068,"about_ca_system_score_codex":0.0005146258,"about_ca_system_score_gemma":0.0010155394,"threshold_uncertainty_score":0.9999014},"labels":[],"label_agreement":null},{"id":"W4391463826","doi":"10.1016/s2352-3026(24)00001-2","title":"Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé","keywords":"Medicine; Decitabine; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Venetoclax; Regimen; Internal medicine; Oncology; Transplantation; Leukemia; Bone marrow; Pediatrics; Chronic lymphocytic leukemia","score_opus":0.037061835381769936,"score_gpt":0.32741656185620793,"score_spread":0.290354726474438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391463826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98805374,0.005143658,0.00013563344,0.0045331074,0.00008199786,0.0019008799,0.000035661546,0.00006302268,0.00005228529],"genre_scores_gemma":[0.99765426,0.0008955718,0.0005726546,0.00025738517,0.00015680255,0.00024933284,0.00005207264,0.00005173239,0.000110218236],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99854267,0.00013073943,0.00026154984,0.00036890586,0.00021482058,0.00048133914],"domain_scores_gemma":[0.99842525,0.0007862127,0.00007602057,0.0005059326,0.00009920076,0.000107362845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000447398,0.00022639178,0.0008363731,0.00009880755,0.00010663097,0.00003698119,0.00024567012,0.00010756282,0.0000226018],"category_scores_gemma":[0.00011736155,0.000106541105,0.000041104267,0.00019074875,0.00066007173,0.000092326,0.00010236745,0.00033536815,0.000004844577],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15181425,0.0019011451,0.1714978,0.048283868,0.01778169,0.0058860993,0.03836855,0.0015076173,0.028382067,0.11494059,0.052540433,0.3670959],"study_design_scores_gemma":[0.14341101,0.0513943,0.3763539,0.004344239,0.004106364,0.029002612,0.0013863727,0.29011318,0.016283575,0.01695742,0.0641053,0.0025417306],"about_ca_topic_score_codex":0.000035735684,"about_ca_topic_score_gemma":0.000046209207,"teacher_disagreement_score":0.36455417,"about_ca_system_score_codex":0.00025576237,"about_ca_system_score_gemma":0.00067639357,"threshold_uncertainty_score":0.434462},"labels":[],"label_agreement":null},{"id":"W4391544344","doi":"10.1016/s2352-3026(23)00377-0","title":"Diagnosis and management of pyruvate kinase deficiency: international expert guidelines","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Centre for Social Innovation; University of Toronto; Mount Sinai Hospital","funders":"Agios Pharmaceuticals","keywords":"Medicine; Guideline; Pyruvate kinase deficiency; Expert opinion; Pediatrics; MEDLINE; Inclusion (mineral); Family medicine; Intensive care medicine; Pyruvate kinase; Pathology; Internal medicine","score_opus":0.08962958820728362,"score_gpt":0.3701990562500991,"score_spread":0.28056946804281546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391544344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9027668,0.015820196,0.0005150446,0.071731165,0.0015857957,0.00024118216,0.000011397989,0.00011374951,0.007214632],"genre_scores_gemma":[0.96716917,0.025038898,0.0022290624,0.0044350657,0.00034862998,0.00008676814,0.000016512759,0.000012440396,0.00066348596],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99943167,0.000029190966,0.00018908599,0.0001548103,0.00007716052,0.00011806134],"domain_scores_gemma":[0.99963254,0.000083113155,0.000030405145,0.00018176499,0.00004916187,0.000023028466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014240819,0.0000713887,0.00029420562,0.00005631637,0.000025482701,0.000005869953,0.000085202824,0.000042410484,0.0002079137],"category_scores_gemma":[0.000032445158,0.000042744396,0.00003866157,0.00008779286,0.00013272496,0.000020491467,0.000075547054,0.00007487852,0.000041486495],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000852813,0.00027239032,0.020417586,0.0037059172,0.00067860313,0.002555494,0.0022119342,0.000030436193,0.013118405,0.40555882,0.42941004,0.12118755],"study_design_scores_gemma":[0.0026165908,0.00039387817,0.027693337,0.0015231387,0.00032760616,0.002367577,0.0010523638,0.0033205904,0.009654047,0.011034628,0.939714,0.00030222785],"about_ca_topic_score_codex":0.000015503845,"about_ca_topic_score_gemma":0.0000038293733,"teacher_disagreement_score":0.510304,"about_ca_system_score_codex":0.000008480801,"about_ca_system_score_gemma":0.000012107417,"threshold_uncertainty_score":0.22765093},"labels":[],"label_agreement":null},{"id":"W4392304116","doi":"10.1016/s2352-3026(24)00030-9","title":"Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; Public Health Ontario; University of Toronto","funders":"National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; China-Japan Friendship Hospital; Medical Research Council; Fogarty International Center; Canadian Institutes of Health Research; National Institutes of Health; Public Health England; University of Melbourne; King's College London; Novo Nordisk; National Institute on Aging; National Institute for Health and Care Research; Alnylam Pharmaceuticals; Barts Health NHS Trust; Maze Therapeutics; National Health and Medical Research Council; AstraZeneca; Barts Charity; World Health Organization; Wellcome Trust; Hospital for Sick Children; Broad Institute; GlaxoSmithKline; Bristol-Myers Squibb; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Bill and Melinda Gates Foundation; National Institute for Nutrition and Health; State Government of Victoria; Carolina Population Center, University of North Carolina at Chapel Hill; Pfizer","keywords":"Medicine; Anemia; Pediatrics; Internal medicine","score_opus":0.05589305139803471,"score_gpt":0.3413870395701451,"score_spread":0.2854939881721104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392304116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9568217,0.0053240885,0.0013165299,0.031202648,0.0011568948,0.00031611425,0.0009736659,0.00021314021,0.0026752353],"genre_scores_gemma":[0.9769964,0.00018072149,0.011147023,0.008548523,0.0011714469,0.000036052323,0.0015180279,0.000042465985,0.00035932352],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861676,0.00004446469,0.00025747705,0.00050734496,0.00024011369,0.00033381963],"domain_scores_gemma":[0.99843097,0.00026998593,0.000033716246,0.0011113136,0.000024239895,0.00012978529],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020936856,0.00017987867,0.0006682643,0.000113118076,0.000042500473,0.00008428775,0.00091011915,0.00010525619,0.00073364715],"category_scores_gemma":[0.00031102262,0.0001266349,0.000048897164,0.00019331973,0.000097547185,0.00009210441,0.00058318593,0.00022649873,0.0012781399],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009979204,0.00015112832,0.07682362,0.00014604087,0.00041944053,0.003990271,0.006989958,0.00024026455,0.0040352833,0.012495831,0.8719958,0.021714425],"study_design_scores_gemma":[0.003074192,0.00014747902,0.22824267,0.0005670805,0.00077547494,0.0003831711,0.001245891,0.0029194115,0.0018938233,0.018523902,0.74156046,0.00066642446],"about_ca_topic_score_codex":0.0017512832,"about_ca_topic_score_gemma":0.00088274106,"teacher_disagreement_score":0.15141906,"about_ca_system_score_codex":0.000019650352,"about_ca_system_score_gemma":0.00005606159,"threshold_uncertainty_score":0.9994995},"labels":[],"label_agreement":null},{"id":"W4393238711","doi":"10.1016/s2352-3026(24)00045-0","title":"Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Janssen Research and Development; National Institutes of Health; Incyte; bluebird bio; National Center for Advancing Translational Sciences; Health Resources and Services Administration; Agios Pharmaceuticals; Chiesi Farmaceutici; Bayer Corporation; CSL Behring; Novo Nordisk; Teva Pharmaceutical Industries; United Therapeutics Corporation; Celgene; Bayer HealthCare; Sanofi; Alexion Pharmaceuticals; Penn State College of Medicine; University of Pittsburgh; National Heart, Lung, and Blood Institute; Vifor Pharma; Pfizer","keywords":"Medicine; Riociguat; Placebo; Proteinuria; Internal medicine; Sickle cell anemia; Disease; Clinical trial; Anemia; Gastroenterology; Pulmonary hypertension; Kidney; Pathology","score_opus":0.02517269675344845,"score_gpt":0.2861932875726454,"score_spread":0.26102059081919693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393238711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845622,0.0021671513,0.000019478834,0.00412673,0.00030814187,0.008166084,0.0000094132665,0.00009128915,0.0005494787],"genre_scores_gemma":[0.9977561,0.00021404623,0.000036217607,0.0004944533,0.00014992603,0.0006652507,0.000034315788,0.000037640704,0.00061201304],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984524,0.00015960094,0.00041146288,0.00037102267,0.00020594306,0.00039954347],"domain_scores_gemma":[0.99908364,0.0002556849,0.00009484888,0.00035201566,0.000052108648,0.00016171332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030243926,0.00024679204,0.0013099645,0.00011875516,0.0000923348,0.00004403818,0.00010010947,0.00016612,0.00009393581],"category_scores_gemma":[0.00007653811,0.000112658905,0.0000737878,0.00021182957,0.0001927415,0.00006449755,0.000049254853,0.00039338303,0.000033031687],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9941584,0.001186407,0.00033469548,0.00045708026,0.00014037022,0.0013400627,0.00046319363,0.000008195557,0.000049828217,0.000109019085,0.0010524539,0.00070029823],"study_design_scores_gemma":[0.9933881,0.0026986809,0.000059438287,0.000384151,0.0005326305,0.00017279894,0.00015874227,0.00092054845,0.000045771267,0.000097583106,0.001372149,0.00016936928],"about_ca_topic_score_codex":0.00003905859,"about_ca_topic_score_gemma":0.000035965695,"teacher_disagreement_score":0.0131939035,"about_ca_system_score_codex":0.00002690834,"about_ca_system_score_gemma":0.00016824913,"threshold_uncertainty_score":0.45940968},"labels":[],"label_agreement":null},{"id":"W4393952544","doi":"10.1016/s2352-3026(24)00072-3","title":"Transplant without salvage: cut out the middleman","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myeloid leukaemia; Salvage therapy; Medicine; Refractory (planetary science); Chemotherapy; Transplantation; Hematology; Induction chemotherapy; Oncology; Hematopoietic stem cell transplantation; Internal medicine; Orthodoxy; Stem cell; Intensive care medicine; Haematopoiesis; Biology","score_opus":0.06128884652059418,"score_gpt":0.35350729072832854,"score_spread":0.29221844420773435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393952544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64118683,0.0063376785,0.00125708,0.31271213,0.000991261,0.0011674908,0.000045734112,0.00060078327,0.035701018],"genre_scores_gemma":[0.98654735,0.0005741603,0.00016190528,0.004862401,0.0009360313,0.00009296301,0.000023675266,0.000049485796,0.0067520174],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982189,0.00026234216,0.00026145735,0.00032267132,0.00030292873,0.0006316814],"domain_scores_gemma":[0.9983995,0.0005437038,0.00003253067,0.0008897798,0.00004303645,0.000091465336],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008630398,0.00019295205,0.0007306722,0.00008055628,0.00015823588,0.000051461782,0.00044835955,0.0001392396,0.00029396385],"category_scores_gemma":[0.000092070724,0.000085951506,0.00012858443,0.00022148881,0.00050139066,0.000044817683,0.00009236753,0.0010456002,0.0016723693],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002027188,0.0001527061,0.03255169,0.0034741235,0.0015099297,0.01923494,0.024618026,0.000012603458,0.009146999,0.16968957,0.72916377,0.00841843],"study_design_scores_gemma":[0.0045168316,0.00046354582,0.010113872,0.0011103163,0.0011518401,0.06262108,0.001088329,0.0070944806,0.010679535,0.011654942,0.88889074,0.0006144747],"about_ca_topic_score_codex":0.000047664846,"about_ca_topic_score_gemma":0.00016786714,"teacher_disagreement_score":0.34536055,"about_ca_system_score_codex":0.000078709934,"about_ca_system_score_gemma":0.00024411416,"threshold_uncertainty_score":0.9991049},"labels":[],"label_agreement":null},{"id":"W4394564034","doi":"10.1016/s2352-3026(24)00067-x","title":"Methodological challenges in the development of endpoints for myelofibrosis clinical trials","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Myeloproliferative neoplasm; Clinical trial; Myeloid; Oncology; Clinical endpoint; Janus kinase 2; Surrogate endpoint; Internal medicine; Myeloid leukemia; Bone marrow","score_opus":0.8278153183857964,"score_gpt":0.584567789265612,"score_spread":0.24324752912018432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394564034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85458,0.018015547,0.0024938623,0.11858418,0.0006745292,0.0027470044,0.00003071339,0.00007260161,0.0028016018],"genre_scores_gemma":[0.9659759,0.0033973702,0.028212465,0.00095787994,0.00038979185,0.0009931412,0.000017008393,0.000014858565,0.00004162912],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99554497,0.0026710865,0.0010486464,0.00030997497,0.00015640829,0.0002689009],"domain_scores_gemma":[0.97722554,0.02220941,0.00014548612,0.00033906027,0.00004336479,0.000037121543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016333688,0.0001518566,0.0019026793,0.0000631004,0.00005064748,0.000010973878,0.00019308008,0.000158062,0.00006762013],"category_scores_gemma":[0.003661953,0.00006113868,0.00024756457,0.0001076199,0.00015085281,0.000016989341,0.000048390608,0.00023702194,0.00002711667],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004248204,0.0017614926,0.041262645,0.003117128,0.0019801953,0.00044920732,0.02338117,0.0000032018859,0.00062856916,0.42488518,0.015956908,0.4823261],"study_design_scores_gemma":[0.019314462,0.00478648,0.4936278,0.002700109,0.0023004925,0.002868936,0.0072394703,0.0006926561,0.045520052,0.10138297,0.31876037,0.0008062171],"about_ca_topic_score_codex":0.0000018696007,"about_ca_topic_score_gemma":0.000056004563,"teacher_disagreement_score":0.48151988,"about_ca_system_score_codex":0.000025022979,"about_ca_system_score_gemma":0.000141481,"threshold_uncertainty_score":0.56609625},"labels":[],"label_agreement":null},{"id":"W4396517457","doi":"10.1016/s2352-3026(24)00099-1","title":"Diversity, equity, and inclusion in ASH guidelines","year":2024,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; University of British Columbia","funders":"","keywords":"Inclusion (mineral); Psychology; Guideline; Autonomy; Scopus; Political science; Public relations; Library science; Social psychology; MEDLINE; Law","score_opus":0.48860161706903926,"score_gpt":0.541388175330978,"score_spread":0.05278655826193879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396517457","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01431504,0.0015976478,0.000043613716,0.97958344,0.0008588533,0.00053453905,0.000029174951,0.000089655616,0.0029480509],"genre_scores_gemma":[0.02672778,0.0011168282,0.0006038694,0.96589714,0.0047254744,0.000017149565,0.0002111652,0.000039205646,0.0006613709],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972317,0.00028393732,0.00097053597,0.00045253805,0.00063936686,0.00042190126],"domain_scores_gemma":[0.99746794,0.0015071402,0.00026528368,0.0005669247,0.00015072883,0.000041961688],"candidate_categories":["open_science"],"consensus_categories":[],"category_scores_codex":[0.0029348556,0.00024597548,0.0012398481,0.0001929087,0.0004810472,0.000029954283,0.0005922443,0.0006134111,0.00014466929],"category_scores_gemma":[0.002519647,0.00016421323,0.000091208094,0.00019636878,0.0002005471,0.00006517597,0.14022818,0.002273021,0.00012784242],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009014551,0.000013747096,0.0025461311,0.0008076119,0.000054413664,0.0033527513,0.0005773279,5.798617e-7,0.000011200246,0.0003011147,0.9846902,0.0075547844],"study_design_scores_gemma":[0.0014031165,0.00009862725,0.0005158537,0.00043260652,0.0004993552,0.0027110248,0.00006361512,0.00019820956,0.000008846644,0.115516365,0.87836754,0.00018484458],"about_ca_topic_score_codex":0.0007949682,"about_ca_topic_score_gemma":0.00070304377,"teacher_disagreement_score":0.13963594,"about_ca_system_score_codex":0.00008753995,"about_ca_system_score_gemma":0.00013006081,"threshold_uncertainty_score":0.98752713},"labels":[],"label_agreement":null},{"id":"W4396520704","doi":"10.1016/s2352-3026(24)00078-4","title":"Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University of Toronto; University Health Network","funders":"National Heart, Lung, and Blood Institute; Kenya Medical Research Institute; Wellcome Trust; Cincinnati Children’s Research Foundation; Cincinnati Children's Hospital Medical Center; Bristol-Myers Squibb","keywords":"Medicine; Sickle cell anemia; Open label; Pediatrics; Anemia; Clinical trial; Internal medicine; Disease","score_opus":0.036976754108189396,"score_gpt":0.3190857287698329,"score_spread":0.2821089746616435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396520704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98483175,0.00626679,0.00023126054,0.0025899669,0.00029672674,0.003824598,0.000064373235,0.00007862508,0.0018158978],"genre_scores_gemma":[0.99714655,0.0009435882,0.0009068605,0.00018207698,0.000104686376,0.00021746597,0.00016524042,0.000040490013,0.000293046],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984984,0.00012595384,0.00043576324,0.0003511222,0.00015241379,0.0004363512],"domain_scores_gemma":[0.99909896,0.00021156491,0.00013500714,0.00042374502,0.00004953818,0.000081180115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004631583,0.00020959921,0.0009700148,0.00013143673,0.00006408312,0.000026502341,0.00028482536,0.00021148357,0.000039291295],"category_scores_gemma":[0.00009760184,0.0001267655,0.00007126814,0.00036144705,0.0001553216,0.00008740996,0.00006431035,0.00033798866,0.000017993278],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6760037,0.015909113,0.00210395,0.0043398226,0.002730638,0.0016491786,0.021311017,0.0005053034,0.031453125,0.008196139,0.15651532,0.07928272],"study_design_scores_gemma":[0.93949795,0.007391391,0.0006923071,0.0010499067,0.001856449,0.0007282218,0.0007365242,0.023141569,0.012307459,0.0014723366,0.010449401,0.0006765177],"about_ca_topic_score_codex":0.00012853192,"about_ca_topic_score_gemma":0.00008916264,"teacher_disagreement_score":0.26349425,"about_ca_system_score_codex":0.00004209305,"about_ca_system_score_gemma":0.00018944978,"threshold_uncertainty_score":0.51693475},"labels":[],"label_agreement":null},{"id":"W4396626940","doi":"10.1016/s2352-3026(24)00081-4","title":"Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; University of Alberta; Ottawa Allergy Research Corporation; University of Ottawa","funders":"CSL Behring","keywords":"Medicine; Hereditary angioedema; Quality of life (healthcare); Angioedema; Open label; Intensive care medicine; Adverse effect; Term (time); Pediatrics; Internal medicine; Dermatology","score_opus":0.2819201216959628,"score_gpt":0.4705432997549764,"score_spread":0.18862317805901357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396626940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96640086,0.022305975,0.002364854,0.0040933397,0.00050468906,0.0035897023,0.00054493174,0.00009916278,0.00009645975],"genre_scores_gemma":[0.99626887,0.00028780854,0.00078291877,0.00038397888,0.0006306457,0.00008861349,0.001212931,0.000038646675,0.00030559988],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974849,0.0004001515,0.00088518084,0.0006884683,0.00022892187,0.00031235442],"domain_scores_gemma":[0.9963434,0.0018025887,0.00024140843,0.0013978893,0.000094392264,0.00012032655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001706493,0.00024782628,0.0017328558,0.000062242834,0.00015704831,0.000052921838,0.000571247,0.000126326,0.00017089756],"category_scores_gemma":[0.0005496468,0.00016966189,0.000103503124,0.00016894823,0.00021940818,0.00021294162,0.0004156791,0.00016383636,0.000013948799],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3555373,0.024917265,0.25351048,0.008356917,0.009300968,0.0020066563,0.009907442,0.000017526421,0.0031242454,0.005216506,0.21790579,0.1101989],"study_design_scores_gemma":[0.5189177,0.0035296143,0.44864678,0.0020848613,0.003748986,0.0012355282,0.0010614399,0.011509192,0.0005284057,0.0031559975,0.0046619675,0.00091958087],"about_ca_topic_score_codex":0.00013489307,"about_ca_topic_score_gemma":0.00023420468,"teacher_disagreement_score":0.21324383,"about_ca_system_score_codex":0.000017376055,"about_ca_system_score_gemma":0.00018317098,"threshold_uncertainty_score":0.6918611},"labels":[],"label_agreement":null},{"id":"W4399993461","doi":"10.1016/s2352-3026(24)00103-0","title":"The origin of ferritin reference intervals: a systematic review","year":2024,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; St. Michael's Hospital; University of Toronto","funders":"","keywords":"Ferritin; Computational biology; Biology; Biochemistry","score_opus":0.1398024338734693,"score_gpt":0.42366653195324216,"score_spread":0.28386409807977286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399993461","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000013154464,0.98931205,0.0000073213646,0.0025445586,0.00042077043,0.0027502708,0.000038364105,0.00006543024,0.004859898],"genre_scores_gemma":[0.0000082491015,0.9964144,0.000031372212,0.00091297337,0.00014350927,0.0005985436,0.00003967645,0.00004713076,0.0018041282],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965532,0.0010889684,0.0014071674,0.00030785584,0.00025510573,0.00038773986],"domain_scores_gemma":[0.99674755,0.000844399,0.00067187723,0.001600889,0.00008241812,0.000052891584],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018537065,0.00039011802,0.008352675,0.000078194666,0.00006788122,0.000020551635,0.0008703075,0.00021713918,0.00006351812],"category_scores_gemma":[0.0011455194,0.00014449393,0.00059515366,0.00037040803,0.00030870008,0.000016354896,0.00018993011,0.0007871903,0.0007917777],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000065659187,0.000012584772,2.7766373e-7,0.9229749,0.00015496665,0.000060772192,0.000035603833,1.9116886e-9,1.9072042e-8,0.038377315,0.027771857,0.010605144],"study_design_scores_gemma":[0.00008374557,0.000018333032,1.0945652e-7,0.46619913,0.009733515,0.0016570607,0.000031706135,3.7497452e-7,7.4514475e-8,0.00035691183,0.5218378,0.00008123133],"about_ca_topic_score_codex":0.00001736191,"about_ca_topic_score_gemma":0.0000171736,"teacher_disagreement_score":0.49406594,"about_ca_system_score_codex":0.000026913951,"about_ca_system_score_gemma":0.00029262854,"threshold_uncertainty_score":0.99998623},"labels":[],"label_agreement":null},{"id":"W4399993470","doi":"10.1016/s2352-3026(24)00143-1","title":"Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Associazione Italiana per la Ricerca sul Cancro; Novartis; Sierra Oncology; GlaxoSmithKline","keywords":"Medicine; Follicular lymphoma; Radiation therapy; Rituximab; Oncology; Stage (stratigraphy); Lymphoma; Internal medicine; Immunotherapy; CD20; Follicular phase; Cancer","score_opus":0.021878447465958302,"score_gpt":0.28960860053651144,"score_spread":0.26773015307055315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399993470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920648,0.0042300127,0.000043168,0.0014232995,0.00009992395,0.0018218898,0.00014539064,0.00005066187,0.000120878045],"genre_scores_gemma":[0.9986977,0.00041368793,0.00030440866,0.00013552292,0.000072721385,0.00018465528,0.000046618436,0.00003152797,0.00011313655],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99837375,0.00019733909,0.00038457525,0.0004003147,0.00029529276,0.00034872798],"domain_scores_gemma":[0.99906814,0.00022775804,0.00011138587,0.00043807394,0.00006201375,0.00009262429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022272284,0.00022898476,0.0008961404,0.000105563944,0.000056729372,0.000026604308,0.000110179106,0.000083018385,0.0000216308],"category_scores_gemma":[0.00004359346,0.00013041597,0.00008076942,0.0002059374,0.00028273166,0.00007228805,0.00002346704,0.000098445606,0.0000051802335],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52450824,0.004918811,0.45220864,0.00031191317,0.0010460386,0.0023652664,0.00292183,0.000047347457,0.00007844074,0.0017838799,0.0006942323,0.009115391],"study_design_scores_gemma":[0.437101,0.003197758,0.55552286,0.00045763428,0.00022478592,0.000072712304,0.00006222997,0.00070869556,0.0007290045,0.00011622221,0.0016248149,0.00018228813],"about_ca_topic_score_codex":0.0003518111,"about_ca_topic_score_gemma":0.000092210066,"teacher_disagreement_score":0.10331421,"about_ca_system_score_codex":0.00022441855,"about_ca_system_score_gemma":0.00023816129,"threshold_uncertainty_score":0.5318209},"labels":[],"label_agreement":null},{"id":"W4400481895","doi":"10.1016/s2352-3026(24)00174-1","title":"Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Ruxolitinib; Interim analysis; Refractory (planetary science); Interim; Graft-versus-host disease; Internal medicine; Disease; Clinical trial; Surgery; Physical therapy","score_opus":0.051263907041721145,"score_gpt":0.34409163184741504,"score_spread":0.2928277248056939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400481895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963066,0.0009347283,0.00010954754,0.00026773888,0.00024180631,0.0016376425,0.00026746618,0.00008298311,0.00015151074],"genre_scores_gemma":[0.999102,0.00014978251,0.000052074407,0.000057514804,0.00007736501,0.00014714214,0.00033517717,0.000035970323,0.000042999163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786484,0.00034792352,0.0006118761,0.00045042948,0.0002953991,0.00042951157],"domain_scores_gemma":[0.99797845,0.0010299948,0.00018561099,0.0005708357,0.000081865735,0.00015324533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018636648,0.00028753496,0.0013128205,0.0005277537,0.00003635836,0.000019140525,0.00015421244,0.000072252384,0.000264017],"category_scores_gemma":[0.00011010681,0.00016220173,0.00014602249,0.0010643831,0.00015226859,0.00008434784,0.00003057122,0.0001777428,0.00002973493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036975622,0.019593902,0.90826595,0.0019240391,0.0056279395,0.006396502,0.01568535,0.000048374877,0.00044837716,0.00014236437,0.00006710038,0.0048244623],"study_design_scores_gemma":[0.13310327,0.033987567,0.7611655,0.0014692916,0.05287099,0.00019674569,0.0062006502,0.008534126,0.0010299581,0.00002647837,0.00051226333,0.000903189],"about_ca_topic_score_codex":0.00013302514,"about_ca_topic_score_gemma":0.0010392336,"teacher_disagreement_score":0.1471005,"about_ca_system_score_codex":0.00027232393,"about_ca_system_score_gemma":0.00022281466,"threshold_uncertainty_score":0.6614395},"labels":[],"label_agreement":null},{"id":"W4400763660","doi":"10.1016/s2352-3026(24)00185-6","title":"SintraREViewed: practice changing, or validation required?","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematological disorders and diagnostics","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.09016371120597517,"score_gpt":0.3947698178445033,"score_spread":0.30460610663852816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400763660","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12726372,0.059090216,0.017468365,0.6508049,0.002683119,0.0024146966,0.00003612681,0.0016434666,0.1385954],"genre_scores_gemma":[0.96091795,0.008841561,0.003373475,0.023727292,0.0007952781,0.00012563897,0.000060541493,0.000041232797,0.002117057],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988899,0.00014428297,0.0002497546,0.00021865738,0.00014213462,0.0003552351],"domain_scores_gemma":[0.99799323,0.0014732204,0.000053500553,0.00035048882,0.00006643618,0.000063138425],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054510456,0.00011824273,0.0006075301,0.000065278386,0.00007711011,0.000039540766,0.00012218177,0.00011285912,0.0005506419],"category_scores_gemma":[0.0038634574,0.00006075279,0.00006842321,0.00036724395,0.00011235549,0.000093380884,0.00005688916,0.00024173803,0.0009435703],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006403342,0.00025683458,0.0006343026,0.0027764167,0.00019223623,0.007296214,0.0014185117,0.0000050495646,0.000110977664,0.6850146,0.27453905,0.027115488],"study_design_scores_gemma":[0.0006056718,0.00032511682,0.00014281503,0.00063546415,0.0004227683,0.012796222,0.00049488194,0.0005317775,0.0005029774,0.00848542,0.97489476,0.00016214704],"about_ca_topic_score_codex":0.000005638971,"about_ca_topic_score_gemma":0.0000024853443,"teacher_disagreement_score":0.8336542,"about_ca_system_score_codex":0.000017449418,"about_ca_system_score_gemma":0.0000804123,"threshold_uncertainty_score":0.9998343},"labels":[],"label_agreement":null},{"id":"W4401322439","doi":"10.1016/s2352-3026(24)00223-0","title":"Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List","year":2024,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Canadian Hemophilia Society","funders":"","keywords":"Medicine; Haemophilia; Harm; Do no harm; Intensive care medicine; Family medicine; Environmental health; Pediatrics; Psychiatry; Law","score_opus":0.02926762519966622,"score_gpt":0.3212455867381156,"score_spread":0.29197796153844935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401322439","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15376367,0.0025845491,0.000017876026,0.8392767,0.00069505116,0.0010881843,0.00049324107,0.00006993496,0.0020108384],"genre_scores_gemma":[0.1361024,0.0039058046,0.00037358224,0.7753174,0.04123698,0.0006247474,0.0020230336,0.00035642667,0.040059667],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99710196,0.00039800926,0.00045056085,0.00058936456,0.0007639278,0.0006962011],"domain_scores_gemma":[0.9965175,0.0015004261,0.00019541151,0.001512586,0.00017327374,0.000100845915],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0004837836,0.00043220673,0.002221966,0.00015343,0.00015778802,0.000035623027,0.00078262616,0.0005400764,0.0008203483],"category_scores_gemma":[0.00028538908,0.00017217873,0.00021702611,0.0005203333,0.00068396673,0.000021308222,0.00028842085,0.002491908,0.00062302395],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046311278,0.000032584885,0.0125150485,0.0006666145,0.001149192,0.0034263954,0.0015686501,0.0000010593317,0.000059274043,0.00007744419,0.9798364,0.00020424913],"study_design_scores_gemma":[0.0027035705,0.00075180444,0.0072092838,0.0023585695,0.004201173,0.0019348993,0.00043374978,0.00006579197,0.0012856502,0.0023808456,0.9762525,0.0004221639],"about_ca_topic_score_codex":0.0025696845,"about_ca_topic_score_gemma":0.0014869339,"teacher_disagreement_score":0.0639593,"about_ca_system_score_codex":0.000044177774,"about_ca_system_score_gemma":0.0002526011,"threshold_uncertainty_score":0.9998094},"labels":[],"label_agreement":null},{"id":"W4401931977","doi":"10.1016/s2352-3026(24)00239-4","title":"Management of pregnancies with anti-K alloantibodies and the predictive value of anti-K titration testing","year":2024,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Blood groups and transfusion","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University Health Network; Mount Sinai Hospital","funders":"University of Toronto","keywords":"Medicine; Predictive value; Value (mathematics); Titration; Obstetrics; Internal medicine; Statistics","score_opus":0.04740498930240186,"score_gpt":0.31936736402540483,"score_spread":0.271962374723003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401931977","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037782514,0.9916475,0.000120647856,0.0005066047,0.00009127367,0.0014015216,0.000029024266,0.00003436269,0.002390821],"genre_scores_gemma":[0.02969118,0.9694882,0.00057403673,0.00002432515,0.000064965185,0.00006083602,0.000017514361,0.000024678164,0.000054247255],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9988356,0.00015480188,0.0004314301,0.00023224756,0.00017352124,0.00017239354],"domain_scores_gemma":[0.9989198,0.0003235232,0.00029094436,0.000381702,0.00006715053,0.000016869868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042436458,0.00022594527,0.0025070643,0.00006693152,0.000056364075,0.000008450772,0.00015306,0.00011319308,0.000002448614],"category_scores_gemma":[0.000024442968,0.00008755827,0.0001235423,0.00024748492,0.00068957487,0.000023354502,0.0000905256,0.00028998457,0.0000022317483],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046344052,0.00022053986,0.0022955255,0.5603831,0.00703168,0.0007315209,0.0022344545,0.000010462705,0.000015507192,0.27251127,0.00043002298,0.15367249],"study_design_scores_gemma":[0.012678718,0.00226653,0.009444189,0.69052094,0.12893878,0.019361839,0.0015881361,0.0008810277,0.00024794167,0.0071946816,0.12580135,0.0010758298],"about_ca_topic_score_codex":0.00002905255,"about_ca_topic_score_gemma":0.000005293317,"teacher_disagreement_score":0.26531658,"about_ca_system_score_codex":0.000006094751,"about_ca_system_score_gemma":0.000059241076,"threshold_uncertainty_score":0.35705227},"labels":[],"label_agreement":null},{"id":"W4402712904","doi":"10.1016/s2352-3026(24)00274-6","title":"Transplantation and long-term overall survival in acute myeloid leukaemia","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myeloid leukaemia; Transplantation; Term (time); Oncology; Overall survival; Internal medicine","score_opus":0.03384350003317645,"score_gpt":0.3370490494081314,"score_spread":0.303205549374955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402712904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783617,0.001754081,0.0003266802,0.016598964,0.0002237989,0.00034630232,0.000017762228,0.00011234052,0.00225834],"genre_scores_gemma":[0.99379987,0.0042518815,0.00014999641,0.0007247233,0.0002289555,0.000037025464,0.00006111003,0.00002730325,0.00071915716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987376,0.00014927467,0.00022231498,0.00029351327,0.00017804033,0.00041929792],"domain_scores_gemma":[0.99926496,0.00032694882,0.000022729353,0.00029245444,0.000023090008,0.00006980048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046273932,0.00014403371,0.0006025855,0.00014648758,0.00004338744,0.000034696142,0.00015756684,0.00014156607,0.00009558296],"category_scores_gemma":[0.000031020627,0.00009456961,0.000044743392,0.00019996664,0.00019351304,0.00008637409,0.00005268916,0.0005921726,0.0001157537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050623165,0.0001329898,0.76402503,0.0071468065,0.0008838299,0.06352679,0.008409533,0.000014786606,0.02793299,0.08788858,0.013021888,0.021954438],"study_design_scores_gemma":[0.006531953,0.00027348846,0.94891834,0.00070112356,0.0004131194,0.03137468,0.000091604314,0.0021778105,0.003634967,0.0035848732,0.0019507362,0.00034732645],"about_ca_topic_score_codex":0.00007159516,"about_ca_topic_score_gemma":0.00021705823,"teacher_disagreement_score":0.18489327,"about_ca_system_score_codex":0.000107673455,"about_ca_system_score_gemma":0.00015548078,"threshold_uncertainty_score":0.38564366},"labels":[],"label_agreement":null},{"id":"W4403014078","doi":"10.1016/s2352-3026(24)00276-x","title":"Radiation target nomenclature for lymphoma trials: consensus recommendations from the National Clinical Trials Network groups","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Canadian Centre for Applied Research in Cancer Control","funders":"National Institutes of Health; National Comprehensive Cancer Network; National Cancer Institute; American Association of Physicists in Medicine","keywords":"Medicine; Clinical trial; Nomenclature; Lymphoma; Medical physics; Intensive care medicine; Internal medicine; Taxonomy (biology)","score_opus":0.2870654028184923,"score_gpt":0.48311623671278964,"score_spread":0.19605083389429734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403014078","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13917731,0.031258382,0.0027503776,0.8088201,0.009111188,0.004598767,0.0019400335,0.00031403312,0.0020297782],"genre_scores_gemma":[0.9483481,0.0022543678,0.0086333025,0.020011166,0.017408542,0.0012676752,0.0017693735,0.000044789747,0.00026267546],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99548215,0.0024620413,0.0012240398,0.00034234452,0.00018953781,0.0002998674],"domain_scores_gemma":[0.9538224,0.045346636,0.00035750857,0.00030443902,0.000102205224,0.00006681854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011622675,0.00017928035,0.0017171034,0.00003509896,0.00023807454,0.00006770411,0.00016475581,0.00023071941,0.0002822081],"category_scores_gemma":[0.007950005,0.000084333224,0.00049123063,0.00017652733,0.00011135244,0.000030422661,0.000038661987,0.00016222411,0.00010457752],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084685156,0.00016804856,0.008090861,0.000029679619,0.0012727912,0.000032592274,0.0003008796,0.000013588562,0.0000072520747,0.114823386,0.84689593,0.027518155],"study_design_scores_gemma":[0.010018677,0.00020791977,0.026824748,0.00017776605,0.0013333915,0.0003228516,0.00008494611,0.0031068628,0.0000777547,0.13017212,0.8275245,0.00014850465],"about_ca_topic_score_codex":0.000032537868,"about_ca_topic_score_gemma":0.000027831451,"teacher_disagreement_score":0.8091708,"about_ca_system_score_codex":0.0001524114,"about_ca_system_score_gemma":0.00046112377,"threshold_uncertainty_score":0.95174736},"labels":[],"label_agreement":null},{"id":"W4403087733","doi":"10.1016/s2352-3026(24)00275-8","title":"The Global Fund should extend its mandate to include universal access to hydroxyurea","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"Fogarty International Center; National Heart, Lung, and Blood Institute","keywords":"Medicine; Mandate; Expanded access; Internal medicine","score_opus":0.07488841540356138,"score_gpt":0.380341841491127,"score_spread":0.3054534260875656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403087733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5737087,0.0061219204,0.00051077886,0.37559658,0.0014600769,0.0009094052,0.00005114552,0.00030554913,0.04133581],"genre_scores_gemma":[0.98612916,0.0007649796,0.000053587548,0.011024979,0.00028191184,0.000028929513,0.00000942044,0.000023727516,0.0016833051],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859303,0.00009388573,0.00021961244,0.00031076817,0.00020794418,0.0005747633],"domain_scores_gemma":[0.9990583,0.0001580958,0.000028623741,0.00051025074,0.000049006805,0.00019571478],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034309636,0.00018216061,0.0004953776,0.00005715138,0.0002584307,0.00011260054,0.000586744,0.00016063933,0.00011078454],"category_scores_gemma":[0.0001059395,0.00009229967,0.00008087952,0.000577715,0.00010742237,0.00007012494,0.0004492511,0.0003721154,0.0008655647],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024467928,0.00013832486,0.009053885,0.00072025455,0.00083732634,0.0059253415,0.0032373199,0.00048141115,0.0007177848,0.32654956,0.61604905,0.033842936],"study_design_scores_gemma":[0.0010204639,0.000276788,0.0041507753,0.00027824292,0.00024304181,0.002391659,0.0005366645,0.000987776,0.00044461837,0.0042257737,0.98519254,0.0002516481],"about_ca_topic_score_codex":0.000077117336,"about_ca_topic_score_gemma":0.0002602636,"teacher_disagreement_score":0.41242042,"about_ca_system_score_codex":0.000090987814,"about_ca_system_score_gemma":0.0001152653,"threshold_uncertainty_score":0.9999124},"labels":[],"label_agreement":null},{"id":"W4403274656","doi":"10.1016/s2352-3026(24)00251-5","title":"Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes","year":2024,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"HORIZON EUROPE Framework Programme; Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute; Agence Nationale de la Recherche","keywords":"Myelodysplastic syndromes; Medicine; Consensus conference; International Prognostic Scoring System; Intensive care medicine; Internal medicine; Bone marrow","score_opus":0.2527579179498377,"score_gpt":0.4168192831024565,"score_spread":0.16406136515261877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403274656","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002827361,0.9393344,0.0025060163,0.022679357,0.00452568,0.009734919,0.019962117,0.0004811351,0.00049365795],"genre_scores_gemma":[0.0041695978,0.9643767,0.002519659,0.00096723624,0.0031892746,0.006747455,0.015826385,0.0004069663,0.0017967161],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945876,0.0006127786,0.0016290537,0.001524421,0.0006290577,0.0010170896],"domain_scores_gemma":[0.98048645,0.01510944,0.0008384633,0.0029884155,0.00038728403,0.00018996066],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015407646,0.0008568372,0.004881515,0.00027555472,0.00037221005,0.00022560169,0.003144737,0.00074032735,0.00010675312],"category_scores_gemma":[0.0030304138,0.00045044697,0.0005620468,0.00040403235,0.00087728136,0.00008157343,0.0008117494,0.0014204279,0.00084935897],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017262138,0.00017656777,0.000040033516,0.125655,0.013095982,0.0017413804,0.00028098212,0.000006953646,0.0000803112,0.06314835,0.7557351,0.03831313],"study_design_scores_gemma":[0.002434092,0.00017306783,0.000023459015,0.014791118,0.011162994,0.014441703,0.0003819406,0.0090924315,0.0000023014125,0.00036960805,0.9466792,0.00044810423],"about_ca_topic_score_codex":0.000043166383,"about_ca_topic_score_gemma":0.0000550742,"teacher_disagreement_score":0.19094408,"about_ca_system_score_codex":0.0008429709,"about_ca_system_score_gemma":0.0023156903,"threshold_uncertainty_score":0.9999286},"labels":[],"label_agreement":null},{"id":"W4404095781","doi":"10.1016/s2352-3026(24)00307-7","title":"Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Novo Nordisk","keywords":"Medicine; Haemophilia; Open label; Haemophilia A; Clinical trial; Physical therapy; Pediatrics; Internal medicine","score_opus":0.08556698565095941,"score_gpt":0.3977124130320215,"score_spread":0.3121454273810621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404095781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715552,0.0014018611,0.000034214037,0.011007232,0.0005551326,0.013193879,0.000037696558,0.0002521064,0.0019627213],"genre_scores_gemma":[0.99226695,0.0002540132,0.00050858164,0.00031612036,0.00064539677,0.002612579,0.000051682317,0.0001061901,0.0032384987],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99599004,0.0005354828,0.00077027373,0.0009856183,0.00061587483,0.0011027217],"domain_scores_gemma":[0.99753696,0.00092252926,0.00013939157,0.00095413387,0.00017069728,0.00027631267],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010634657,0.00054412044,0.0025072515,0.00035707967,0.00023395511,0.00020897873,0.0006307747,0.00028945165,0.00040053134],"category_scores_gemma":[0.00067955157,0.0002624944,0.000121046316,0.0012810327,0.00062461937,0.00028430825,0.00030454615,0.0010923583,0.00025795054],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94839334,0.0038806465,0.009172672,0.0013627029,0.0008192573,0.01366578,0.0071064853,0.000004183163,0.0007120592,0.002508771,0.0072302055,0.0051439097],"study_design_scores_gemma":[0.9705164,0.01140459,0.0003570026,0.0014013747,0.000508979,0.004530971,0.0007432553,0.002499808,0.003184915,0.0016897158,0.002575468,0.0005875094],"about_ca_topic_score_codex":0.0002422998,"about_ca_topic_score_gemma":0.0012119431,"teacher_disagreement_score":0.022123085,"about_ca_system_score_codex":0.00030839676,"about_ca_system_score_gemma":0.0011235694,"threshold_uncertainty_score":0.9999827},"labels":[],"label_agreement":null},{"id":"W4404170455","doi":"10.1016/s2352-3026(24)00314-4","title":"Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood groups and transfusion","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Observational study; Retrospective cohort study; Fetus; Cohort study; Haemolytic disease; Cohort; Pediatrics; Obstetrics; Pregnancy; Intensive care medicine; Internal medicine","score_opus":0.030588238713342614,"score_gpt":0.31609669898152226,"score_spread":0.28550846026817966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404170455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98724693,0.00020452644,0.000054005923,0.0112852715,0.00015494351,0.0006841762,0.00002096828,0.000013769258,0.00033543693],"genre_scores_gemma":[0.999318,0.00014080467,0.00014350476,0.00023180262,0.000024563913,0.00004449986,0.000009963511,0.000006128336,0.00008072789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993441,0.00006360911,0.00017969371,0.00018266839,0.00013741544,0.00009251883],"domain_scores_gemma":[0.99964863,0.00007328222,0.000024948775,0.0002091306,0.000019644165,0.000024367118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025677183,0.00006868352,0.00029796016,0.00008173047,0.000030175765,0.000013271575,0.00009302557,0.000022813492,0.000013138952],"category_scores_gemma":[0.000038803497,0.000038461243,0.000018621417,0.00016471076,0.00007883433,0.000071901464,0.000070660404,0.00013168804,6.168583e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008122712,0.0002174356,0.9599096,0.00007386862,0.00008443399,0.00023296097,0.0005142349,0.000003145218,0.00000705032,0.038633894,0.000019142291,0.00022296721],"study_design_scores_gemma":[0.0012839354,0.000041844345,0.99189603,0.000086298205,0.00010717539,0.00007880284,0.00017508921,0.0018949452,0.0000023774373,0.004357679,0.00004085099,0.000034942095],"about_ca_topic_score_codex":0.00015810515,"about_ca_topic_score_gemma":0.0006016567,"teacher_disagreement_score":0.034276217,"about_ca_system_score_codex":0.00002418838,"about_ca_system_score_gemma":0.000018995222,"threshold_uncertainty_score":0.1568404},"labels":[],"label_agreement":null},{"id":"W4404942943","doi":"10.1016/s2352-3026(24)00285-0","title":"Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia","year":2024,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Acute lymphocytic leukemia; Disease; Minimal residual disease; Pediatrics; Blinatumomab; Intensive care medicine; Lymphoblastic Leukemia; Oncology; Immunology; Internal medicine; Leukemia","score_opus":0.03919398901172815,"score_gpt":0.3430738836277233,"score_spread":0.3038798946159951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404942943","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011373922,0.99295306,0.00016078018,0.00064539135,0.00033639043,0.002668668,0.00032669285,0.00017486866,0.0015967776],"genre_scores_gemma":[0.0005241017,0.9938412,0.0010960561,0.00012755812,0.00076057983,0.00072016474,0.00041092446,0.00021192583,0.0023075053],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962413,0.0003299435,0.0010378348,0.0008606468,0.0005535261,0.0009767796],"domain_scores_gemma":[0.99580115,0.0015327684,0.0005165072,0.0017525445,0.00015314487,0.00024388215],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021516856,0.00092251925,0.007850668,0.0003416613,0.00006936832,0.000025361269,0.0006890723,0.000620926,0.00014005796],"category_scores_gemma":[0.00010771241,0.00041617244,0.0006553248,0.0006630666,0.00061837357,0.00003314058,0.0002123351,0.000570746,0.0010216407],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00609857,0.0022258796,0.000112312744,0.23803575,0.011860927,0.060139433,0.0022550584,0.000010369739,0.0000080137315,0.0014624763,0.088849984,0.5889412],"study_design_scores_gemma":[0.01833781,0.00375594,0.0000071832237,0.03206095,0.027596049,0.025118958,0.00009886863,0.0003704034,0.000048481183,0.00006561069,0.8919266,0.0006131381],"about_ca_topic_score_codex":0.00020278171,"about_ca_topic_score_gemma":0.000074339565,"teacher_disagreement_score":0.8030766,"about_ca_system_score_codex":0.0013643781,"about_ca_system_score_gemma":0.0033414494,"threshold_uncertainty_score":0.999829},"labels":[],"label_agreement":null},{"id":"W4405009230","doi":"10.1016/s2352-3026(24)00319-3","title":"Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Agios Pharmaceuticals","keywords":"Medicine; Placebo; Clinical trial; Internal medicine; Double blind; Physical therapy; Pediatrics; Intensive care medicine; Alternative medicine; Pathology","score_opus":0.023369943051360653,"score_gpt":0.3126086637001989,"score_spread":0.28923872064883827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405009230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97036767,0.010942561,0.00004667024,0.012728397,0.000465925,0.0038721322,0.00015802104,0.00003741145,0.0013811952],"genre_scores_gemma":[0.99781257,0.0016073982,0.000017777726,0.00015090093,0.0001533921,0.000069313915,0.00007205035,0.000012694746,0.000103877275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99805915,0.00032391658,0.00089693436,0.0002800997,0.00018529902,0.00025457065],"domain_scores_gemma":[0.997653,0.0014880765,0.0002561712,0.0004724866,0.000042554002,0.00008769125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009600186,0.000174014,0.0013256874,0.000044895078,0.00004910631,0.000010917956,0.00015967245,0.00015696333,0.00003869324],"category_scores_gemma":[0.0005394723,0.00008693995,0.00019918325,0.00026807954,0.00031263113,0.00003368109,0.000055431756,0.00028884373,0.000008611372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99408126,0.0004474635,0.00023724214,0.00016302132,0.00017429172,0.00017895958,0.0009923797,0.000055891393,0.00013295363,0.0008960635,0.0019405802,0.0006999185],"study_design_scores_gemma":[0.9948518,0.0002673873,0.00025440537,0.00023702778,0.0007824817,0.00003872274,0.0003335441,0.0014540303,0.00017328358,0.0005715199,0.0009483025,0.00008749452],"about_ca_topic_score_codex":0.00026670514,"about_ca_topic_score_gemma":0.00005350687,"teacher_disagreement_score":0.027444907,"about_ca_system_score_codex":0.000026013831,"about_ca_system_score_gemma":0.0001978513,"threshold_uncertainty_score":0.35453084},"labels":[],"label_agreement":null},{"id":"W4406080334","doi":"10.1016/s2352-3026(24)00346-6","title":"Patient reported outcomes with earlier use of chimeric antigen receptor-T cell therapy in multiple myeloma","year":2025,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Multiple myeloma; Chimeric antigen receptor; Food and drug administration; Standard of care; Oncology; Overall survival; Progression-free survival; Immunotherapy; Cancer; Confidence interval; Pharmacology","score_opus":0.06945262945612482,"score_gpt":0.31280173439360864,"score_spread":0.24334910493748382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406080334","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76243025,0.00054532546,0.000011333541,0.2331147,0.000286845,0.0018884881,0.000041759016,0.00007104318,0.0016102332],"genre_scores_gemma":[0.22170648,0.0066463426,0.0031595838,0.72201306,0.001481465,0.00077922776,0.0011368567,0.00042723186,0.042649783],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965671,0.00060000824,0.0008270206,0.00060924893,0.0006068866,0.00078976696],"domain_scores_gemma":[0.9961467,0.0011600001,0.0005492611,0.001879643,0.00021180988,0.00005263139],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035514665,0.00046037056,0.0027680874,0.00043036233,0.000057069097,0.000020335294,0.00040612693,0.0006734625,0.0010249516],"category_scores_gemma":[0.0001992229,0.000266293,0.0002214701,0.000589045,0.000464019,0.00004372784,0.00013922769,0.0021711814,0.00002954558],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025458669,0.00022530647,0.4327664,0.0005819743,0.0007306873,0.0030173806,0.00091700954,0.000006342224,0.0035404346,0.0000073921433,0.5500374,0.0056238016],"study_design_scores_gemma":[0.0055513433,0.0008146323,0.06875738,0.0004135583,0.00009480636,0.00058724795,0.00007313079,0.000026456497,0.010216805,0.00003367381,0.91304517,0.00038578385],"about_ca_topic_score_codex":0.0007558734,"about_ca_topic_score_gemma":0.00008066488,"teacher_disagreement_score":0.5407238,"about_ca_system_score_codex":0.00008659303,"about_ca_system_score_gemma":0.00034263576,"threshold_uncertainty_score":0.9999789},"labels":[],"label_agreement":null},{"id":"W4406080377","doi":"10.1016/s2352-3026(24)00379-x","title":"Building health advocacy campaigns to engage sexual and gender minority populations with health care","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Food Security and Health in Diverse Populations","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto; University of Ottawa; Stem Cell Network; McGill University","funders":"","keywords":"Medicine; Sexual minority; Health care; Reproductive health; Consumer Advocacy; Nursing; Family medicine; Environmental health; Gerontology; Gender studies; Public relations; Sexual orientation; Population; Political science; Law; Sociology","score_opus":0.2747260672061095,"score_gpt":0.5167277979070518,"score_spread":0.24200173070094233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406080377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8360464,0.0031386777,0.0052806293,0.14793152,0.000958033,0.0027697582,0.0001707394,0.0002671327,0.0034370979],"genre_scores_gemma":[0.9453718,0.000052006148,0.014351003,0.03946403,0.00023261811,0.00021303479,0.00006142417,0.000017800665,0.00023626006],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.996256,0.001569589,0.0006238933,0.00040985015,0.0001452991,0.0009953737],"domain_scores_gemma":[0.9981846,0.0005276949,0.00026697296,0.0006106377,0.00013633531,0.00027374513],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0011237381,0.0002046096,0.0008908412,0.00019474726,0.0039477986,0.000014036701,0.00027528722,0.0001648516,0.000053610616],"category_scores_gemma":[0.0001993648,0.00015227341,0.000025722195,0.00046202439,0.00012477585,0.00007182528,0.00023656018,0.0010443169,0.000042104377],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017090839,0.000048739563,0.16282173,0.0041837897,0.000043957883,0.000007594713,0.10479206,0.000105851155,0.0000015083873,0.6644522,0.062201988,0.0011696906],"study_design_scores_gemma":[0.0057761637,0.0010811072,0.6284673,0.00087716046,0.00017336837,0.00012810538,0.20204362,0.00055127573,0.0000028498619,0.034401596,0.12562579,0.0008716182],"about_ca_topic_score_codex":0.0042548575,"about_ca_topic_score_gemma":0.024751559,"teacher_disagreement_score":0.6300506,"about_ca_system_score_codex":0.00028759695,"about_ca_system_score_gemma":0.0013983054,"threshold_uncertainty_score":0.9973489},"labels":[],"label_agreement":null},{"id":"W4406561879","doi":"10.1016/s2352-3026(24)00338-7","title":"Low-dose aspirin versus placebo in postpartum venous thromboembolism: a multi-national, pilot, randomised, placebo-controlled trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McMaster University; Ottawa Hospital; University of British Columbia; University of Ottawa; Lunenfeld-Tanenbaum Research Institute; McGill University; University of Calgary","funders":"Canadian Institutes of Health Research; Eli Lilly Canada; International Society on Thrombosis and Haemostasis; McMaster University; Eli Lilly and Company","keywords":"Medicine; Aspirin; Placebo; Venous thromboembolism; Randomized controlled trial; Internal medicine; Intensive care medicine; Thrombosis; Alternative medicine","score_opus":0.06894980532997748,"score_gpt":0.34984768618087064,"score_spread":0.2808978808508932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406561879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9547448,0.00046305693,0.00056003,0.015567094,0.0029592454,0.008700739,0.000010462683,0.0002282197,0.016766332],"genre_scores_gemma":[0.99411243,0.00007822609,0.00042580883,0.0032727916,0.0003286681,0.0010955461,0.000032679196,0.00002879834,0.0006250753],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974202,0.00059443724,0.00071487034,0.00040682184,0.0003366512,0.0005270144],"domain_scores_gemma":[0.99767137,0.0013369526,0.00022520265,0.00053323485,0.00014797179,0.00008526181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013826069,0.0002906563,0.0024414873,0.000283406,0.00014451104,0.00002973326,0.00031633815,0.00021035297,0.00017785079],"category_scores_gemma":[0.0010677545,0.00020916107,0.00020229693,0.00036963072,0.00016056934,0.00006262474,0.000101005426,0.00046914205,0.0001639424],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9514509,0.0015915399,0.000099400495,0.00013492435,0.00046144857,0.000089885754,0.00030628828,0.000072616225,0.0010526166,0.042575024,0.0020279062,0.0001374736],"study_design_scores_gemma":[0.9906288,0.0008523466,0.0010827902,0.00017369278,0.0003733805,0.00008342627,0.00012054209,0.0026374615,0.0010136786,0.0024279046,0.00041765286,0.00018833691],"about_ca_topic_score_codex":0.000039401013,"about_ca_topic_score_gemma":0.0002208017,"teacher_disagreement_score":0.04014712,"about_ca_system_score_codex":0.000109310735,"about_ca_system_score_gemma":0.00045924346,"threshold_uncertainty_score":0.85293406},"labels":[],"label_agreement":null},{"id":"W4407313924","doi":"10.1016/s2352-3026(24)00376-4","title":"Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Acceleron; Bristol-Myers Squibb","keywords":"Medicine; Anemia; Term (time); Blood transfusion; Thalassemia; Pediatrics; Intensive care medicine; Randomized controlled trial; Surgery; Internal medicine","score_opus":0.01966854971311297,"score_gpt":0.29627536648236924,"score_spread":0.27660681676925625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407313924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924837,0.0007163083,0.00029361653,0.0022500565,0.00014868926,0.0037764322,0.00019722064,0.000010669981,0.00012330677],"genre_scores_gemma":[0.99779344,0.0017482023,0.00005928641,0.00008249774,0.000031387102,0.00009468229,0.00011866104,0.000009585729,0.00006227163],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987252,0.0001373333,0.0005660743,0.00023219033,0.00012379451,0.00021544156],"domain_scores_gemma":[0.99833846,0.0010101824,0.00017604884,0.00038555372,0.000056916077,0.000032857308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023313235,0.00016136256,0.0010664887,0.00006552756,0.00006513201,0.0000036038311,0.0001157325,0.00014468856,0.00001934602],"category_scores_gemma":[0.0001023296,0.00007328936,0.00008879751,0.00012825332,0.00023071215,0.000014007958,0.00001572,0.00012660203,4.2108232e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93694746,0.0019867516,0.033592217,0.0001330035,0.00042103708,0.000026197127,0.0024308178,0.0000312787,0.00013215652,0.000049197824,0.00010085407,0.024149043],"study_design_scores_gemma":[0.8795093,0.0035934288,0.114179485,0.00032020692,0.0006816474,0.0000084698295,0.00015278967,0.000117037205,0.0011742718,0.00005451483,0.00013180349,0.00007702439],"about_ca_topic_score_codex":0.00023391937,"about_ca_topic_score_gemma":0.00023490933,"teacher_disagreement_score":0.08058727,"about_ca_system_score_codex":0.000035769437,"about_ca_system_score_gemma":0.00008265321,"threshold_uncertainty_score":0.29886535},"labels":[],"label_agreement":null},{"id":"W4408110711","doi":"10.1016/s2352-3026(25)00002-x","title":"Epistemic limitations of measurable residual disease in haematological malignancies","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Residual; Minimal residual disease; Intensive care medicine; Disease; Internal medicine; Oncology; Leukemia; Algorithm","score_opus":0.11428568297166725,"score_gpt":0.33325165608240176,"score_spread":0.2189659731107345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408110711","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010240657,0.99595064,0.000057226385,0.00078135275,0.0002338843,0.0005764789,0.00027687405,0.000010126765,0.0010893502],"genre_scores_gemma":[0.0035884085,0.99507666,0.00014980184,0.0001823794,0.00014228183,0.00025796675,0.00030204825,0.000022041031,0.0002784205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980929,0.00036918707,0.0006670149,0.00040616645,0.00010002352,0.00036472248],"domain_scores_gemma":[0.9979134,0.00078250514,0.00032369085,0.00084756175,0.000075788725,0.000057059926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035858148,0.00028879024,0.0020565821,0.00010893759,0.00005748697,0.000013651116,0.0006577741,0.0003363318,0.000006732848],"category_scores_gemma":[0.0017925388,0.00020248511,0.00026659627,0.00022140019,0.00028264723,0.0000016365595,0.00029657735,0.00023654086,0.000012015438],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011307625,0.0011596926,0.0055676787,0.17791194,0.001486524,0.0014844419,0.0003851236,0.0007102646,0.00024634824,0.327066,0.1431611,0.33969012],"study_design_scores_gemma":[0.00041697602,0.0000645137,0.00009662665,0.0048718625,0.0004895364,0.00017759138,0.000027411137,0.0000035503783,0.00006897148,0.0031409287,0.99030244,0.00033957246],"about_ca_topic_score_codex":0.000027534626,"about_ca_topic_score_gemma":0.00024230052,"teacher_disagreement_score":0.8471414,"about_ca_system_score_codex":0.000027304506,"about_ca_system_score_gemma":0.00076924945,"threshold_uncertainty_score":0.8257103},"labels":[],"label_agreement":null},{"id":"W4408110727","doi":"10.1016/s2352-3026(25)00042-0","title":"Global paediatric haematopoietic stem-cell transplantation training and access: providing strategies to overcome challenges","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Stem cell; Haematopoiesis; Transplantation; Intensive care medicine; Oncology; Internal medicine; Genetics","score_opus":0.0614272692537836,"score_gpt":0.3513424632251694,"score_spread":0.28991519397138577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408110727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9356114,0.0060144565,0.0058180466,0.032640576,0.0002154253,0.000981672,0.000020335776,0.00016503976,0.018533025],"genre_scores_gemma":[0.9955621,0.0023779196,0.00043655836,0.001238479,0.00013054535,0.0000958984,0.00000606264,0.000013994449,0.0001384635],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9984187,0.00017319633,0.00029191616,0.0003615766,0.00023258023,0.0005220653],"domain_scores_gemma":[0.99888504,0.0005252867,0.000066230285,0.00035140867,0.000064188585,0.0001078765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044092874,0.00019041565,0.0007959903,0.00015365804,0.00012928915,0.00008395255,0.0003472755,0.00014437224,0.000013318219],"category_scores_gemma":[0.00005723811,0.00013170512,0.000045829467,0.00044746045,0.00014893062,0.00015183786,0.00014587738,0.00020392305,0.000019413497],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006113499,0.00061542384,0.085941605,0.04181122,0.0010458756,0.00656531,0.07145126,0.0007483775,0.0024192773,0.6435356,0.020126062,0.119626485],"study_design_scores_gemma":[0.068294376,0.003920452,0.5495463,0.0060383,0.0053514554,0.046866935,0.111723736,0.012385395,0.008957988,0.16345611,0.019946277,0.0035126815],"about_ca_topic_score_codex":0.000055115906,"about_ca_topic_score_gemma":0.00010005925,"teacher_disagreement_score":0.4800795,"about_ca_system_score_codex":0.00015804898,"about_ca_system_score_gemma":0.00056752446,"threshold_uncertainty_score":0.5370779},"labels":[],"label_agreement":null},{"id":"W4408110767","doi":"10.1016/s2352-3026(24)00357-0","title":"Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Adolescent and Pediatric Healthcare","field":"Health Professions","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Ask price; Family medicine; MEDLINE; Intensive care medicine","score_opus":0.12637953908093394,"score_gpt":0.4263011003547665,"score_spread":0.2999215612738325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408110767","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008488632,0.9733762,0.000096775075,0.002040986,0.0013233138,0.007447466,0.0006710545,0.00010280309,0.0064527714],"genre_scores_gemma":[0.0075314455,0.9885791,0.00019832936,0.0026860533,0.0002446865,0.00019727889,0.00015112443,0.00008225418,0.00032973583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99358594,0.0031876692,0.0015999414,0.00038451486,0.00030136606,0.00094055565],"domain_scores_gemma":[0.9943824,0.0031939894,0.0010827368,0.0008286857,0.00036436832,0.00014784349],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008823012,0.00044858633,0.0039327503,0.00054942514,0.00026203587,0.000005892346,0.00058804324,0.000551216,0.00011164313],"category_scores_gemma":[0.0010362319,0.0002699202,0.000109587694,0.0018603159,0.00012772693,0.000030364015,0.00043091679,0.0017739341,0.00013596074],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010233545,0.0003119573,0.16241793,0.28653863,0.00021973076,0.00011828399,0.025701681,0.0000056463077,1.9395683e-8,0.008606084,0.040757574,0.4742991],"study_design_scores_gemma":[0.0018234128,0.00023446004,0.0018026592,0.026736943,0.00037194337,0.000005467394,0.0036905,8.066661e-7,8.165317e-8,0.000054095646,0.96483165,0.000447991],"about_ca_topic_score_codex":0.00013586014,"about_ca_topic_score_gemma":0.00023274319,"teacher_disagreement_score":0.92407405,"about_ca_system_score_codex":0.00020257622,"about_ca_system_score_gemma":0.0017554151,"threshold_uncertainty_score":0.9999753},"labels":[],"label_agreement":null},{"id":"W4409318643","doi":"10.1016/s2352-3026(25)00067-5","title":"Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Children's Hospital","funders":"Janssen Research and Development; Bayer","keywords":"Medicine; Venous thromboembolism; Anticoagulant therapy; Cohort; Phase (matter); Intensive care medicine; Pediatrics; Internal medicine; Thrombosis","score_opus":0.03844310607800945,"score_gpt":0.37265058045917515,"score_spread":0.3342074743811657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409318643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99059093,0.0005935302,0.00014782324,0.0034050203,0.0005137544,0.0041902144,0.00007521147,0.000065254564,0.00041828013],"genre_scores_gemma":[0.9982081,0.00024265541,0.00009251143,0.0008372119,0.00023729708,0.00022333743,0.00008579414,0.000018386794,0.000054703334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798715,0.0004336974,0.0006065755,0.00038520474,0.00023660979,0.0003507333],"domain_scores_gemma":[0.99835545,0.00023969728,0.00020858333,0.0010973538,0.000049333485,0.000049574748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039823042,0.0002539028,0.002192973,0.000109269895,0.00012204335,0.000015719486,0.00030707932,0.00012814008,0.00010429849],"category_scores_gemma":[0.00004434282,0.00013730816,0.00015414764,0.00032884447,0.00017546857,0.00003004066,0.0000753989,0.00019547761,0.000020865058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10585031,0.15846671,0.5557733,0.00012565931,0.027814845,0.0019745585,0.018494615,0.000015371375,0.016549112,0.07484476,0.0027574112,0.03733334],"study_design_scores_gemma":[0.40112013,0.010748097,0.56148547,0.00015025954,0.0064361263,0.00035552867,0.0008441249,0.0004631687,0.0123779625,0.005450373,0.0002877938,0.00028100226],"about_ca_topic_score_codex":0.0005799724,"about_ca_topic_score_gemma":0.00010366832,"teacher_disagreement_score":0.29526982,"about_ca_system_score_codex":0.000052000556,"about_ca_system_score_gemma":0.0001475426,"threshold_uncertainty_score":0.55992645},"labels":[],"label_agreement":null},{"id":"W4409875243","doi":"10.1016/s2352-3026(25)00109-7","title":"Lessons from EINSTEIN-Jr and next steps for extended-phase anticoagulation in paediatric venous thromboembolism","year":2025,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Venous thromboembolism; Intensive care medicine; Surgery; Thrombosis","score_opus":0.0626778142135177,"score_gpt":0.35813543995717967,"score_spread":0.29545762574366197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409875243","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11481169,0.0067049493,0.00051190186,0.87211907,0.0012799517,0.002956952,0.00026626867,0.00012974025,0.0012194639],"genre_scores_gemma":[0.23517542,0.007312374,0.0013204487,0.74488777,0.00755675,0.0009247634,0.0020241104,0.00014591259,0.00065244373],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972773,0.00023211139,0.0006526343,0.00077094143,0.00026375588,0.0008032559],"domain_scores_gemma":[0.99758536,0.00092215434,0.00033282465,0.001015962,0.00008337824,0.00006034907],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041504498,0.00047127108,0.0035144747,0.00039936518,0.00016693633,0.000071121416,0.0003849223,0.0008277418,0.00007089954],"category_scores_gemma":[0.0001718264,0.00035991584,0.00018819062,0.00027796978,0.00020097436,0.00007959395,0.00024221162,0.0011590758,0.000028136381],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017542344,0.00072056655,0.00030754172,0.0023056504,0.0005386395,0.0012591773,0.0011483611,0.0000083208415,0.000046283087,0.0062737716,0.9697034,0.017512897],"study_design_scores_gemma":[0.0112615805,0.0007095958,0.029191233,0.0010476855,0.003568432,0.00023371083,0.00027344955,0.0009883653,0.00007887776,0.019084923,0.93282187,0.00074030034],"about_ca_topic_score_codex":0.00046305446,"about_ca_topic_score_gemma":0.000112695205,"teacher_disagreement_score":0.1272313,"about_ca_system_score_codex":0.00009299687,"about_ca_system_score_gemma":0.00016284068,"threshold_uncertainty_score":0.99988526},"labels":[],"label_agreement":null},{"id":"W4409875303","doi":"10.1016/s2352-3026(25)00038-9","title":"Management of iron deficiency in children, adults, and pregnant individuals: evidence-based and expert consensus recommendations","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; St. Michael's Hospital","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Child Health and Human Development; National Institutes of Health; American College of Physicians","keywords":"Medicine; Iron deficiency; MEDLINE; Pediatrics; Consensus conference; Intensive care medicine; Family medicine; Gerontology; Psychiatry; Anemia; Internal medicine","score_opus":0.06256811193594253,"score_gpt":0.36502193617817963,"score_spread":0.3024538242422371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409875303","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022660324,0.99279946,0.00001583044,0.0027499218,0.00008634676,0.0015832211,0.00005039798,0.000019253657,0.0004295552],"genre_scores_gemma":[0.0006944811,0.99761283,0.0010403374,0.00031375897,0.000020504078,0.00017690199,0.00006971761,0.000012868512,0.000058619575],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99836564,0.0003627493,0.000548145,0.00034736487,0.00011254246,0.00026357354],"domain_scores_gemma":[0.99864966,0.00055228156,0.00025889912,0.00047705858,0.000022945935,0.00003917698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004454243,0.00024333056,0.0020257866,0.000238194,0.00005267629,0.000007864055,0.00018107926,0.0001678168,0.000022861996],"category_scores_gemma":[0.00013615962,0.00015204508,0.00007562002,0.00026933564,0.00028593978,0.000018502684,0.00014237348,0.00024168873,0.0000027397805],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058637444,0.00013138317,0.004062505,0.07971178,0.000047909034,0.000033936998,0.00026384386,2.7741285e-7,5.192211e-8,0.0062050484,0.0021054526,0.90737915],"study_design_scores_gemma":[0.011917528,0.00043074868,0.019001253,0.5663213,0.007546133,0.0020760042,0.0016562832,0.000016608734,0.0000062479708,0.000871759,0.3889974,0.0011586868],"about_ca_topic_score_codex":0.000058405116,"about_ca_topic_score_gemma":0.000013921952,"teacher_disagreement_score":0.9062205,"about_ca_system_score_codex":0.00001428781,"about_ca_system_score_gemma":0.00013567765,"threshold_uncertainty_score":0.6200218},"labels":[],"label_agreement":null},{"id":"W4410799986","doi":"10.1016/s2352-3026(25)00051-1","title":"Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Astellas Pharma; Swedish Orphan Biovitrum; Else Kröner-Fresenius-Stiftung; Incyte; BeiGene; Eli Lilly and Company; AstraZeneca; Arnold Ventures; Adaptive Biotechnologies; Gilead Sciences; Sanofi; Amgen; National Heart, Lung, and Blood Institute; Pfizer; Seagen; Cidara Therapeutics; National Institute of Allergy and Infectious Diseases; Celgene; GlaxoSmithKline","keywords":"Medicine; Tolerability; Oncology; Immunotherapy; Internal medicine; Intensive care medicine; Adverse effect; Cancer","score_opus":0.09745188310624656,"score_gpt":0.37481295902621686,"score_spread":0.2773610759199703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410799986","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009536797,0.9844064,0.000017797514,0.001708119,0.0002551234,0.0027599512,0.000091163995,0.000073758136,0.001150897],"genre_scores_gemma":[0.0017630084,0.9957379,0.00028051727,0.00036675346,0.000094494906,0.00035456495,0.00013877633,0.000064075466,0.0011998806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99481285,0.0016353792,0.0014468285,0.0007842218,0.00043811722,0.0008826025],"domain_scores_gemma":[0.9961634,0.0014701975,0.00048248886,0.0016634071,0.00012085111,0.00009961771],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016520213,0.0006782862,0.008143624,0.00043616263,0.00009992574,0.000027411426,0.0008438682,0.0008437851,0.0012523094],"category_scores_gemma":[0.00030936053,0.0004109819,0.0005259038,0.00088183593,0.0012491031,0.000041469706,0.00040168088,0.0013586652,0.000017121887],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014702254,0.0014345144,0.008097814,0.20919843,0.00288026,0.0027837942,0.0025269147,7.552357e-7,0.0007742955,0.017308705,0.0058697187,0.74765456],"study_design_scores_gemma":[0.0031792426,0.0003401646,0.00074702944,0.012046858,0.00078151457,0.0023839127,0.00017940115,0.000010369346,0.00027928763,0.011291949,0.96815175,0.0006085444],"about_ca_topic_score_codex":0.0001404334,"about_ca_topic_score_gemma":0.000049580125,"teacher_disagreement_score":0.962282,"about_ca_system_score_codex":0.00014378695,"about_ca_system_score_gemma":0.0005243448,"threshold_uncertainty_score":0.9998342},"labels":[],"label_agreement":null},{"id":"W4410800008","doi":"10.1016/s2352-3026(25)00068-7","title":"Machine-learning models to predict iron recovery after blood donation: a model development and external validation study","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Lady Davis Institute for Medical Research; National Heart, Lung, and Blood Institute; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; AABB","keywords":"Medicine; Donation; Intensive care medicine; Blood donor; Immunology","score_opus":0.03151211067397029,"score_gpt":0.2796090024901398,"score_spread":0.2480968918161695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410800008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9656555,0.0010285845,0.02833002,0.0019293773,0.000094899944,0.00057575863,0.0000028809925,0.000054158383,0.0023287912],"genre_scores_gemma":[0.99202067,0.00009100569,0.005010664,0.0014536656,0.00004615611,0.00015840541,0.000009724501,0.000010325277,0.0011993992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990899,0.00010995249,0.00022487443,0.00022902609,0.00014687586,0.0001993641],"domain_scores_gemma":[0.9996024,0.000049975195,0.000046779252,0.00021607308,0.000040265928,0.000044554246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035367857,0.00012038731,0.00040241628,0.00011296068,0.00009969709,0.000019579888,0.000092548704,0.000055619643,0.000021789463],"category_scores_gemma":[0.000049219943,0.00008479106,0.000021853562,0.00010963662,0.000029480527,0.00006782266,0.00010651241,0.00015065905,0.000009095597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011777821,0.0021783956,0.7575966,0.0019546088,0.000470095,0.0004682072,0.04155956,0.09822662,0.0009816843,0.03724417,0.0025625855,0.044979632],"study_design_scores_gemma":[0.06057611,0.0026349933,0.43682215,0.001362087,0.0051242635,0.0018947979,0.0076842294,0.38438052,0.006216266,0.08226932,0.008810506,0.00222475],"about_ca_topic_score_codex":0.000022630877,"about_ca_topic_score_gemma":0.000041768802,"teacher_disagreement_score":0.32077447,"about_ca_system_score_codex":0.0000133278345,"about_ca_system_score_gemma":0.00007245045,"threshold_uncertainty_score":0.34576795},"labels":[],"label_agreement":null},{"id":"W4410800025","doi":"10.1016/s2352-3026(25)00027-4","title":"Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series","year":2025,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institutes of Health","keywords":"Medicine; Hematology; Series (stratigraphy); Internal medicine; Adverse effect; Intensive care medicine","score_opus":0.039359635684619206,"score_gpt":0.31519938223615945,"score_spread":0.27583974655154025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410800025","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012281624,0.00051997136,0.00018509648,0.97369105,0.0055346694,0.0021146878,0.00005018589,0.00028088648,0.0053418167],"genre_scores_gemma":[0.00645053,0.0008853205,0.0010305917,0.94940287,0.03130572,0.00089073967,0.000623127,0.00010848756,0.00930259],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950387,0.00057852146,0.0015474551,0.0010205766,0.0005057153,0.0013090664],"domain_scores_gemma":[0.9951321,0.00028464582,0.0015235483,0.0027843644,0.00019463593,0.000080697704],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016317328,0.0006138987,0.004649709,0.0002894375,0.00043418753,0.000028992508,0.0010020621,0.0007486506,0.00028466104],"category_scores_gemma":[0.0013091541,0.00037300377,0.00034053784,0.0004912942,0.00030391625,0.000082189494,0.0007073992,0.0024215134,0.00038333389],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013016933,0.00008308878,0.0014898388,0.0016072225,0.0006316782,0.0034056632,0.00049144775,0.000026550932,0.000009168017,0.0065802406,0.9850811,0.0004638646],"study_design_scores_gemma":[0.0008330028,0.0001569949,0.0028849265,0.00031947592,0.001071312,0.0076031745,0.00025049716,0.0000075031808,0.00011851881,0.008440356,0.9779762,0.00033803147],"about_ca_topic_score_codex":0.00016032475,"about_ca_topic_score_gemma":0.00021302294,"teacher_disagreement_score":0.025771048,"about_ca_system_score_codex":0.00013983724,"about_ca_system_score_gemma":0.00017766812,"threshold_uncertainty_score":0.99987996},"labels":[],"label_agreement":null},{"id":"W4410800040","doi":"10.1016/s2352-3026(25)00136-x","title":"Optimising communication to patients with venous thromboembolism: development of a provider toolkit","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Healthcare Systems and Technology","field":"Business, Management and Accounting","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Queen's University; University of Toronto","funders":"Bristol-Myers Squibb","keywords":"Medicine; Venous thromboembolism; Intensive care medicine; MEDLINE; Internal medicine; Thrombosis","score_opus":0.023476279336365907,"score_gpt":0.26827996300928675,"score_spread":0.24480368367292085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410800040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811962,0.00010013105,0.0012947916,0.0102645485,0.00012248481,0.0005539312,8.2163467e-7,0.00009316588,0.0063739046],"genre_scores_gemma":[0.99381924,0.0000022774188,0.00363829,0.0023923337,0.000042682514,0.000059502356,0.000010221617,0.000009599203,0.000025881092],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99919194,0.000025322304,0.00029482483,0.00014373886,0.000101575766,0.00024258558],"domain_scores_gemma":[0.9990675,0.000046575027,0.00017925362,0.0004976032,0.0002036761,0.0000054248144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029480967,0.00009640893,0.00052327063,0.00016210593,0.0001911327,0.000031521868,0.00044384136,0.00007531262,0.000011342],"category_scores_gemma":[0.0000850681,0.00006263615,0.000015055781,0.0004147211,0.00007067025,0.00010927538,0.0002635537,0.00011980882,0.000037562266],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025760182,0.00042068606,0.24955817,0.002556987,0.00021015148,0.000008532624,0.0019458451,0.000083367,0.00006488312,0.6276973,0.009855541,0.10734096],"study_design_scores_gemma":[0.0027597412,0.00006583887,0.5234632,0.0012970681,0.000118731725,0.000015709482,0.0010499259,0.00023663827,0.00046066646,0.014409602,0.45561746,0.0005054542],"about_ca_topic_score_codex":0.00065504527,"about_ca_topic_score_gemma":0.0010070105,"teacher_disagreement_score":0.6132877,"about_ca_system_score_codex":0.000025587853,"about_ca_system_score_gemma":0.00006811375,"threshold_uncertainty_score":0.25542283},"labels":[],"label_agreement":null},{"id":"W4411313705","doi":"10.1016/s2352-3026(25)00144-9","title":"Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Calgary","funders":"Schleswig-Holstein; Amgen","keywords":"Medicine; Post-hoc analysis; Blinatumomab; Refractory (planetary science); Clinical trial; Internal medicine; Post hoc; Oncology; Pediatrics; Lymphoblastic Leukemia; Leukemia","score_opus":0.015348107925319815,"score_gpt":0.3009847296719843,"score_spread":0.2856366217466645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411313705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99164826,0.00048947363,0.0011478274,0.0038048723,0.00019141247,0.0015791112,0.00018732515,0.00012311462,0.00082862953],"genre_scores_gemma":[0.99686146,0.0004357728,0.0007383866,0.0008144643,0.00013391608,0.00007304193,0.0001422827,0.000043144286,0.00075752457],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99646854,0.0006224594,0.0006618432,0.0008815998,0.0004657133,0.00089986925],"domain_scores_gemma":[0.99420077,0.0039549903,0.0003156095,0.0011056733,0.00021352868,0.00020945494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042938045,0.0004465316,0.0023661556,0.0006064092,0.00016393137,0.000042123083,0.0004342718,0.00044084268,0.00015332035],"category_scores_gemma":[0.0008792596,0.00027033643,0.00015192264,0.0016245269,0.0005469453,0.000116967676,0.00026505993,0.0008932938,0.000027899729],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96984935,0.0033356594,0.0010193507,0.00035128495,0.0018116551,0.015242229,0.0012314303,0.000038647042,0.002360909,0.00006997466,0.000487419,0.004202115],"study_design_scores_gemma":[0.9027593,0.020528525,0.0028777972,0.001036208,0.009743153,0.004028171,0.0013292938,0.051518306,0.004110088,0.00014756634,0.0010861576,0.0008353908],"about_ca_topic_score_codex":0.0009363159,"about_ca_topic_score_gemma":0.0028935496,"teacher_disagreement_score":0.06708998,"about_ca_system_score_codex":0.0009958742,"about_ca_system_score_gemma":0.0013053876,"threshold_uncertainty_score":0.9999749},"labels":[],"label_agreement":null},{"id":"W4412461070","doi":"10.1016/s2352-3026(25)00163-2","title":"Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Daratumumab; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Oncology; Open label; Refractory (planetary science); Surgery; Clinical trial","score_opus":0.04989390241174046,"score_gpt":0.35109203108008247,"score_spread":0.301198128668342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412461070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98346037,0.00054905424,0.000046146997,0.0016166653,0.00026304074,0.012960102,0.0003327264,0.000097105265,0.00067477446],"genre_scores_gemma":[0.994009,0.00020260924,0.003149669,0.00039609207,0.000051294388,0.0011976371,0.0006536496,0.0000643585,0.00027564826],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994837,0.0010758913,0.0013610024,0.0011578284,0.00060549,0.0009628121],"domain_scores_gemma":[0.98991174,0.007330055,0.00081206986,0.0013103791,0.00028920436,0.00034658203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010291507,0.00067732035,0.004008747,0.0003529364,0.0003236693,0.000120425975,0.00037106412,0.00032167198,0.00004475755],"category_scores_gemma":[0.0055939187,0.0003518,0.00007654741,0.0005478144,0.00062855793,0.00024675176,0.00032732764,0.0007851985,0.0000055226888],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8356673,0.0034797236,0.14834078,0.00006133103,0.0025939287,0.0017828433,0.00045302333,9.4937764e-7,0.00006924748,0.00002779799,0.00039459314,0.0071285],"study_design_scores_gemma":[0.8712431,0.009048402,0.11677016,0.0003323621,0.0010524865,0.00008337036,0.00024404719,0.0004213665,0.00019095556,0.000033800217,0.00024337924,0.0003365417],"about_ca_topic_score_codex":0.0014762575,"about_ca_topic_score_gemma":0.0027422276,"teacher_disagreement_score":0.035575837,"about_ca_system_score_codex":0.00015378714,"about_ca_system_score_gemma":0.0005086482,"threshold_uncertainty_score":0.9998934},"labels":[],"label_agreement":null},{"id":"W4413707382","doi":"10.1016/s2352-3026(25)00146-2","title":"Getting back on track to meet global anaemia reduction targets: a Lancet Haematology Commission","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Public Health Ontario; University of Toronto","funders":"University of California, Davis; Instituto Tecnológico y de Estudios Superiores de Monterrey; University of South Carolina; World Health Organization; World Bank Group; National Institute for Nutrition and Health; Bill and Melinda Gates Foundation","keywords":"Medicine; Hematology; Reduction (mathematics); Track (disk drive); Commission; Internal medicine; Fast track; Intensive care medicine; Surgery; Computer science","score_opus":0.05768926400618695,"score_gpt":0.3826757696689444,"score_spread":0.32498650566275744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413707382","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019922099,0.9339314,0.0001354103,0.0143053485,0.0017983034,0.0020886634,0.00015799787,0.00022784919,0.047155783],"genre_scores_gemma":[0.0001098679,0.9904886,0.0018582648,0.0041097743,0.0013278326,0.0002374795,0.00029389086,0.0000710373,0.0015032389],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99551225,0.001013771,0.0011133926,0.0009362482,0.00032964326,0.0010946752],"domain_scores_gemma":[0.9970133,0.0004004062,0.0005432761,0.0016948985,0.00010437653,0.0002437643],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007722287,0.00078697584,0.008040432,0.00028043278,0.00023777357,0.00003377065,0.0008429985,0.0009185401,0.0002900873],"category_scores_gemma":[0.0007869219,0.00050766976,0.0005307111,0.0009001277,0.0002516051,0.000050217794,0.00027343092,0.0008687621,0.00082013704],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051958865,0.00018909437,0.00008175779,0.05180982,0.00018945117,0.00048723834,0.00021913947,0.0000062673857,0.0000019552624,0.04207189,0.674889,0.22953478],"study_design_scores_gemma":[0.001417988,0.00015015222,0.00003225726,0.010544674,0.0013724562,0.005173855,0.00013255616,0.0000035309179,0.000007640536,0.0012893555,0.97943586,0.000439675],"about_ca_topic_score_codex":0.000059239035,"about_ca_topic_score_gemma":0.00005107599,"teacher_disagreement_score":0.30454683,"about_ca_system_score_codex":0.000171335,"about_ca_system_score_gemma":0.0005106102,"threshold_uncertainty_score":0.99995786},"labels":[],"label_agreement":null},{"id":"W4414300162","doi":"10.1016/s2352-3026(25)00204-2","title":"Sustainable anticoagulation for climate resilient care","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Climate Change and Health Impacts","field":"Environmental Science","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute","funders":"","keywords":"Multidisciplinary approach; Sustainability; Stakeholder engagement; Procurement; Portfolio; Stewardship (theology); Health care; Scarcity; General partnership; Consumables","score_opus":0.10087812522687645,"score_gpt":0.41177500734611683,"score_spread":0.3108968821192404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414300162","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000053485095,0.98969823,0.000025721169,0.0010340179,0.00025936778,0.0022715568,0.0001053726,0.00005418551,0.0064980653],"genre_scores_gemma":[0.000035700483,0.9975627,0.00013161496,0.00051978085,0.00017381755,0.00040710665,0.00021885853,0.000023862445,0.0009265295],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99806166,0.00017865925,0.00040324085,0.00034740014,0.00009524151,0.0009137901],"domain_scores_gemma":[0.9985246,0.00052050996,0.00026900362,0.000603458,0.000018717554,0.00006368399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004609294,0.00025014553,0.001815279,0.000059748687,0.00036746843,0.00002891753,0.00045414257,0.00025178542,0.00021815726],"category_scores_gemma":[0.0001702918,0.00015739322,0.00017429401,0.00025390738,0.00011842883,0.00005092683,0.0003951543,0.00020026436,0.00025152223],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000616769,0.000042453135,0.0003053381,0.3304522,0.000028676097,0.00008012165,0.0014847906,0.000027139853,1.381101e-7,0.017553572,0.13477683,0.5151871],"study_design_scores_gemma":[0.00018679709,0.00003774009,0.000027698477,0.002592217,0.0002700399,0.00005955785,0.00028717122,0.000010639117,6.363546e-7,0.0011640548,0.9952058,0.0001576368],"about_ca_topic_score_codex":0.00008265182,"about_ca_topic_score_gemma":0.0001364083,"teacher_disagreement_score":0.860429,"about_ca_system_score_codex":0.00027179695,"about_ca_system_score_gemma":0.00006412621,"threshold_uncertainty_score":0.6418309},"labels":[],"label_agreement":null},{"id":"W4414984131","doi":"10.1016/s2352-3026(25)00254-6","title":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Celgene; AbbVie; Bristol-Myers Squibb","keywords":"Venetoclax; Myeloid leukaemia; Refractory (planetary science); Myelodysplastic syndromes; Myeloid leukemia; Myeloid; Clinical trial","score_opus":0.03281879553664856,"score_gpt":0.3313487312351916,"score_spread":0.298529935698543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414984131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914822,0.00018455557,0.00017474871,0.002316971,0.0006454478,0.004236147,0.000080601916,0.00025045633,0.0006288561],"genre_scores_gemma":[0.9937637,0.00012701593,0.00078992994,0.0013699253,0.00018057188,0.00041523157,0.00026881884,0.00010925862,0.002975567],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99490196,0.0007711841,0.0011223656,0.00093965017,0.0007232526,0.0015415653],"domain_scores_gemma":[0.99556834,0.0020010723,0.00041903325,0.0014265254,0.00029698797,0.00028805027],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000684594,0.00062752253,0.0026503138,0.0006508374,0.00022116634,0.00005983642,0.0008402269,0.0005334605,0.00037877346],"category_scores_gemma":[0.0019232497,0.00035987305,0.00013872434,0.0015725343,0.00063484634,0.00020201683,0.00033791419,0.0017431446,0.00021118396],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9486426,0.004130279,0.0044859634,0.0009542775,0.0015509023,0.025499102,0.0015819916,0.00011054521,0.0009988021,0.00026634667,0.009291973,0.0024871824],"study_design_scores_gemma":[0.94187975,0.022176819,0.012514682,0.0022865443,0.0016900451,0.0046325056,0.00058316515,0.0045156586,0.0018061337,0.00022367493,0.006665692,0.0010253577],"about_ca_topic_score_codex":0.00019040094,"about_ca_topic_score_gemma":0.00046333147,"teacher_disagreement_score":0.020866595,"about_ca_system_score_codex":0.0025540483,"about_ca_system_score_gemma":0.0034684364,"threshold_uncertainty_score":0.9998853},"labels":[],"label_agreement":null},{"id":"W4415900074","doi":"10.1016/s2352-3026(25)00264-9","title":"Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Phase (matter); Clinical trial; Phases of clinical research; MEDLINE","score_opus":0.05743628741329941,"score_gpt":0.4161781471176606,"score_spread":0.3587418597043612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415900074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681416,0.0009835789,0.00014288741,0.012799998,0.00062957115,0.01079567,0.000037779177,0.00011083884,0.006358091],"genre_scores_gemma":[0.99174845,0.00049398065,0.0002402838,0.0030487052,0.00018493077,0.0028896995,0.00006371364,0.000058811605,0.0012713949],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99490714,0.0016295321,0.001157771,0.0009955785,0.00038885715,0.0009211074],"domain_scores_gemma":[0.9961169,0.0019144536,0.0004267751,0.0011967358,0.00016475725,0.00018040398],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012231865,0.0007020744,0.004523632,0.0003091112,0.00025746907,0.00013244404,0.0007828618,0.00025601397,0.0005724908],"category_scores_gemma":[0.0006190625,0.00039430906,0.00019191434,0.00047234056,0.00025433267,0.00024066141,0.00045133414,0.0009090685,0.00011820417],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80850655,0.066887215,0.05176089,0.00066064135,0.008194263,0.01279076,0.013422751,0.00009032237,0.005394163,0.004897799,0.015479263,0.011915358],"study_design_scores_gemma":[0.9645314,0.004085801,0.009714996,0.00092438614,0.0022169605,0.0005187921,0.0019118472,0.0029263105,0.008360059,0.0004290421,0.0037487582,0.000631625],"about_ca_topic_score_codex":0.00087337545,"about_ca_topic_score_gemma":0.0045086485,"teacher_disagreement_score":0.15602484,"about_ca_system_score_codex":0.0003358798,"about_ca_system_score_gemma":0.0005244573,"threshold_uncertainty_score":0.99985087},"labels":[],"label_agreement":null},{"id":"W4415900075","doi":"10.1016/s2352-3026(25)00262-5","title":"Von Willebrand factor and von Willebrand disease in ageing: mechanisms, evolving phenotypes, and clinical implications","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Third Health Programme; Ministero dell'Università e della Ricerca; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Università degli Studi di Milano; Swedish Orphan Biovitrum; Ministero della Salute; CSL Behring; Dipartimenti di Eccellenza; Sanofi; European Commission; Pfizer","keywords":"Von Willebrand factor; Von Willebrand disease; Coagulation; Disease; Thrombosis; Population; Hemostasis; Coagulopathy","score_opus":0.05715202487120226,"score_gpt":0.3800579027299175,"score_spread":0.3229058778587153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415900075","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0063107074,0.9889525,0.00006226032,0.0024533048,0.00014693852,0.0014292212,0.00016112709,0.000050472365,0.0004334511],"genre_scores_gemma":[0.012038106,0.9867548,0.0001993234,0.00038144828,0.00007344139,0.00012993923,0.00018735536,0.000032863336,0.00020272238],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980092,0.00029935842,0.0006429682,0.0005697751,0.0000956106,0.0003830665],"domain_scores_gemma":[0.9980319,0.0009318236,0.00023609784,0.0005954528,0.000030386955,0.00017430173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024985764,0.00038103995,0.0036109868,0.00016411029,0.00013084117,0.000031304153,0.00017530742,0.0003362366,0.000032531596],"category_scores_gemma":[0.00038782667,0.00023630999,0.00018102046,0.00020609521,0.00019143113,0.000049272076,0.00016546431,0.0005105308,0.0000123288755],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036626626,0.0005044354,0.036436263,0.037555818,0.0012160523,0.0034425296,0.00017538683,1.4831375e-7,6.448334e-7,0.016634868,0.002760836,0.90090674],"study_design_scores_gemma":[0.014350131,0.00044625753,0.056490805,0.038918536,0.012443225,0.003989929,0.000052729752,0.00013104432,7.6024196e-7,0.051665694,0.8200585,0.0014523454],"about_ca_topic_score_codex":0.000036227088,"about_ca_topic_score_gemma":0.00010545245,"teacher_disagreement_score":0.8994544,"about_ca_system_score_codex":0.000038003476,"about_ca_system_score_gemma":0.00023686443,"threshold_uncertainty_score":0.96364415},"labels":[],"label_agreement":null},{"id":"W4415900082","doi":"10.1016/s2352-3026(25)00287-x","title":"Perspectives of potential haematopoietic stem-cell donors on education TikToks","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stem Cell Network; University of Toronto","funders":"","keywords":"Haematopoiesis; Social media; Public health; Affect (linguistics); Commercialization; Health care","score_opus":0.04806970459555981,"score_gpt":0.3879551075529508,"score_spread":0.339885402957391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415900082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8862138,0.0011445399,0.000077162265,0.050758068,0.0055853967,0.0008824798,0.0000021490564,0.000059952865,0.055276472],"genre_scores_gemma":[0.99717057,0.0004111549,0.00015148301,0.0006822276,0.00060918595,0.00028800216,0.0000018788191,0.000007356484,0.00067812914],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.9983661,0.0006723215,0.0002572295,0.0001955435,0.0001968989,0.00031191643],"domain_scores_gemma":[0.9980899,0.0011673933,0.0001964236,0.00033306138,0.00016375113,0.000049431732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070756377,0.00009038699,0.00041259456,0.00012111231,0.0003764867,0.000017729599,0.00041980177,0.00014463879,0.00008850791],"category_scores_gemma":[0.0005202292,0.00007421467,0.000056456047,0.00039296946,0.00057525386,0.000048779573,0.000031667274,0.00020285338,0.000056464218],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005976566,0.0002756289,0.008466447,0.00021816565,0.00001694854,0.0000014356984,0.09445255,0.000007645237,0.000059908,0.8808321,0.008518974,0.0070904843],"study_design_scores_gemma":[0.0016932689,0.00025179493,0.06468811,0.0005645916,0.00028049762,0.000025863632,0.67333746,0.00004908318,0.004252737,0.17358655,0.080669984,0.0006000467],"about_ca_topic_score_codex":0.0021686056,"about_ca_topic_score_gemma":0.0004757041,"teacher_disagreement_score":0.70724547,"about_ca_system_score_codex":0.00014336722,"about_ca_system_score_gemma":0.0011250682,"threshold_uncertainty_score":0.32782975},"labels":[],"label_agreement":null},{"id":"W4415900084","doi":"10.1016/s2352-3026(25)00256-x","title":"Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Dexamethasone; Multiple myeloma; Refractory (planetary science); Randomized controlled trial; Phases of clinical research","score_opus":0.047484709287832494,"score_gpt":0.3549491914005954,"score_spread":0.3074644821127629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415900084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814653,0.0006274901,0.000056478497,0.0016150783,0.00022552453,0.015231529,0.00006332678,0.00009788091,0.0006173983],"genre_scores_gemma":[0.9937383,0.00017874133,0.0030558119,0.000555857,0.000042872496,0.0018150868,0.00015697465,0.00007108098,0.0003852549],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950137,0.001161521,0.0012119291,0.0009887227,0.0005799817,0.0010441062],"domain_scores_gemma":[0.9914764,0.006064899,0.00071145303,0.0010895744,0.00030342326,0.00035426064],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011470208,0.0006845467,0.004232742,0.00044111922,0.00029961125,0.00011988487,0.00035725386,0.00030016754,0.000068672714],"category_scores_gemma":[0.0046221237,0.0003519372,0.000088008775,0.0006168304,0.0006647369,0.0002552596,0.00033770635,0.0006803943,0.0000057032535],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7096312,0.002913233,0.27817872,0.000110626745,0.0021440962,0.0016098982,0.00021052899,7.759107e-7,0.00007186587,0.00007082801,0.00020503376,0.0048532034],"study_design_scores_gemma":[0.8807054,0.009898067,0.10654588,0.00029943947,0.0010688638,0.0002443864,0.00021362257,0.00027079455,0.00022583352,0.000037204987,0.00014651052,0.00034397474],"about_ca_topic_score_codex":0.0006360518,"about_ca_topic_score_gemma":0.0013252241,"teacher_disagreement_score":0.17163283,"about_ca_system_score_codex":0.00015406712,"about_ca_system_score_gemma":0.00050749636,"threshold_uncertainty_score":0.99989325},"labels":[],"label_agreement":null},{"id":"W4417231207","doi":"10.1016/s2352-3026(25)00291-1","title":"Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Pfizer; Bristol-Myers Squibb","keywords":"Venous thromboembolism; Major bleeding; Pulmonary embolism; MEDLINE; Clinical trial; Thrombosis","score_opus":0.0258051171126176,"score_gpt":0.3478896615024365,"score_spread":0.32208454438981887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417231207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249846,0.00034124567,0.0003729301,0.0024767034,0.00079803413,0.0030741754,0.00008790834,0.000062938576,0.00028760204],"genre_scores_gemma":[0.997507,0.0011902943,0.00031050178,0.00031054483,0.00019815538,0.0003536912,0.0000665522,0.000021370604,0.00004194135],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99726754,0.00019449789,0.001435199,0.0003805876,0.00026900915,0.00045315793],"domain_scores_gemma":[0.997143,0.0007973753,0.0009768513,0.0006026843,0.00041971655,0.000060419927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015199786,0.00022644263,0.004235385,0.000413714,0.00014753708,0.000012111915,0.00029136654,0.00022695212,0.000040037652],"category_scores_gemma":[0.0011823132,0.00016778923,0.00060719805,0.0008240782,0.00021483883,0.000049936556,0.00012790202,0.00017349908,9.7592e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6397821,0.013743834,0.14593834,0.009144334,0.090983465,0.000103686965,0.013699798,0.0021810003,0.05785535,0.01798805,0.0027245858,0.005855479],"study_design_scores_gemma":[0.23022929,0.0028487314,0.71904975,0.0008575319,0.034374774,0.000009538588,0.0005727774,0.0070399623,0.0035360162,0.0010816305,0.000098748016,0.0003012314],"about_ca_topic_score_codex":0.00048464097,"about_ca_topic_score_gemma":0.00029341807,"teacher_disagreement_score":0.5731114,"about_ca_system_score_codex":0.000102959515,"about_ca_system_score_gemma":0.0002574843,"threshold_uncertainty_score":0.6842246},"labels":[],"label_agreement":null},{"id":"W7116844175","doi":"10.1016/s2352-3026(25)00318-7","title":"Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Université de Montréal; Université de Sherbrooke; McGill University Health Centre","funders":"Fonds de recherche du Québec","keywords":"Bispecific antibody; Chimeric antigen receptor; Sequence (biology); Antibody; Antigen; Antibody therapy; Immunotherapy","score_opus":0.10609664797253764,"score_gpt":0.39051698920371775,"score_spread":0.2844203412311801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116844175","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14032172,0.8248948,0.0012399887,0.022788228,0.00009152913,0.007993149,0.00016012204,0.00012251432,0.002387977],"genre_scores_gemma":[0.6010231,0.35297126,0.0019676827,0.017554678,0.00011134402,0.0017397265,0.00019176795,0.00009874352,0.02434172],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99755585,0.00059228693,0.0005751314,0.00052573025,0.00021330104,0.0005377245],"domain_scores_gemma":[0.9977043,0.00072093244,0.00023696947,0.001090109,0.00015613678,0.00009152759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00179105,0.00029622592,0.0048559285,0.00024558554,0.00018348025,0.00004289541,0.00033131387,0.00012128113,0.0005886104],"category_scores_gemma":[0.00012385387,0.00016667967,0.00051697996,0.0009639907,0.00020908729,0.00004314465,0.0001037838,0.00016897352,0.000024822188],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013551994,0.0019450352,0.006037166,0.6954398,0.17055345,0.00020788405,0.0016040575,9.4895466e-7,0.08892169,0.011693589,0.021834591,0.0004066109],"study_design_scores_gemma":[0.029960657,0.0010972796,0.0014257865,0.0039038754,0.86795586,0.0016989772,0.00096601446,0.0013192056,0.02318631,0.0018219323,0.06508586,0.0015782351],"about_ca_topic_score_codex":0.000030541298,"about_ca_topic_score_gemma":0.000011910774,"teacher_disagreement_score":0.6974024,"about_ca_system_score_codex":0.00003207955,"about_ca_system_score_gemma":0.00009360292,"threshold_uncertainty_score":0.67969996},"labels":[],"label_agreement":null}]}